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The single-humped Arabian camel (Camelus dromedarius) thrives in the hot 
arid Arabian desert. Many unique adaptations permit it to accomplish this. Camel 
erythrocytes or red blood cells (RBCs) have a peculiar elliptical shape and are 
amenable to large variations in physical conditions resulting from dehydration and 
rehydration cycles. The oxygen transport protein hemoglobin is found abundantly in 
RBCs and is also believed to behave differently in camels. While several 
physiological and biochemical studies have been performed on camel hemoglobin, 
very little is known about genetic and structural adaptions in this protein. The camel 
genome harbors several unique variations which are being investigated for the 
treatment of several disorders such as diabetes, cancer, and hepatitis.  In this study, 
several aspects of camel hemoglobin were investigated from genetic, 
pharmacological and molecular modeling perspectives. Genetic analysis of camel 
hemoglobin revealed that camels harbor a unique variation in the region of 
hemoglobin that harbors a peptide called hemorphin. Hemorphins are endogenous 
bioactive peptides produced during proteolytic cleavage of hemoglobin and are 
highly conserved among mammals. Several therapeutic properties of mammalian 
hemorphins have been reported. However, their precise molecular binding behavior 
remain elusive. This study extensively investigated the binding behavior and 
pharmacologic effects of human and camel hemorphins, with angiotensin-converting 
enzyme (ACE), mu-opioid receptor (MOR), and insulin-regulated aminopeptidase 
(IRAP) receptor using in silico and in vitro approaches. Camel hemorphins produced 
more potent activity, better binding affinity, and more stable interactions with critical 
residues of ACE, MOR and IRAP receptors when compared to human hemorphins. 
This study also identified, for the first time, a G protein-coupled receptor angiotensin 
II type 1 receptor (AT1R) that is a target of hemorphins. In silico and in vitro data 
demonstrated that LVV-hemorphin-7 binds to the intracellular side of AT1R and 
allosterically potentiated the potency of AngII as well as its downstream signaling. 
Lastly, 1000 nanosecond (ns) comparative molecular dynamics (MD) simulations 
were performed using camel and human hemoglobin protein structures to see how 






hemoglobin demonstrated limited fluctuations, especially near the heme binding 
regions at higher salt and temperature conditions, compared to human hemoglobin.  
Additionally, the binding pose, energetics and interaction stability of oxygen-affinity 
determining energy molecules, adenosine triphosphate (ATP) and 2,3-
bisphosphoglycerate (2,3-BPG) were determined in silico. 2,3-BPG is abundantly 
present in erythrocytes and plays a significant role in the unloading of oxygen 
molecules in peripheral tissues, compared to ATP.  In simulations, 2,3-BPG formed 
more stable interactions with camel hemoglobin at severe dehydrated conditions 
compared to human hemoglobin. In summary, this study provides insights into the 
overall stability of camel hemoglobin as well as the binding behavior of ATP and 
2,3-BPG at different dehydrated conditions, along with pharmacological and 
therapeutic activity of the hemoglobin derived hemorphin peptides.  
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Title and Abstract (in Arabic) 
 
 ة في بروتين الهيموجلوبين المستخلص من الجمالتقيم اإلختالفات الجينية والبنائي
 الملخص
( في الصحراء العربية القاحلة Camelus dromedariusينمو الجمل العربي وحيد السنام )
الحارة حيث يتميز بالعديد من الخصائص الفريدة التي تسمح لهم بالعيش في ظل هذه الظروف 
جمل أو كريات الدم الحمراء لها شكل بيضاوي فريد المناخية القاهرة. خاليا الدم الحمراء لهذا ال
وهي قابلة للتغيرات الكبيرة في ظل الظروف الفيزيائية الناتجة عن دورات الجفاف ودورات 
معالجة الجفاف. وتم العثور على بروتين الهيموجلوبين الناقل األساسي لألكسجين في كريات 
لفة في اإلبل. في حين أنه تم إجراء العديد من الدم الحمراء ويعتقد أيًضا أنه يعمل بطريقة مخت
الدراسات الفسيولوجية والكيميائية الحيوية على بروتين الهيموجلوبين في اإلبل، إلى اآلن ال 
يُعرف سوى القليل جدًا عن التكيفات الوراثية والهيكلية في هذا البروتين. تحتوي المعلومات 
ات المميزة التي يتم دراستها لعالج العديد من الجينية في اإلبل على العديد من االختالف
 األمراض.
، تم دراسة الهيموجلوبين في اإلبل من جوانب مختلفة كالنمذجة الوراثية في هذه الدراسة 
والدوائية والجزيئية. أظهر التحليل الجيني للهيموجلوبين في اإلبل أنه يحتوي على اختالف فريد 
في ببتيد يسمى الهيمورفين. الهيمورفين هوعبارة عن ببتيدات في منطقة الهيموجلوبين وبالتحديد 
نشطة بيولوجيًا يتم إنتاجها أثناء االنقسام البروتيني للهيموجلوبين وهي موجودة بشكل متشابه في 
للهيمورفين في الثدييات. ومع جميع الثدييات كما تم التأكد من العديد من الخصائص العالجية 
 لهيمورفين الجزئي مبهما إلى اآلن. ، فإن ترابط بيبتيد اذلك
توصلت هذه الدراسة إلى نتائج تخص التأثيرات العالجية و سلوك الترابط الجزئي لببتيد 
(، ومستقبالت ACEالهيمورفين في األبل والبشر، وارتباطه مع إنزيم المحول لألنجيوتنسين )
( IRAPا األنسولين )( التي ينظمهIRAP، ومستقبالت أمينوببتيداز )(MORميو أفيونيد )
. ومن المثير (in silico( و تقنيات معلوماتيه حيوية )in vitroباستخدام تقنيات مختبرية )
، وارتباط أفضل تماسكا، وتفاعالت ي اإلبل أظهر نشاًطا أكثر فاعليةلالهتمام أن الهيمورفين ف
البشري. كما عند مقارنتها بالهيمورفين  IRAPو  MORو  ACEأكثر ثباتًا مع مستقبالت 






 inوالتي تستهدف الهيمورفين. أظهرت البيانات باستخدام تقنيات مختبرية ) Gالمقترنة ببروتين 
vitro( و تقنيات معلوماتيه حيوية )in silico)  أنLVV-hemorphin-7 يرتبط بالجانب 
، تم إجراء محاكاة . أخيًرا AngIIويقوي فاعلية اإلشارات الحيوية ل AT1Rالداخلي من 
( باستخدام هياكل بروتين الهيموجلوبين البشري واإلبل MDنانوثانية للحركة الجزيئية ) 1000
 لمعرفة كيفية إختالف هذه الجزيئات في ظروف مختلفة من األسموزية ودرجة الحرارة. 
، خاصة بالقرب من بين في اإلبل أظهر تقلبات محدودةهتمام، أن الهيموجلوومن المثير لال
، مقارنة بالهيموجلوبين البشري. ظروف ارتفاع الملح ودرجة الحرارةمناطق ارتباط الحديد في 
، واستقرار تفاعل جزيئات الطاقة شكل االرتباط ، وتقارب االرتباط عالوة على ذلك ، تم تحديد
بيسفوسفوجليسيرات -2،3( و ATPكسجين ، وثالثي فوسفات األدينوزين )التي تحدد تقارب األ
(2،3-BPG 2،3( باستخدام التقنيات المعلوماتيه الحيوية. وفي نموذج المحاكاة، أظهر-BPG 
تفاعالت مستقرة مع هيموجلوبين األبل في ظل الظروف الجافة مقارنتا بالهيموجلوبين البشري. 
ق من استقرارية بروتين الهيموجلوبين في األبل، إضافة الى سلوك وفي الختام ، هذا البحث تحق
، إلى جانب النشاط الدوائي في حاالت الجفاف المختلفة BPG-2،3و  ATPارتباطه مع ال 
 .والعالجي لببتيدات الهيمورفين المشتقة من الهيموجلوبين
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Chapter 1: Introduction 
1.1 Overview 
Camels play a vital role in the survival of mankind, particularly those living 
in arid regions, due to their versatile role and unique capability to acclimatize to 
these extreme environmental conditions (Beuzen, Stear, & Chang, 2000; Burger, 
2016; Soman & Tinson, 2016). Despite the huge economic, cultural, and biological 
significance, the genetic architecture of camels has not been extensively studied to 
gain a deeper understanding of the molecular biology that underlies these unique 
adaptations. The camel genome contains approximately 20,000 genes and is roughly 
2.38 gigabases in size (Jirimutu et al., 2012). The genetic architecture of camels has a 
profound impact that enables them to survive under extreme conditions (Andersson 
& Georges, 2004; Wu et al., 2014). Variations in the genome and proteome of the 
camel are also being explored for the treatment of a number of disorders (Agrawal, 
Jain, Shah, Chopra, & Agarwal, 2011; Jirimutu et al., 2012; Muyldermans et al., 
2009).  
Camels harbor numerous unique traits that permit them to live and thrive in 
distant areas, scorched lands, and high mountains (Jirimutu et al., 2012). They have 
an inherent ability to endure thirst and hunger for longer period of times in extremely 
harsh environmental conditions. Studies focused on the camel genome have 
demonstrated the contribution of numerous genes that permit them to acclimatize to 
severe ecological conditions (Elmahdi, Sallmann, Fuhrmann, von Engelhardt, & 
Kaske, 1997; Jirimutu et al., 2012; Kasahara et al., 2007; Muyldermans, 2001). 
Additionally, multiple studies have assessed the therapeutic potential of camel 






Mohandesan, Corander, & Burger, 2016; Jirimutu et al., 2012; Muyldermans et al., 
2009). 
1.1.1 Unique physiological characteristics of camels 
Camels harbor unique attributes that permit them to survive in extreme desert 
conditions. Previous studies have shown that camels store energy in their humps in 
the form of fat which permits them to survive without food and water for a longer 
period of time when compared to other closely related mammals (Emmanuel & 
Nahapetian, 1980). The body temperature of camels fluctuate between 34 to 41°C 
within the day (Schmidt-Nielsen, Schmidt-Nielsen, Jarnum, & Houpt, 1956). Camels 
have the ability to lose water up to 25% of its body weight (Macfarlane, Morris, & 
Howard, 1963). Another study revealed that camels could lose water up to 30% of its 
body weight in severe dehydrated conditions. Compared to this, other closely related 
mammals will not be able to withstand such drastic changes and will probably die 
because of circulatory failure when the water loss surpasses 12% of their body 
weight (McKinley, McBurnie, & Mathai, 2001). Several factors are involved in 
regulating the body water balance including tissue osmolality and particularly blood 
osmolality (Andersson, Olsson, & Rundgren, 1980).  
Camel kidneys are primarily involved in the conservation of water by raising 
the osmolarity of urine. The camel kidney has the ability to reabsorb more water and 
produce highly concentrated urine compared to other mammals. Furthermore, unlike 
other mammals, a camel’s intestine has the unique capability to reabsorb water and 
water loss via feces is extremely low (Davidson, 2014). Surprisingly, camels can 






any signs of diabetes. Camels can also ingest approximately eight times more salt 
compared to other mammals without demonstrating any signs of hypertension (Al-
Ali, Husayni, & Power, 1988; Jirimutu et al., 2012). 
1.1.2 Unique genetic characteristics of camels 
Although camels have huge economic, cultural, and biological significance, 
very little is reported about the camel genome and the evolutionary preferences it 
confers. Camels along with other domestic animals and livestock, possess unique 
attributes and genetic variations (Andersson & Georges, 2004). The camel genome is 
nearly 2.38 gigabases and encodes around 20,821 genes (Jirimutu et al., 2012).  
Recent genomic and transcriptomic studies have unlocked the characteristics 
of the unique adaptations in camels (Jirimutu et al., 2012; Wu et al., 2014). 
Researchers have explored the importance of ‘rapidly evolving genes’ in species 
differentiation and adaptation in camels (Kasahara et al., 2007; Ming et al., 2017; 
Muyldermans et al., 2009). Fast divergence of protein-coding genes are typically 
estimated by a high ratio of non-synonymous-to-synonymous substitutions (dN/dS) 
(Jirimutu et al., 2012). Jirimutu et al. (2012) reported approximately 2,730 notably 
faster evolving genes in camels compared its adjacent cattle orthologs. Importantly, 
these genes were augmented in metabolic pathways such as lipid and carbohydrate 
metabolism, adipocytokine signaling pathways, and insulin signaling pathways.  
They suggested that these genes might have assisted the camel to enhance their 
energy storage and production in the desert. 
Camels are ruminant herbivores with a large forestomach. Nevertheless, they 






mammals. Cytochrome 2E (CYP2E) and cytochrome 2J (CYP2J) genes, which 
belong to a set rapidly evolving genes, could be associated with type II diabetes 
mellitus (Jirimutu et al., 2012). Phosphoinositide 3-kinases (PI3K) and protein kinase 
(PKB) are two crucial genes in the insulin signaling pathway that has seen rapid 
divergence in camels and could have altered their sensitivity to insulin (Ming et al., 
2017). This reinforces earlier findings that a higher glucose blood level in camels is 
primarily due to their high insulin resistance (Kaske, Elmahdi, Engelhardt, & 
Sallmann, 2001). Additionally, cytochrome P450 (CYP450) genes distribution has 
also be reported to be different in camels compared to other mammals. CYP genes 
are principally involved in arachidonic acid metabolism. Interestingly, an analysis of 
the Bactrian camel genome revealed more copies of CYP450 genes. For instance, 
camels have eleven copies of CYP2J gene and two copies of CYP2E gene compared 
to other mammals including humans. However, copies of CYP4A and CYP4F genes 
were found to be lower in camels in comparison to other mammals (Jirimutu et al., 
2012). CYP2E and CYP2J support to convert arachidonic acid into 19(S)-hydroxy-
eicosatetraenoic acid [19(S)-HETE], while CYP4F and CYP4A convert it into 20-
HETE (Wu et al., 2014). 19(S)-HETE is a strong vasodilator of renal preglomerular 
vessels that potentiate water reabsorption and is particularly important for its survival 
in deserts (Carroll et al., 1996). Several copies of CYP2J genes enable them to 
withstand high amount of salt without exhibiting hypertension (Wu et al., 2014). The 
prime activity of CYP2J2 gene is controlled by high-salt diet and the inhibition of 
this gene can lead to high blood pressure (Zhao, Pollock, Inscho, Zeldin, & Imig, 
2003). The impact of extreme desert conditions results in substantial increase in 
sodium levels of serum, urea, creatinine, and plasma arginine vasopressin (AVP) 






1988). These findings support earlier studies that demonstrated that renin-angiotensin 
system is vital for the regulation of water balance during dehydration. Additionally, 
studies have also shown an upsurge of serum creatinine and serum urea levels in 
dehydration (Finberg, Yagil, & Berlyne, 1978; Siebert & Macfarlane, 1971). Camels 
also have the inherent ability to survive starvation while maintaining a consistent 
nitrogen level via urea-nitrogen recycling (Mousa, Ali, & Hume, 1983).  
Camels are comparatively more resistant to many infectious diseases, 
compared to other mammals residing in the same terrestrial area. However, the 
immunogenome of camel remains elusive (Burger, 2016; Muyldermans et al., 2009; 
Wernery & Kaaden, 2004). The camel’s immune system comprises of a unique 
heavy chain antibody homodimer. More importantly, camels are the only mammals 
that possess heavy-chain antibodies (HCAbs) that is devoid of the light chain 
(Hamers-Casterman et al., 1993; Tillib, Vyatchanin, & Muyldermans, 2014). 
However, very little is known about the major histocompatibility complex (MHC) 
region of the camel genome (Antczak, 2013). The immune response (IR) genes that 
demonstrate a critical role in host–pathogen interactions are present in the genomic 
MHC region (Janeway, Travers, Walport, & Shlomchik, 2001).  
1.1.3 The model protein, camel hemoglobin 
The protein hemoglobin is abundantly present in red blood cells (RBCs) or 
erythrocytes. Hemoglobin is the oxygen carrying protein that gives the typical red 
color to blood. Adult vertebrate hemoglobin is composed of four protein chains, two 
 chains and two  chains. These chains were produced as a result of gene 
duplication (Storz, 2016). A ferrous ion (Fe
2+






in each chain acts as a cofactor for this tetrameric protein. Oxygen is transported in 
blood by reversibly binding to these Fe
2+
 ions. Structurally, hemoglobin chains retain 
the classic globin fold, which is shared by several proteins. Myoglobin, for example, 
a monomer, retains the same fold albeit with just around 25% sequence identity to 
hemoglobin. 
Camel hemoglobin contains more charged amino acid residues and are more 
hydrophilic than hemoglobins of other mammalian species (Bogner, Csutora, 
Cameron, Wheatley, & Miseta, 1998). The availability of a three dimensional X-ray 
crystal structure of the camel hemoglobin molecule now permits structural 
comparisons of this molecule with that of several other well-studied species 
including humans, rats and mice (Balasubramanian, Moorthy, Neelagandan, & 














Figure 1: Three dimensional structure of camel hemoglobin (PDB ID: 3GDJ) with  
chains shown in red and  chains shown in green. The heme group is shown in blue 
stick representation. 
 
1.2 Relevant literature  
Camels play an important role in less economically compromised parts of 
Asian, Arabian, and African deserts. Camels have been used as a source food, for 
transportation, and for protection for a very long time. Currently, they are 
enormously vital in various parts of the scorched world as sustainable livestock 
species (Burger, 2016). Camels belong to Camelidae family. The Camelidae family 
could be traced back to North America approximately 35 million years ago during 
the Eocene period (Reed, 1972). Camels are broadly classified into two major types – 
small and large camels – which are further subdivided into Camelus, Lama, and 






Nevertheless, the most frequently used and known classification is given in Figure 2 
(Wu et al., 2014). Irrespective of their classification, camels are usually differentiated 
based on habitat, function, and color. Camels has roughly the same shape but deviate 
in body size, color, and conformation (Al-Swailem et al., 2010). The large camelids 
comprise of two domestic species: the single-humped dromedary camel Camelus 
dromedarius, and the two-humped Bactrian camel Camelus bactrianus. Dromedary 
camels are also referred to as Arabian camels and are predominantly found in the hot 
and barren region between the northern part of Africa and east of Asia. The 
domestication of dromedary camel first started around five thousand or six thousand 
years ago in the Arabian peninsula (Almathen et al., 2016; Trinks, Burger, Beneke, 
& Burger, 2012). Bactrian camels are primarily found in deserted areas of central 
Asia and colder regions. The llama and the alpaca are the two members of small 
camelids which are limited to South America. 
 






1.2.1 Camel hemoglobin 
Camel red blood cell (RBC) is a fascinating case study of adaptation to severe 
environmental conditions (Oyewale et al., 2011). It has been well established that the 
shape of the erythrocytes in all mammals is spherical or concave. However, camels 
erythrocytes are extremely enucleated, ovaloid, small, flat, and circulates in large 
numbers (Azwai, Abdouslam, Al-Bassam, Al Dawek, & Al-Izzi, 2007; 
Goniakowska-Witalinska & Witalinski, 1976). This unique elliptical shape of camel 
erythrocytes enables their flow in dehydrated conditions and permit them to cross 
small capillaries (Eitan, Aloni, & Livne, 1976). Moreover, camel RBCs are 
extremely resistant to osmotic hemolysis and has the ability to swell up to 240% of 
their normal volume without rupturing (Oyewale et al., 2011). It is believed that this 
could be because of different arrangement of membrane phospholipids in its 
erythrocytes (Wardeh, 2004). There are several possible hypotheses on how the cells 
could survive severe osmotic shock. This includes: (1) erythrocyte membrane 
plasticity and its composition (Eitan et al., 1976); (2) variations in the cytoskeleton 
molecules of camel erythrocyte including erythrocytic spectrin (Ralston, 1975); (3) 
the water holding capacity of camel hemoglobin and its packaging inside the 
erythrocyte (Bogner et al., 2005); (4) the concentration of energy rich compounds in 
the erythrocyte cytosol, including adenosine triphosphate (ATP), 2,3-
bisphosphoglycerate (2,3-BPG) and cofactors such as chloride ions and its binding 
affinity to hemoglobin in different stages of osmotic stress (Garby, Gerber, & De 
Verdier, 1969). 
Camels have inherent ability to survive without drinking water for longer 






conditions. Studies have shown that a dehydrated camel can regain the lost water 
(approximately 30 gallons) within 10 minutes. Notwithstanding, the high flow of 
water into the bloodstream, camel’s erythrocytes remained intact (Perk, 1963). 
However, in humans entry of only 600 ml of water into the blood circulation cause 
hemoglobinuria (Perk, 1963). It has been suggested that the ability of camel 
erythrocytes to resist high dilutions are due to higher binding capacity of camel 
erythrocytes with water (Perk, 1963). 
Studies have shown that 2,3-bisphosphoglycerate (2,3-BPG)  and ATP 
interact with hemoglobin and substantially decreases its affinity for oxygen (Chu, 
Breite, Ciraolo, Franco, & Low, 2008; Macdonald, 1977). The hemoglobin 
oxygenation is critically controlled by the 2,3-BPG levels in the RBCs (Berg, 
Tymoczko, & Stryer, 2002). 2,3-BPG is the most abundant phosphate compound 
present in red blood cells and is generally formed from the rearrangement of 1,3 
bisphosphoglycerate during glycolysis (Chen, Yu, Zulfajri, Lin, & Wang, 2017). The 
presence of 2,3-BPG and ATP in erythrocytes promote the unloading of oxygen in 
tissue capillaries and subtle changes in their levels could substantially affects the 
release of oxygen. The molecular binding of 2,3-BPG and ATP with human 
hemoglobin has been explored using in vitro and in silico studies (Gerber, Berger, 
Jänig, & Rapoport, 1973; Lennon, Scott, Chapman, & Kuchel, 1994). However, the 
stability of binding residues, especially critically important residues of human and 
other mammalian hemoglobin, with these abundantly present co-factors under 







    The cryptome is a part of the proteome that forms cryptic peptides with 
important biological activities (Pimenta & Lebrun, 2007). The cryptome is naturally 
incorporated in protein sequences and has the ability to form multiple biologically 
active peptides called cryptides when exposed to proteolytic cleavage (Ivanov, 
Karelin, Philippova, Nazimov, & Pletnev, 1997; Pimenta & Lebrun, 2007). Cryptides 
produce similar or, entirely different biological activities, compared to the protein 
from which it was excised. Lately, numerous cryptides have been reported and their 
putative pharmacological activities in several diseases have been described (Fesenko 
et al., 2019; Gaglione et al., 2019; Haines et al., 2019). Hemorphins are known 
endogenous cryptides. They belong to the family of atypical opioid peptides and are 
released during the serial degradation of hemoglobin proteins (Blishchenko et al., 
2005; Jinsmaa & Yoshikawa, 2002). Generally, opioid peptides are roughly divided 
into typical and atypical opioid peptides. Typical opioid peptides include 
enkephalins, betaendorphins and dynorphins. These bioactive peptides are formed by 
the degradation of proenkephalin, proopiomelanocortin and prodynorphin, 
respectively, and possessed the same N-terminal amino acid sequence tyrosine-
glycine-glycine-phenylalanine (Goldstein, Tachibana, Lowney, Hunkapiller, & 
Hood, 1979; Hughes et al., 1975). Sequential lysis of some proteins releases another 
group of peptides known as atypical opioid peptides. Casomorphins, cytochrophins, 
and hemorphins, produced from casein, cytochrome b, and hemoglobin, respectively, 
belong to this group (Brantl et al., 1985). All atypical opioid peptides possess a 
single common factor, which is an N-terminal tyrosine residue. Compared to typical 






residue at the N terminal is possible in atypical opioid peptides (Teschemacher, 
1993). 
Hemorphins are 4–10 amino acid long bioactive peptides formed by the 
sequential degradation of hemoglobin proteins (Brantl et al., 1985). The initial well-
characterized hemoglobin-derived peptide was hemorphin-4 obtained from bovine 
blood (Brantl et al., 1986). Afterwards, Glamsta and colleagues described longer 
isoforms of hemorphins in the human pituitary (Glamsta et al., 1991). Serial cleavage 
of hemoglobin generates a chain of biologically active peptides with overlapping 
sequences. These endogenous peptides have been identified and produced from 
several biological fluids such as brain, plasma, hypothalamic tissues, cerebrospinal 
fluids, pituitary glands, peripheral and central nervous systems, and adrenal tissues 
(Glamsta, Meyerson, Silberring, Terenius, & Nyberg, 1992). Studies have reported 
the association of hemorphins to several physiological and pathological conditions 
such as long distance running, inflammation, cancer, and cerebrovascular bleeding 
(Glamsta et al., 1992; Sanderson, Andren, Caprioli, & Nyberg, 1996). These peptides 
are also produced during alteration from usual behavior and the action of certain 
enzymes in particular tissues (Ivanov et al., 1997). These bioactive short peptides 
contain an essential tetrapeptide core - tyrosine-proline-tryptophan-threonine 
(YPWT) (Nyberg, Sanderson, & Glamsta, 1997). Extended hemorphin peptides have 
been produced in human and bovine tissues due to N- and C- terminal extensions of 
this core sequence (Glamsta et al., 1992). Known hemorphin peptides of different 
lengths are given in Table 1. Amongst all known hemorphins, LVV-hemorphin-7 and 
VV-hemorphin-7 are considered to be the longest and most stable form of 






enable them to cross the blood-brain barrier (BBB) (Glamsta et al., 1992). The 
sequence of hemorphin is highly conserved among mammals. Several studies have 
reported promising therapeutic potential of hemorphins in various disorders (Ali, 
Baby, Soman, & Vijayan, 2019; Cheng, Tao, Cheng, & Huang, 2012). Nevertheless, 
the detailed cellular and molecular mechanisms that trigger the interaction of 
hemorphins and their targets remain elusive. 
Table 1: Sequence of hemorphin peptides. 
Name Amino acid sequence 
Hemorphin-4 Tyr-Pro-Trp-Thr (YPWT) 
Hemorphin-5 Tyr-Pro-Trp-Thr-Gln (YPWTQ) 
Hemorphin-6 Tyr-Pro-Trp-Thr-Gln-Arg (YPWTQR) 
Hemorphin-7 Tyr-Pro-Trp-Thr-Gln-Arg-Phe (YPWTQRF) 
LVV-hemorphin-4 Leu-Val-Val-Tyr-Pro-Trp-Thr (LVVYPWT) 
LVV-hemorphin-5 Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln (LVVYPWTQ) 




1.2.3 Therapeutic properties of hemorphins 
Hemorphin-4 (YPWT) was the first short hemorphin peptide obtained from 
hemoglobin. This peptide was extracted from bovine blood that was subjected to a 
mixture of gastrointestinal enzymes (Lau & Dunn, 2018). After that, a number of 
other peptides, such as hemorphin-4 to -7 and LVV-hemorphin-4, -6, and -7, were 
identified that also have the YPWT sequence (Dagouassat, Garreau, Sannier, Zhao, 
& Piot, 1996; Moisan et al., 1998). These peptide are generally formed in the 






Philippova, Karelina, & Ivanov, 1994). Different lengths of hemorphins have been 
associated with several biological activities such as pharmacological actions on 
spatial learning, inflammation, analgesia and transient hypotension (Cheng et al., 
2012; Lee et al., 2004). Out of all hemorphins, LVV-hemorphin-7 (LVV-H7 or 
LVVYPWTQRF) is the longest with 10 amino acids. Several reports have indicated 
that LVV-hemorphin-7 is the most hydrophobic peptide and is abundantly present in 
mammalian central nervous system (CNS) (Karelin et al., 1994; Moeller et al., 1997). 
The existence and discovery of different opioid binding sites in the 
mammalian brain started several studies to determine their precise natural ligands. 
Met- and Leu-enkephalin were the earliest endogenous opioid peptides to be reported 
(Hughes et al., 1975). After that, different bioactive peptides were reported that were 
released from controlled cleavage of protein precursors. Classical opioid peptides 
such as enkephalins, dynorphins, and -endorphins are produced by the lysis of 
proenkephalin, prodynorphin and proopiomelanocortin, respectively. These are 
mostly present in the CNS (Kakidani et al., 1982). Three opioid receptors namely , 
, and  have been investigated extensively. Several groups of peptides are produced 
as a result of partial proteolysis of proteins. For example, cytochrophins are produced 
from mitochondrial cytochrome b, casomorphins released from the milk protein -
casein, and hemorphins derived from hemoglobin (Karelin et al., 1994). Investigating 
the agonistic activity of peptides to opioid receptors is of great importance as their 
binding produces profound analgesia in inflamed tissue (Stein, Schäfer, & 
Machelska, 2003). Studies have illustrated that hemorphins could also bind to opioid 
receptors (Glamsta et al., 1992). Moreover, a study conducted on electrically 






demonstrated that hemorphin-5, -6, and -7 possessed opioid-like activity. Glucose 
phosphate isomerase (GPI) bioassay has shown agonistic opioid-like effects of 
different hemorphins (Zadina, Kastin, Kersh, & Wyatt, 1992). Furthermore, opioid 
receptor affinity of hemorphin was evaluated in membranes from rat brain and the 
findings indicated IC50 values in the micromolar range (Yukhananov, Glämsta, & 
Nyberg, 1994). Additionally, studies have also suggested that hemorphins mimic 
opioid peptides in terms of their analgesic activities. A dose-dependent 
antinociceptive response of hemorphins have also been reported in mice (Davis, 
Gillespie, & Porreca, 1989). Chow and colleagues have also reported that intrathecal 
doses of angiotensin IV (Ang IV) and LVV-hemorphin-7 causes anti-hyperalgesia in 
rats (Chow et al., 2018). The proposed binding of hemorphins and canonical opioid 
receptor signaling is given in Figure 3. 
 
Figure 3: Proposed pharmacological action of hemorphinson different opioid 
receptors and its regulation of signaling pathways leading to analgesia. Analgesic 
effects of μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor 
(DOR) are mainly correlated with Gi-protein signaling.  Hemorphins exhibit its pain 
killing effects by activating the MOR induced Gi-dependent signaling pathway. The 
pharmacological action of hemorphin on DOR and KOR are remain elusive. + 






Hypertension is considered to be one of the most significant health problems 
that prevail globally. The mortality rate is highly dependent on its timely discovery 
and management. Worldwide, approximately 13.5% of total deaths are associated 
with hypertension (Lawes, Vander Hoorn, & Rodgers, 2008). Recent studies also 
suggest that hypertension affects approximately 972 million adults and this number is 
expected to further increase up to 1.56 billion by the year 2025 (Kearney et al., 
2005). Hypertension is also considered to be one of the major risk factors for 
disorders related to the heart and contributes to over nine million deaths every year 
(Sawicka et al., 2011). The pathophysiology of hypertension is extremely 
complicated, and it involves various risk factors such as stress, smoking, and 
consumption of alcohol, elevated sodium, genetics, obesity and some environmental 
factors. Apart from these factors the activity of the renin-angiotensin system (RAS) 
has also been observed to play a well-known role in the pathogenesis of hypertension 
(Schütten, Houben, de Leeuw, & Stehouwer, 2017). 
The zinc metallopeptidase angiotensin-I converting enzyme (ACE) is found 
in many tissues and biological fluids and is one of an important player in regulating 
RAS and kallikrein-kinnin system (KKS). ACE causes hypertension by two 
mechanisms. Firstly, two amino acids are cleaved by ACE from the decapeptide 
angiotensin I for producing the octapeptide angiotensin II which is a relatively 
stronger vasoconstrictor. Secondly, ACE is associated with the degradation of 
bradykinin which is considered a potent vasodilator (Ondetti, Rubin, & Cushman, 
1977; Priyanto et al., 2015). ACE is linked closely to hypertension and is an 
important target for discovering the anti-hypertensive drugs as a result of these 






these drugs are limited in their use because of well-documented side effects such as 
angioedema, kidney problems, cough and allergic reactions (Yu et al., 2018). In 
addition to that, increase in the incidence of cardiovascular diseases has led the 
search for safer and novel alternatives.   Endogenous or biologically active peptides 
are a few of the alternatives that are being considered and explored due to their long-
term regulation of tissue homeostasis, high bioavailability, and better safety profile 
(Iwaniak, Minkiewicz, & Darewicz, 2014; Wang, Chen, Fu, Li, & Wei, 2017). 
It has been demonstrated that hemorphins have beneficial effects in the 
control of blood pressure. The observations also revealed that hemorphins can 
significantly reduce blood pressure in hypertensive rats (Cejka, Zelezna, Velek, 
Zicha, & Kunes, 2004). Additionally, it has been reported in various studies that anti-
hypertensive effects are produced by hemorphins while inhibiting ACE, the key 
component of RAAS (Fruitier-Arnaudin, Cohen, Bordenave, Sannier, & Piot, 2002; 
Lantz, Glämsta, Talbäck, & Nyberg, 1991).  
RAS in the brain is believed to be involved in processes other than 
homeostatic control. It has been associated with neuronal differentiation, nerve 
regeneration, learning and memory (Lee et al., 2004). Ang IV has been associated 
with various physiological functions, including the facilitation of memory (Albiston 
et al., 2004; Moeller et al., 1997). LVV-hemorphin-7 was recognized as an 
endogenous high-affinity ligand of the presumed angiotensin IV receptor (AT4R) 
(Moeller et al., 1997). Further studies characterize this putative receptor and 
indicated that this protein was analogous to IRAP, a type II integral membrane 
protein whose catalytic activity is inhibited by LVV-hemorphin-7 and Ang IV (Lee 






that LVV-hemorphin-7 could play a pivotal role in learning and memory. When an 
intracerebral administration of LVV-hemorphin-7 was carried out, it enhanced the 
spatial learning in rats and lessened the effects of scopolamine-induced learning 
deficits in spatial learning tests and fear conditioning (Albiston et al., 2004). LVV-
hemorphin-7 has also been shown to modify the behavior of rats. Additionally, LVV-
hemorphin-7, reduced depression and increased locomotion in rats. However, this 
depended on the activation of oxytocin receptors most likely due to changes in the 
oxytocinase activity of AT4R (Da Cruz et al., 2017). It was presumed that by 
inhibiting IRAP activity, LVV-hemorphin-7 protects the substrates of IRAP such as 
oxytocin and vasopressin. These substrates play a key role in memory and learning 
(Engelmann, Wotjak, Neumann, Ludwig, & Landgraf, 1996). In vivo microdialysis 
showed that LVV-hemorphin-7 improved spatial working memory without a 
significant increase in blood flow or hippocampal glucose uptake (De Bundel et al., 
2009). 
1.2.4 Molecular mechanism of the interaction of hemorphins and their targets 
Several in vitro studies have shown the high stability of hemorphins, 
specifically LVV-hemorphin-7 in human plasma and tissue (Lantz et al., 1991;  
Sanderson, Nyberg, & Khalil, 1998). Furthermore, in vivo studies have demonstrated 
that peptidase enzyme present in extracellular fluid, especially amastatin-sensitive 
amino peptidase, cleaves hemorphin peptide (Nydahl, Pierson, Nyberg, Caprioli, & 
Andren, 2003). Nevertheless, LVV-hemorphin-7 has shown high stability in the 
blood for longer periods of time when incubated with numerous proteolytic enzymes. 
Notably, resistance of LVV-hemorphin-7 to proteolytic cleavage could be of major 






Forssmann, 2007; Sanderson et al., 1998). Hemorphins exist not only in blood, but 
also in numerous organs and brain regions, such as adrenal, hypothalamus and 
pituitary glands. Hemorphins have been reported to be involved in several cellular 
and molecular mechanisms and determining the complex molecular interactions is a 
challenging task. Based on previous reports, hemorphins have been revealed to 
interact with opioid, RAS, immune and neuroendocrine and immune systems (Figure 
4). 
Ligand-dependent biased signaling is an interesting concept in the field of 
GPCRs pharmacology where the same receptor could exhibit either Gi-dependent 
signaling pathway or β-arrestin-dependent signaling pathway based on the bound 
ligand.  opioid receptor (MOR) induced analgesia is correlated with Gi-dependent 
signaling whereas β-arrestin-dependent signaling is linked with different side effects 
such as constipation and respiratory. Hemorphins demonstrate their activities by 
activating the Gi-dependent signaling of MOR. Nevertheless, MOR β-arrestin-2 
associated activity of hemorphins are still unknown. The putative action of 
hemorphins on KOR and DOR, however, remain elusive. Hemorphins may also 
produce selective agonism through the recruitment of β-arrestin-2 and internalization 









Figure 4: Therapeutic targets of hemorphins and the molecular mechanism of action. 
Blocked, dashed, and pointed, represent inhibition, release of ions, and activation of 
target, respectively.  
1.3 Statement of the problem 
Hemoglobin is one of the well-characterized and widely studied protein 
genetically, biochemically, and structurally. Studies have elucidated the structural 
and genetic variations amongst the mammalian hemoglobin. However, camel 
hemoglobin has not been greatly explored. Some physiological and biochemical 
studies have been performed on camel hemoglobin. However, very little is known 
from a structural perspective. Therefore, a comparative study principally focused on 






the camel hemoglobin behaves in varying conditions of osmolarity and temperature 
that it is normally susceptible to in contrast to human hemoglobin. 
The co-factors ATP and 2,3-BPG are abundantly present in RBCs and are 
involved in the release of oxygen molecule during hypoxic and dehydrated 
conditions. Several studies on different mammals including humans have shown that 
ATP, and 2,3-BPG preferentially bind to β subunits of hemoglobin and helps in the 
unloading of oxygen molecules into tissues. Despite the inherent ability of camel to 
survive severe dehydrated conditions, the role of these energy molecules in camel 
hemoglobin have not been studied yet. Hence, it would benefit from a comparative 
investigation aimed at elucidating the molecular interactions of these molecules with 
camel and human hemoglobin under different stress conditions such as different 
conditions of temperature and salt concentrations in greater depth. 
Several bioactive peptides are generally produced from proteolytic 
degradation of precursors proteins including hemoglobin. Numerous studies have 
identified the existence of several hemoglobin derived peptides such as hemorphins 
from different mammals including humans and these have been shown to diverse 
biological activities. However, functional and biological activities of camel 
hemoglobin derived peptides remain elusive. Thus, it is important to identify the 
genetic variations among these bioactive peptides in closely related mammals and 
determine the impact of small variation on the overall functioning of the therapeutic 








1.4 Hypothesis and objectives 
The physiological function of camel hemoglobin is not affected by sudden 
changes in osmolarity and temperature. This is an evolutionary advantage for 
dromedaries to endure the dehydration. The main hypothesis is that the extreme 
adaptive features of camel hemoglobin could be attributed to its primary as well as 
quaternary structures and its interaction with co-factors. The overreaching aim of this 
study was to determine the structural and genetic variations of camel hemoglobin and 
to identify the activity of hemoglobin-derived biologically active peptides. This 
project adopted computational modeling and molecular approaches to investigate 
several aspects of camel hemoglobin to address these issues. 
The objectives of this study are to: 
1) Study the behavior of camel hemoglobin protein under a range of osmolarity and 
temperature variations using long time scale molecular dynamics (MD) 
simulations under different salt and temperature conditions. 
2) Compare the binding of ATP and 2,3-BPG in camel and other mammalian 
hemoglobin structures using binding site analysis, molecular docking and MD 
simulations to identify any mechanistic differences in the action of these 
molecules.  
3) Sequence and analyze  and  hemoglobin genes to identify SNPs in camels 
belong to different breeds to identify SNPs that could potentially be correlated 






4) Identify the most likely binding pose of human or other mammals and camel 
LVV-hemorphin-7 with ACE, MOR and IRAP and to calculate the binding 
affinity using molecular docking and MD simulations. 
5) Investigate the binding and activation of AT1R by human and camel LVV-
hemorphin-7 by in silico approaches and in transfected human embryonic kidney 








Chapter 2: Methods 
2.1 Ethical approval 
Ethical approval was obtained from United Arab Emirates University to 
collect blood samples. Ethical approval no: ERA_2017_5655, was granted on 24 
January 2018. 
2.2 Sample collection and storage condition 
10 ml of whole blood was taken from three different breeds of camels (50 
Sudani, 50 Omani, 50 Mixed breeds, and 20 dairy) into vacuum collection tubes 
containing dipotassium EDTA (Ethylene Diamine Acetate) and transferred to the 
Department of Biology, United Arab Emirates University, for further analysis. In 
ordered to store them for longer period of time, all blood samples obtained in EDTA 
tubes were stored at -50°C in the Molecular Biology Lab of the Department of 
Biology. 
2.3 DNA extraction 
DNA was isolated from camel blood using Norgen blood DNA isolation kit 
(Norgen Biotek, Canada) following manufacturer’s guidelines. Briefly, 20 µl of 
proteinase K was added to the microcentrifuge tube and 200 µl of camel blood was 
then added to the same tube. After that, 300 µl of lysis buffer B was added to the 
tube containing blood and peoteinase K, and was vortexed for 10 seconds. After 
mixing the reaction mixture, the centrifuge tubes were incubated for 10 minutes at 
55ºC.  After incubation, tubes were briefly spun and 110 µl of 96% ethanol was 
added to each tube containing the samples and mixed well by vortexing for 10 






with the kit. Reaction mixture from each tube was transferred to the column and 
centrifuged for 1 minute at approximately 8,000 rpm. Flowthrough was discarded 
and columns were reassembled again with the collection tube. After that, the column 
was washed with washing buffer provided with the kit in two steps by adding 500 µl 
of washing buffer in each step and centrifuged for 1 minute at 8000 rpm. After each 
step of washing, the flowthrough was discarded and columns were assembled with 
new collection tubes. In order to dry the columns, the columns were centrifuged for 2 
minutes at 14000 rpm and collection tubes were discarded. Next, the columns were 
placed into the elution tubes provided with the kit and approximately 200 µl of 
elution buffer was added to each column. The elution tubes containing elution buffer 
and column were incubated at room temperature for 1 minute.  After incubation, the 
elution tubes were centrifuged at 8000 rpm for 1 minute. After eluting the DNA, the 
quality and quantity of DNA was measured by loading 1 µl of extracted DNA in 
NanoDrop 2000/c (Thermo Fisher Scientific, USA) which is a microvolume 
spectrophotometers. After that, the extracted DNA samples were stored at -20ºC.  
2.4 Primers 
The sequence of camel hemoglobin  and  genes were retrieved from 
National Center for Biotechnology Information (NCBI) browser. Several overlapping 
primers were designed using Primer-Basic Local Alignment Search Tool (BLAST) 
to amplify the full genes of hemoglobin α and . Melting temperature and Guanine 
Cytocine (GC) content of each primer were also determined. Designed primers were 
purchased from Macrogen (Korea). The optimum conditions for the primers were 
then determined experimentally. The list of primers and their optimal conditions are 






Table 2: Primer sets used in PCR to amplify hemoglobin  and  genes. 
Forward (F) / 
Reverse (R) 





F GCACACTTCCGATCCTGACCTA  
45 
 
59 R GCTTAACGGTATTTGGAGGTC 
F CCCATCATGGTGCTGTCTTCC  
37 
 
57 R CGGTATTTGGAGGTCAGCACG 
F CTGGGCATAAAAGGAAGAGCAG  
31 
 
54 R GCATAGGTGCCCTTGAGGTT 
F GGTGCTAAACTCCTTTGGTG  
38 
 
59 R GACAGAGGCCAGATGCTCAA 
F CTCACATCAAGAGCAACCTC  
36 
 
54 R GAGGTTGCTCTTGATGTGAG 
F ACCTTCTTGCCATGGGCCTTG  
38 
 
59 R CAAGGCCCATGGCAAGAAGGT 
 
2.5 PCR amplification and purification 
In this study a premixed ready-to-use solution called the Go Taq® Green 
Master Mix (Promega, USA), was used. Go Taq® Green Master Mix comprises an 
optimal concentration of dNTPs, Taq DNA polymerase, MgCl2 and reaction buffers. 
A total reaction volume of 50 µl was prepared and used for each PCR run. For 
amplification of hemoglobin genes, 2 µl of extracted DNA from each sample, 1.5 µl 
of forward and reverse primers, 25 µl of green master mix, and 20 µl of deionize 
water were added to each PCR tube. The following reaction conditions were used in 
the Thermal Cycler: 1 cycle of pre-denaturation for 3 minutes at 95ºC for 3 minutes, 
followed by 34 cycles of denaturation at 95ºC for 30 seconds, annealing at specific 






one minute. After the amplification, amplified PCR products were visualized on 
1.5% (w/v) agarose gel using electrophoresis. After visualization of PCR products, 
the amplified PCR products were purified using the Norgen PCR purification kit 
(Norgen Biotek, Canada) following the manufacturer’s guidelines. For this purpose, 
the binding buffer provided in the kit was added in each PCR tube in 5:1 ratio to the 
PCR product. After the addition of binding buffer, the PCR tubes were briefly 
vortexed and pulse-spun. The mixture was then added into a column placed on the 
tube provided in the kit and centrifugation was performed for 1 minute at 8000 rpm. 
The flow-through was discarded and 500 µl of washing buffer (96-100% ethanol) 
was added to the column and again centrifugated for 1 minute at 10,000 rpm. The 
flow-through was discarded again and the spun for 2 minutes at 14,000 rpm in order 
to dry the column. After that, the column was assembled with the 1.7 ml elution tube. 
In order to obtain high concentration of DNA, 10 µl of elution buffer was added to 
the center of the column bed and kept standing at room temperature for 1 minute. 
After that, the column was centrifuged at 14, 000 rpm for 2 minutes. The last step of 
purification was repeated one more time. Finally, the quantity and quality of the 
purified amplified DNA was measured by loading 1 µl of purified DNA in 
NanoDrop 2000/c (Thermo Fisher Scientific, USA) which is a microvolume 
spectrophotometer. 
2.6 DNA sequencing and analysis 
Samples that fulfilled the quality and quantity required were sent for 
sequencing to Macrogen, (Korea). The sequences and chromatograms were provided 
by Macrogen which were then analyzed further. FinchTV chromatogram viewer 






Alignment Editor Version v7.0.5 (Tom Hall Ibis Therapeutics) as used to carry out 
sequence alignment. Reference sequences for hemoglobin  (NCBI Accession: 
105098415) and hemoglobin  genes (NCBI Accession: 105097953) were obtained 
from NCBI RefSeq database. 
2.7 Multiple sequence alignment of hemoglobin  protein 
NCBI protein database was used to obtain the hemoglobin protein 
sequences of Homo sapiens (NP_000509), Camelus dromedarius (XP_010988890), 
Equus caballus (XP_001504239), Bos taurus (NP_776342), Sus scrofa 
(NP_001138313), Ovis aries (NP_001091117), Pan troglodytes (NC_036890) and 
Oryctolagus cuniculus (NP_001075729). Multiple sequence alignment of these 
sequences was carried out using ClustalW (Thompson, Higgins, & Gibson, 1994). 
2.8 Generation of homology model 
In order to dock the hemorphin peptides to the human MOR, a homology 
model was developed using Schrödinger Prime. Briefly, a BLAST search of Protein 
Data Bank (PDB) was carried out to determine homologous protein structures. The 
X-ray crystallographic structure of the active MOR from Mus musculus (PDB ID: 
5C1M) was used as the template, with an overall sequence identity of 72%, to 
produce three-dimensional homology model of the active human MOR (UniProt 
accession: P35372). Protein refinement modules of Schrödinger Prime were used to 






2.9 Protein structure pre-processing 
PDB was used to retrieve three dimensional structures of MOR (PDB ID: 
5C1M), IRAP (PDB ID: 5MJ6), ACE (PDB ID: 2XY9), AT1R (PDB ID: 4ZUD), 
and hemoglobin (PDB ID: 3GDJ, 2HHB) (Akif et al., 2011; Fermi et al., 1984; H. 
Zhang et al., 2015a; H. Zhang et al., 2015b). Protein Preparation Wizard of 
Schrödinger Suite 2016-4 was used to pre-process the protein structure retrieved 
from PDB (Schrödinger, LLC, New York, NY). The preparation of protein involved 
a number of steps including the proper assignment of bond orders, adjustment of 
ionization states, orientation of disorientated groups, creation of disulphide bonds, 
removal of water molecules, metal and co-factors, capping of terminus amide, 
assignment of partial charges, and the addition of missing atoms and side chains. 
Hydrogen atoms were integrated and protonation state at pH 7 was used. In order to 
acquire a geometrically stable structure, optimization and minimization steps were 
carried out (Sastry, Adzhigirey, Day, Annabhimoju, & Sherman, 2013). 
2.10 Ligand preparation 
Two dimensional structures of 2,3 BPG and ATP were retrieved from 
PubChem. These two ligands were prepared and conformers were produced using 
Schrödinger Ligprep (Schrödinger, LLC, New York, NY). Briefly, preparation of 
ligands included conversion of 2D structures to 3D format, addition of hydrogen 
atoms, generation of tautomer and ionization states, neutralization of charged groups, 






2.11 Active site identification and grid generation 
A receptor grid was created, by using default parameters, around the active 
site of the prepared protein. Van der Waal’s scaling factor of 1 and a charge cutoff of 
0.25 were used for this purpose. Lastly, a cubic search space was made which 
focused specifically on the centroid of the active site residues of the studied drug 
targets. 
2.12 Peptide and ligand docking 
In order to predict the binding pose of hemorphins in MOR, IRAP, ACE and 
AT1R, as well as to measure the binding free energy, peptide docking was used. The 
Schrödinger Peptide Docking version 2016-4 was used to perform peptide docking 
with penalties for cis amide bonds (Schrödinger, LLC, New York, NY). All peptides 
were docked into active sites of the MOR, IRAP, ACE, and hemoglobin by using 
default parameters. Additionally, flexible ligand sampling was used to produce 
diverse ligand conformations by the ConfGen algorithm (Watts et al., 2010). The 
OPLS 2005 force field was used to describe the protein and peptide and post docking 
minimization was also executed in the gridded protein field. The GlideScore 
(GScore) scoring function was used to rank different poses (Friesner et al., 2006). 
Finally, the lowest GScore value of the top docked pose was reported for each 
peptide small ligands. 
For predicting the binding pose, activity and affinity of 2,3-BPG and ATP 
molecules with camel and human hemoglobin, ligand docking was carried out. Grid 
based docking was performed using Schrödinger Glide version 2016-4 (Schrödinger, 






followed by extra precision (XP) docking. To soften the potential of nonpolar parts 
of ligands, the scaling factor for the ligand van der Waals radii was set in 0.80 with a 
partial atomic charge of 0.15. In both SP and XP docking procedures, flexible ligand 
sampling was used to generate various ligand conformations. No constraints were 
used in the entire docking studies. Optimized Potentials for Liquid Simulations 
(OPLS) 2005 force field was used and post docking minimization was also carried 
out. Both 2,3-BPG and ATP were docked flexibly to camel and human hemoglobin 
structures. 
2.13 Analysis of docking results and binding free energy calculation 
Schrödinger Maestro was used to visualize and interpret interactions such as 
hydrogen bond interactions, π interactions and hydrophobic interactions involving 
the top pose (Schrödinger, LLC, New York, NY). Binding free energy calculations 
were performed using molecular mechanics-generalized born surface area (MM-
GBSA), in an implicit solvent model. These MM-GBSA based binding energies were 
estimated using the OPLS 2005 force field and Schrödinger Prime employing the 
VSGB 2.0 implicit solvent model (Li et al., 2011). For the purpose of MM-GBSA 
binding energy estimations, the receptor was treated rigidly and the peptide was 
minimized. 
2.14 Molecular dynamics (MD) simulations 
MD simulations were carried out to determine the protein dynamics and 
interaction stability of the top binding pose of the LVVYPWTQRF, 
LVVYPWTRRF, YPWTQRF, YPWTRRF, 2,3-BPG, and ATP in the active site of 






MD simulations of these ligand-protein complexes were carried out using Desmond 
employing the OPLS 2005 force field (Bowers et al., 2006). 
2.14.1 Simulation of membrane bound proteins 
Different systems of human and camel hemorphin peptides docked to MOR, 
and AT1R were prepared. Each of the peptide bound simulations were carried out 
with different initial velocities in triplicates for 100 ns and 500 ns, respectively. The 
complex structures of MOR and AT1R with hemorphin peptides were embedded into 
a pre-equilibrated DPPC membrane in an orthorhombic box. Each prepared system 
of hemorphin bound to MOR and AT1R were solvated using the single point charge 
(SPC) water model with a water box, and a buffer distance of 10 Å was maintained. 
In order to maintain a salt concentration of 0.15 mM NaCl, counterions and 
appropriate number of ions were incorporated. Prior to conducting MD simulations, 
each system was subjected to steepest descent minimization with Desmond’s default 
protocol.  
The default relaxation protocol for membrane proteins was used to initially 
relax the prepared systems. Eight stages of relaxation procedure encompassed 
minimization with constraint on solute heavy atoms, constraint free minimization, 
simulation with heating from 0 K to 300 K heating, H2O barrier and gradual 
constraining, simulation under constant number of particles, pressure and 
temperature NPT equilibration with H2O barrier with heavy atoms restrained, NPT 
equilibration of solvent and lipids, simulation in the presence of NPT ensemble with 
protein heavy atoms constraint decreased from 10.0 to 2.0 kcal/mol, NPT 






constrains  for 1.5 ns under the NPT ensemble. Finally, production simulation runs 
were carried out for 100 ns or 500 ns each system of MOR and AT1R, respectively.  
The simulation runs were carried out under NPT ensemble using the Nose-
Hoover thermostat to maintain a temperature of 300 K and isotropic Martyna-Tobias-
Klein barostat to maintain the pressure at 1 atm (Martyna, Klein, & Tuckerman, 
1992; Martyna, Tobias, & Klein, 1994). The short-range Coulombic interactions 
were investigated with a cut-off value of 9.0 Å using the short-range approach 
(Essmann et al., 1995). A time-reversible reference system propagator algorithm 
(RESPA) integrator was used with a time step of 2.0 fs (Tuckerman, Berne, & 
Martyna, 1992). For the purpose of analysis, the trajectories were saved at an interval 
of 100 ps. When simulation runs were finished, RMSD, RMSF, and protein-ligand 
contacts were evaluated. 
2.14.2 Simulation of non-membrane bound proteins 
Different systems of human and camel hemorphin peptides bound to ACE, 
and IRAP were prepared and each of the peptide bound simulations were carried out 
with different initial velocities in triplicates for 200 ns or 100 ns, respectively. 
Additionally, complex systems of 2,3-BPG and ATP with human and camel 
hemoglobin were prepared and simulated for 200 ns. Briefly, each complex system 
was solvated in an orthorhombic box by using the SPC water model, and a buffer 
distance of 10 Å was maintained (Schrödinger, LLC, New York, NY). In order to 
maintain a salt concentration of 0.15 mM NaCl, counterions and appropriate number 
of ions were incorporated. Prior to conducting MD simulations, each system was 






simulation runs were carried out under NPT ensemble using the Nose-Hoover 
thermostat to maintain a steady temperature of 300 K and isotropic Martyna-Tobias-
Klein barostat to sustain the pressure at 1 atm (Martyna et al., 1992; Martyna et al., 
1994). The short-range Coulombic interactions were investigated with a cut-off value 
of 9.0 Å using the short-range approach (Essmann et al., 1995). A time-reversible 
reference system propagator algorithm (RESPA) integrator was used with a time step 
of 2.0 fs (Tuckerman et al., 1992). For the purpose of analysis, the trajectories were 
saved at an interval of 100 ps. Lastly, root mean square deviation (RMSD), root 
mean square fluctuation (RMSF), and protein-ligand contacts of each complex 
system was determined from the trajectories. 
2.15 In vitro ACE inhibition assay 
The inhibition of ACE was assessed using the ACE Kit WST (Dojindo 
Laboratories, Mashiki-machi, Japan). Custom synthesized hemorphin peptides 
(LVVYPWTQRF, LVVYPWTRRF, YPWTQRF, and YPWTRRF) were purchased 
from New England Peptide (Gardner, MA, USA). Manufacturer’s instructions were 
followed for preparing the indicator working solution and enzyme working solution. 
From each hemorphin peptide, 10 µl of each dose was added to the wells of a 96-
well microplate. While, in blank 1 and blank 2, 20 µl and 40 µl of deionized water 
were added, respectively. A volume of 20 µl of the substrate buffer was added to 
each well. Next, 20 µl of enzyme working solution was added in all of the sample 
wells and blank 1. The plate was then immediately incubated at 37°C for 1 h. After 1 
h of incubation, 200 µl of indicator working solution was added to each well and 
then incubated for 5 min at room temperature. After 5 min of room temperature 






Microplate Reader (Promega, Madison, WI, USA). Finally, the ACE inhibitory 
activity was computed using the following equation: Inhibition rate (%) = (Ablank1 − 
Asample) / (Ablank1 − Ablank2) × 100. From the obtained ACE inhibitory data, IC50 was 
measured using Prism 7 (GraphPad, San Diego, CA, USA) from a non-linear 
regression plot of ACE inhibition (%) against peptide concentration (µM). 
2.16 cDNA constructs and ligands 
The human protein-coding plasmids, AT1R-RlucII, yPET–β-arrestin 2, and 
Venus-Gαq for the brief expression in HEK293 cells were generously provided by 
Dr Stéphane Laporte (McGill University, Montréal, QC, Canada), Dr Mark Scott 
(Cochin Institute, Paris, France), and Dr Nevin Lambert (Augusta University, GA, 
USA), respectively. Irbesartan and AngII (Sigma, St. Louis, MO, USA) and LVV–
hemorphin-7 (LVVYPWTQRF) (New England Peptide, Gardner, MA, USA) were 
used as ligands in this study. 
2.17 Cell culture and transfection 
HEK293 cells were kept at 37°C, 5% CO2 in complete medium (Dulbecco 
modified Eagle medium (DMEM) containing 100 IU/ml of penicillin, 100 µg/ml of 
streptomycin, and 0.3 mg/ml of glutamine), complemented with 10% fetal calf serum 
(GIBCO BRL, Carlsbad, CA, USA). For bioluminescence resonance energy transfer 
(BRET) measurements, brief transfections were performed in 96-well plates. 
However, IP1 experiments were carried out in six-well plates using lipofectamine 
2000 (Invitrogen). Precisely, for BRET experiments, in each 96-well plate, 50 ng of 
either Venus-Gαq or yPET–β-arrestin 2 was mixed with 25 ng of AT1R-Rluc in 25 






serum-free DMEM containing 0.5 µl of Lipofectamine 2000 was added in the 
plasmid solution and kept at room temperature for 20 min. Finally, 96 well plates 
were seeded with cells (10
5
 in 150 µl/well) resuspended in DMEM complemented 
with 10% fetal calf serum (FCS) were then kept with the final DNA-Lipofectamine 
2000 mix (50 µl/well). All experiments were performed after 48 h transfection. 
2.18 Dose–response BRET assay 
For dose-response assays, BRET technology was used as mentioned earlier 
(Ayoub et al., 2015). Briefly, cells were initially washed with 50 µl/well of 
phosphate-buffered saline (PBS) and challenged at 37°C for 30 min with 40 µL of 
PBS containing or not (vehicle) the designated doses of either LVV-hemorphin-7, 
AngII (control), or AngII in the presence of the specified doses of LVV–hemorphin-
7. Immediately after treatment, 10 µl of coelenterazine h (Promega) in PBS was 
incorporated to a final concentration of 5 µM, and BRET signals were measured 
using the Tristar 2 multilabel plate reader (Berthold, Germany), permitting sequential 
measurements of light emission at 480 and 540 nm. While, for the antagonist assays 
using irbesartan, cells were initially incubated with 30 µl of irbesartan (10 µM) at 
37°C for 15 min before their stimulation with 10 µl of LVV–hemorphin-7 (10 µM) 
followed by the activation with 10 µl of AngII (10 nM) at 37°C for 30 min, and 
BRET measurements were carried out as mentioned above. 
2.19 Real-time BRET kinetic assay 
Several protocols were adopted for the real-time BRET kinetics. For this, 
cells were initially washed with 50 µl/well of PBS and resuspended in 40 µl/well of 






for approximately 5 min to estimate the baseline. While, in the direct protocol, 10 
µl/well of PBS with or not (vehicle) either 10 µM of LVV–hemorphin-7, 10 nM of 
AngII (control), or both, was added, after the baseline, and BRET reading were 
measured for 50 min. However, for sequential protocol, after the baseline, BRET 
readings were measured in real time upon two sequential treatments (T1 and then 
T2). This comprises of 10 µl/well of PBS with or not (vehicle) 10 µM of LVV–
hemorphin-7 (T1) and BRET signals were measured for 10 min. Immediately after 
that, 10 µl/well of PBS with or not (vehicle) 10 nM of AngII were added and BRET 
signal were again measured for 25 min. Finally, the BRET measurements were also 
performed in opposite order (10 nM of AngII followed by 10 µM of LVV–
hemorphin-7) as discussed in results section of Chapter 5. 
2.20 IP1 accumulation assay 
Analysis of IP1 accumulation was carried out in HEK293 cells briefly co-
expressing either AT1R-Rluc with Venus-Gαq similar to previous BRET 
experiments or only untagged AT1R (AT1R-WT) with the help of IP-One Tb kit 
(Cisbio Bioassays, France) as per manufacturer’s instructions. For this set of 
experiments, cells were initially incubated or not (control) with 10 µM of LVV–
hemorphin-7 at 37°C for 15 min before activated or not (vehicle) with the different 
doses of AngII at 37°C for 30 min. After that, cells were lysed by using the available 
assay reagents, and the assay was kept at room temperature for 1 h. Finally, 
fluorescence emission was determined after excitation at 340 nm, at 620 nm and 665 






2.21 Data presentation and statistical analysis 
The data obtained from BRET experiments are given as the ratio of light 
emission at 540 nm over 480 nm was initially transformed into “ligand-induced 
BRET” signals by deducting the ratio obtained from vehicle-treated cells from the 
same ratio obtained from AngII/LVV–hemorphin-7–treated cells. Next, for BRET 
and IP1 experiments, % responses were obtained by taking the maximal AngII-
induced signal as 100% in the control condition in different assays. Additionally, the 
kinetic and the sigmoidal dose–response curves were adjusted to appropriate 
nonlinear regression equations using GraphPad Prism software (San Diego, CA, 
USA). The data being measured was demonstrated as mean ± SEM (Standard Error 
of the Mean). As appropriate, one- way or two-way analysis of variance (ANOVA) 
was carried out and Tukey multiple-comparisons test or Sidak’s multiple-
comparisons test was used to compare means for determining the degree of 






Chapter 3: Insights into the Interaction of Hemorphin and its Targets 
3.1 Results 
Extensive computational approaches were employed to investigate the 
binding mode and and binding stability of hemorphin peptides with MOR and IRAP. 
3.1.1 Multiple sequence alignment of hemoglobin  protein sequences 
The reference sequence of hemoglobin (HBB) proteins of closely related 
mammals were obtained from NCBI Protein database. Multiple sequence alignment 
was carried out using ClustalW to identify the similarities and differences in HBB 
protein sequences (Clustal, Thompson, Higgins, & Gibson, 1994). LVV-hemorphin-
7 is a 10 amino acids long peptide, and its sequence is highly conserved among 
mammals. It ranges from amino acid positions 32 to 41 in the HBB protein sequence 
in human, chimpanzee, camel, pig, and rabbit. In the bovine and sheep protein, it lies 
between amino acids positions 30 to 39, and in the horse, the LVV-hemorphin-7 is 
positioned between amino acids 31 to 40. The multiple sequence alignment results 
indicated a single amino acid substitution in the camel HBB protein at position 40, 
where glutamine has been substituted with arginine (Q > R). The remaining residues 







Figure 5: Sequence alignment of hemoglobin  protein sequences of closely related mammals - Homo sapiens (human), Pan troglodytes 
(chimpanzee), Camelus dromedarius (camel), Oryctolagus cuniculus (rabbit), Sus scrofa (wild pig), Equus caballus (horse), Bos taurus (bovine), 
and Ovis aries (sheep). Multiple sequence alignment showed a variation in camel hemoglobin at position 40, where glutamine was changed to 











3.1.2 Structure-based homology modeling of -type opioid receptor 
The X-ray crystallographic structure of MOR from Mus musculus (PDB ID: 
5C1M) was used as a template to generate the three-dimensional (3D) homology 
model of the active state of the human -type opioid receptor (MOR) (UniProt 
accession: P35372) (Figure 7). The generated structural model of the active MOR’s 
active conformation is similar to the conserved seven-transmembrane topology of G 
protein-coupled receptors (GPCRs). Additionally, the Ramachandran plot indicated 
that the produced model’s general stereochemical quality was good with nearly all 
the residues are in the permissible and favorable regions (Figure 6). 
 






3.1.3 Molecular docking 
The binding mode of both non-camel (LVVYPWTQRF) and camel 
(LVVYPWTRRF) LVV-hemorphin-7 peptides was determined through extensive 
docking and free energy calculations. For each binding mode the binding free 
energies were calculated with the help of molecular mechanics generalized Born and 
surface area (MM-GBSA) method. 
3.1.4 -opioid receptor 
The docking of both LVVYPWTRRF and LVVYPWTQRF peptides with 
MOR produced 10 models each. The top five docked poses of LVVYPWTQRF 
peptide produced the GScore of  -10.88  kcal/mol, -10.61 kcal/mol, -10.23 kcal/mol, -
9.83 kcal/mol, -9.35 kcal/mol and the calculated MM-GBSA binding free energies 
corresponding to these poses were -97.82 kcal/mol, -94.38 kcal/mol, -91.86 kcal/mol, 
-87.91 kcal/mol, and -84.79 kcal/mol, respectively. The top five docked poses of 
LVVYPWTRRF peptide produced the GScore of -10.65 kcal/mol, -10.53 kcal/mol, -
10.35 kcal/mol, -10.23 kcal/mol, -9.96 kcal/mol and the calculated MM-GBSA 
binding free energies corresponding to these poses were -108.35 kcal/mol, -115.07 
kcal/mol, -101.61 kcal/mol, -94.73 kcal/mol, and -91.89 kcal/mol, respectively. The 
list of interacting residues of the best pose of each peptide along with their respective 
Gscore and MM-GBSA binding free energy are provided in Table 3. The top-docked 
conformation of LVVYPWTQRF peptide demonstrated that the residues of the N-
terminal of the peptide formed interactions with residues in transmembrane helices 5 
and 6 (TM5 and TM6) present at the bottom of the binding site. The N-terminal 






interactions with TM6 residues Ile298, Tyr301, Val302, Ala306, and Val308. A 
hydrogen bond was formed between Leu1 and the backbone amino group of the 
hydrophilic Asn232 located on TM5. Tyr4 of the peptide produced interactions with 
Asp149 via a hydrogen bond and, along with Pro5, it exhibited hydrophobic 
interactions with Ile146 and Tyr150 located on TM3. However, Pro5, Trp6, and Thr7 
residues of LVVYPWTQRF formed interactions with Arg213, Ile217, Cys219, 
Thr220, and Leu221 on the  sheet. The C-terminal residues (Thr7-Gln8-Arg9-
Phe10) of LVVYPWTQRF peptide formed hydrophobic interactions with Trp320, 
His321, Ile324, and Tyr328 on TM7. His321 located on TM7 formed a π- π stacking 
with Trp6 and a hydrogen bond with Gln8. Additionally, Gln8 also produced 
hydrogen bonds with the side chain of the Glu312 situated on the third extracellular 






Table 3: Interacting residues of the best pose of non-camel (LVVYPWTQRF) and camel (LVVYPWTRRF) hemorphin with MOR, and IRAP. 
Protein Peptide Glide docking 

















Leu58, Pro61, Pro65, 
Tyr77, Tyr130, Met132, 
Ile146, Tyr150, Ile217, 
Cys219, Leu221, 
Trp228, Ile298,  Tyr301, 
Val302, Ala306, 









Ile146, Tyr150, Cys219, 
Leu221, Phe223, 
Trp228, Leu234, Ile236, 
Val238, Ile298, Val302, 
Ile303, Leu307, Val308, 












Table 3: Interacting residues of the best pose of non-camel (LVVYPWTQRF) and camel (LVVYPWTRRF) hemorphin with MOR, and IRAP 
(Continued).  
Protein Peptide Glide docking 




























Ala822, Phe826, Tyr961  
 



























The top pose of LVVYPWTRRF peptide exhibited a GScore of 
−10.53 kcal/mol and MM-GBSA binding energy of −115.08 kcal/mol (Table 1). 
Leu1, Val2, and Val3 residues of LVVYPWTRRF formed interactions with residues 
located on TM5 (Glu231 and Ile236) and TM6 (Val302, Ile303, and Leu307). As 
compared to LVVYPWTQRF, the Pro5 and Trp6 residues produced hydrogen bonds 
with Tyr212 and Lys211, respectively, as well as showed hydrophobic interactions 
with the β-sheet residues. However, the C-terminal residues of LVVYPWTRRF 
peptide showed interactions with residues situated on TM3, TM5 and TM7. A 
hydrogen bond was formed between Arg9 and Asp149 on TM3, while the substituted 
arginine at position 8 exhibited a hydrogen bond with the side chain of Glu312 
located on the third extracellular loop. Moreover, Val3, Tyr4 and Thr7 formed 
hydrogen bonds with Glu231 (Figure 8B). A list of hydrophobic interactions that 















Figure 7: 3D structure of modeled active human MOR. (A) Side view of the binding pocket of MOR; (B) Top view of the binding pocket of 











Figure 8: Interactions of hemorphin peptides with MOR. (A) LVVYPWTQRF (non-camel hemorphin) docked in the binding pocket of MOR. 
(B) LVVYPWTRRF (camel hemorphin) docked in the binding pocket of MOR. The MOR protein is shown with a sea green cartoon 




































3.1.5 Insulin-regulated aminopeptidase 
Binding free energy calculations were performed for the different docking 
conformations of LVVYPWTQRF and LVVYPWTRRF peptides. The top five 
docked poses of LVVYPWTQRF peptide exhibited the GScore of  -14.86  kcal/mol, 
-13.91 kcal/mol, -13.33 kcal/mol, -12.73 kcal/mol, and -12.45 kcal/mol and the 
calculated MM-GBSA binding free energies corresponding to these poses were -
148.04 kcal/mol, -129.41 kcal/mol, -122.81 kcal/mol, -119.71 kcal/mol, and -114.88 
kcal/mol, respectively. The top five docked poses of LVVYPWTRRF peptide 
generated the GScore of -13.65 kcal/mol, -13.41 kcal/mol, -13.19 kcal/mol, -12.81 
kcal/mol, -12.53 kcal/mol and the calculated MM-GBSA binding free energies 
corresponding to these poses were -163.03 kcal/mol, -151.21 kcal/mol, -137.29 
kcal/mol, -129.91 kcal/mol, and -119.44 kcal/mol, respectively. The list of 
interacting residues of the best pose of each peptide along with their respective 
Gscore and MM-GBSA binding free energy are provided in Table 3. The N-terminal 
of LVVYPWTQRF and LVVYPWTRRF peptides occupied the S1 pocket, which is 
adjacent to the binding pocket. Figure 12A displays the binding mode for 
LVVYPWTQRF. In the reported binding mode, the N-terminal residues (Leu1, Val2, 
and Val3) of LVVYPWTQRF occupied the S1 pocket and showed hydrogen bonds 
with Leu541, Tyr549, and Gly428. These three N-terminal residues produced 
hydrophobic interactions with residues in the S1 pocket - Tyr272, Pro296, Phe425, 
Ala427, Ala429, Met430, Phe544, and Tyr961. Hydrogen bonds were formed 
between aromatic residues Tyr4 and Trp6 of LVVYPWTQRF and Glu441 and 
Lys460, respectively. They also interacted hydrophobically with Ala453, Leu457, 









hydrophobically with Ala763, Leu769, Phe770, Ala822, and Phe826. Thr7 exhibited 
a hydrogen bond with Asp510, Gln8 showed hydrogen bonds with Glu509, and 
Glu818 and Arg9 formed hydrogen bonds with the side chain of residues Glu825 and 
Glu895 (Figures 12A, and 13). The interacting residues and binding scores are 
shown in Table 3. 
LVVYPWTRRF demonstrated a similar binding mode with the N-terminal 
stabilized in the S1 pocket. The N-terminal residues (Leu1, Val2, and Val3) bound in 
the S1 pocket and formed interactions hydrophobically with Tyr272, Pro296, 
Ala427, Ala429, Met430, Phe544, Tyr549, Pro957, and Tyr961. Importantly, Val2 
residue formed a hydrogen bond with the amino group of Gly428 of the GAMEN 
loop (Gly428-Ala429-Met430-Glu431-Asn432). Tyr4, Pro5, and Trp6 residues of 
LVVYPWTRRF peptide formed hydrophobic interactions with the active site 
residues Leu457, Ile461, Tyr495, Ala514, and Phe550 and Trp6 produced a 
hydrogen bond with Lys460. Arg8 formed hydrogen bonds with the side chain of 
Glu825 and Glu895. However, Arg9 produced hydrogen bonds with Asp510 and 
Glu818. The last three residues of C-terminal also formed hydrophobic interactions 













Figure 11: 3D structure of IRAP. (A) The active site of IRAP; (B) The enlarged view of the active site of IRAP in A. The hemorphin peptide 
bound in the active site is shown in orange CPK representation, while GAMEN motif is shown in yellow CPK representation. The IRAP protein 














Figure 12: Interactions of hemorphin peptide with IRAP. (A) LVVYPWTQRF (non-camel hemorphin) docked in the binding pocket of IRAP. 
(B) LVVYPWTRRF (camel hemorphin) docked in the binding pocket of IRAP. The IRAP protein is shown with a purple cartoon representation. 
























Figure 14: Interactions of camel LVV-hemorphin-7 residues with IRAP. 
3.1.6 Molecular dynamics simulations 
In order to investigate the stability and dynamics of the docked complexes, 










3.1.7 Simulations of camel and non-camel LVV-hemorphin-7 bound to MOR  
    Three independent 100 ns all atom MD simulations of the LVVYPWTQRF 
bound to modeled MOR structure embedded in a dipalmitoylphosphatidylcholine 
(DPPC) membrane resulted in stable simulations with a protein Cα RMSD below 5 Å 
(Figure 15A). The per-residue RMSF demonstrated that the third intracellular (ICL-
3) and extracellular loop (ECL-2) regions were the most flexible whereas the regions 
that were membrane-embedded were the least flexible (Figure 15B). 
LVVYPWTQRF formed interaction with residues located on TM3 and TM7 during 
MD simulations. Tyr4 and Trp6 produced sustained hydrogen bond and hydrophobic 
interactions with Tyr150 and Asp149, respectively on TM3. Leu1 formed interaction 
with the TM5 residue Glu231. Tyr4 residue showed interaction with Lys305 whereas 
Val3, Trp6, and Arg9 residues formed sustained interactions with Trp320, Ile324 and 
His321, respectively located on TM7 in the simulations. The average percentage of 
equilibrated simulation period during which LVVYPWTQRF formed interactions 
with MOR residues is shown in Figure 16. Contributions from each simulation are 
given in Figure 18A. 
In the case of LVVYPWTRRF peptide bound simulations, the protein 
structure remained stable with RMSD below 4.5 Å in all three independent 
simulations (Figure 15C). Figure 15E shows the distribution of the RMSD values 
extracted from the LVVYPWTQRF and LVVYPWTRRF bound simulations. ECL-2 
and ICL-3 regions demonstrated higher fluctuations. More importantly, ICL-3 
produced higher fluctuations when compared to the MOR-LVVYPWTQRF complex 
(Figure 15D). LVVYPWTRRF exhibited interactions with residues from TM2, TM3, 









duration of all three simulations, whereas Phe10 formed interaction with Tyr150 
during the simulations. Additionally, LVVYPWTRRF peptide also formed 
interaction with Glu231, Asn232, and Lys235 residues of TM5. Leu1 and Tyr4 
residues formed consistent interactions with Ala306 and Lys305, respectively, 
located on TM6 and the C-terminal residues showed interactions with Trp320, and 
Tyr328 present on TM7. They also exhibited consistent interactions with Ile310 and 
Glu312 on the third extracellular loop. The average percentage of equilibrated 
simulation time during which the non-camel LVV-hemorphin-7 interacted with 
MOR residues is given in Figure 17. Contributions from each simulation are shown 











Figure 15: RMSD and RMSF plots of triplicate 100 ns simulations of MOR. Data 
from the three independent runs are represented with red, blue, and green lines. (A) 
RMSD of MOR-LVVYPWTQRF complex. (B) RMSF of MOR-LVVYPWTQRF 
complex. (C) RMSD of MOR-LVVYPWTRRF complex. (D) RMSF of MOR-
LVVYPWTRRF complex. (E) Density functions corresponding to the distribution of 














Figure 16: The average percentage of equilibrium simulation time during which 
residues of MOR maintained contact with LVVYPWTQRF peptide in triplicate 
100 ns simulations. To extract the equilibrium simulation data, the initial 50 ns of run 
1 was removed, whereas the initial 30 ns of runs 2 and 3 were removed. Charged, 















Figure 17: The average percentage of equilibrium simulation time during which 
residues of MOR maintained contact with LVVYPWTRRF peptide in triplicate 
100 ns simulations. To extract the equilibrium simulation data, the initial 50 ns of run 
1 was removed, whereas the initial 30 ns of runs 2 and 3 were removed. Charged, 














Figure 18: Histograms of the percentage of simulation time where a MOR residue 
maintains contact with the hemorphin peptide in triplicate simulations. For 
equilibrium simulation data, the first 50 ns of run 1 was discarded, while the first 30 
ns of runs 2 and 3 were discarded. A) MOR-LVVYPWTQRF. B) MOR-
LVVYPWTRRF. 
3.1.8 Simulations of camel and non-camel LVV-hemorphin-7 bound to IRAP 
100 ns molecular dynamics simulation runs in triplicates were used to 









bound simulations, the IRAP structure maintained stability with RMSD below 2.5 Å 
(Figure 19A). Overall, simulations showed lower fluctuations in the protein residues 
and the secondary structure was preserved during all simulations (Figure 19B). The 
first three residues of the N-terminal of LVVYPWTQRF peptide were stabilized in 
the S1 pocket by forming hydrogen bonds and hydrophobic interactions. Leu1, Val2, 
and Val3 showed sustained hydrogen bonds with Tyr549 and Gly428 throughout the 
simulations and also formed interactions with Phe544. Tyr4, Pro5, and Trp6 formed 
consistent interactions with Glu441, Phe550, and Asn965. However, the C-terminal 
residues sustained their interactions with Asp510, Asp513, Glu818, Gu825, and 
Glu895 residues. Moreover, during the course of simulations, new contacts were 
observed between the first three residues of LVVYPWTQRF and Trp6 with Arg929, 
and Asn965. The average percentage of equilibrated simulation period during which 
LVVYPWTQRF peptide formed interactions with IRAP residues is shown in Figure 
20. Contributions from each simulation are shown in Figure 22A. 
LVVYPWTRRF bound simulations showed stability with an RMSD below 
2.75 Å (Figure 19C). Overall, LVVYPWTRRF bound simulations produced limited 
fluctuations in IRAP residues (Figure 19D). The secondary structure was also 
preserved during the simulations. Figure 19E shows the distribution of the RMSD 
values extracted from the LVVYPWTQRF and LVVYPWTRRF bound simulations. 
The first three residues of LVVYPWTRRF were stabilized in the S1 pocket of IRAP 
by forming hydrogen bonds and hydrophobic interactions. Val2 residue formed a 
sustained hydrogen bond with Gly428 in the GAMEN loop throughout the 
simulation runs. The N-terminal residues (Leu1, Val2, and Val3) also formed 









showed consistent interactions with Lys460, whereas Trp6 formed interaction with 
Asp513. The mutated Arg8 demonstrated sustained hydrogen bonds with the 
negatively charged residues Glu509, Asp510 and Glu818. Lastly, Arg9 and Phe10 
residues of LVVYPWTQRF also formed consistent interactions with Lys517, 
Phe770, Glu825 and Glu895. The average percentage of equilibrated simulation 
period during which LVVYPWTRRF interacted with IRAP residues is shown in 




















Figure 19: RMSD and RMSF plots of triplicate 100 ns simulations of IRAP. Data 
from the three independent runs are represented with red, blue, and green lines. (A) 
RMSD of IRAP-LVVYPWTQRF complex. (B) RMSF of IRAP-LVVYPWTQRF 
complex. (C) RMSD of IRAP-LVVYPWTRRF complex. (D) RMSF of IRAP-
LVVYPWTRRF complex. (E) Density functions corresponding to the distribution of 

















Figure 20: The average percentage of equilibrium simulation time during which 
residues of IRAP maintain contact with LVVYPWTQRF peptide from triplicate 
100 ns simulations. The initial 30 ns of each of the 3 simulations were removed to 
extract the equilibrium simulation data. Charged, hydrophobic and polar amino acids 














Figure 21: The average percentage of equilibrium simulation time during which 
residues of IRAP maintain contact with LVVYPWTRRF peptide from triplicate 
100 ns simulations. The initial 30 ns of each of the 3 simulations were removed to 
extract the equilibrium simulation data. Charged, hydrophobic and polar amino acids 













Figure 22: Histograms of the percentage of simulation time where an IRAP residue 
maintains contact with the hemorphin peptide in triplicate simulations. For 
equilibrium simulation data, the first 30 ns of each run were discarded. A) IRAP-











The therapeutic potential of hemorphins has already been demonstrated by 
multiple in vivo and in vitro studies (Cheng et al., 2012; Fruitier-Arnaudin et al., 
2002; J. Lee et al., 2004). Understanding the binding mode and activity of these 
peptides at the molecular level is important as LVV-hemorphin-7 binds to several 
proteins with high affinity. Computational molecular modeling and simulation 
studies often supplements experimental studies. In this study, extensive 
computational methods were used to explore the precise binding mode of both camel 
and non-camel LVV-hemorphin-7 with MOR, and IRAP to elucidate how the 
peptide interacts with these structurally and functionally different. 
In MOR, camel and non-camel LVV-hemorphin-7 adopted distinct poses. 
The critical residues involved in the binding are in agreement with prior theoretical 
and experimental data (Cui, Yeliseev, & Liu, 2013). Asp149, an acidic residue of 
MOR, was found to make a hydrogen bond with both camel and non-camel LVV-
hemorphin-7 (Figures 8A, and 8B). Interestingly, camel LVV-hemorphin-7 showed 
sustained interaction for the full duration of the three simulations, whereas the same 
interaction was consistent for an average of 90% of the three non-camel LVV-
hemorphin-7 simulations. These results complement several site directed 
mutagenesis studies and structural models that showed the vital role played by 
Asp149 (Asp147 in murine MOR) in opioid ligand recognition and the interaction 
with several opioid ligands (Li et al., 1999; Spivak et al., 1997; Xu et al., 1999). This 
critical interaction therefore should be given special consideration while designing 
future novel MOR ligands. Camel LVV-hemorphin-7 formed interactions 









that hemorphins interact with Tyr326 of mouse MOR49,( Li et al., 1999). 
Additionally, Trp320 residue of TM7 formed interactions with hemorphins and is 
also in agreement with earlier studies (Eguchi, 2004; Noori, Mucksch, & Urbassek, 
2014). Interestingly, camel LVV-hemorphin-7 formed interactions with essential 
residues in the active site for a longer duration than non-camel hemorphin (Figure 
18).  
LVVYPWTRRF formed more stable interactions with Thr220, Glu231, and 
Tyr328 residues when compared to LVVYPWTQRF in the human MOR model. The 
equivalent residues in the murine MOR – Thr200, Glu299, and Tyr326 – have been 
shown to form interactions with agonists (Cui et al., 2013; Noori et al., 2014). 
Moreover, RMSF values were observed to be higher for ICL-3 residues when bound 
to camel LVVYPWTRRF. Camel LVV-hemorphin-7 mostly formed interactions 
with TM3, TM6, and TM7 of MOR, which has been proposed to contain the ionic 
lock important for GPCR activation (Huang et al., 2015). As observed, the peptide-
bound simulations increased the ICL-3 region’s flexibility, which is consistent with 
downstream protein complex interactions and signaling pathways stimulated by 
receptor agonists (Waldhoer, Bartlett, & Whistler, 2004). The simulations of MOR 
bound to camel LVV-hemorphin-7 demonstrated a lower RMSD than non-camel 
LVV-hemorphin-7 (Figure 15). ECL-2 exhibited limited fluctuations upon binding to 
both LVVYPWTRRF and LVVYPWTQRF peptides. This could support the binding 
and selectivity of peptides. This is also in agreement with several mutagenesis 
studies that established the role of ECL-2 in ligand orthosteric and allosteric 
activation (Huang et al., 2015; Venkatakrishnan et al., 2013; Wheatley et al., 2012). 









signaling and are vital in effector coupling (Hothersall et al., 2017). Interestingly, 
LVVYPWTRRF formed interactions with both residues, whereas LVVYPWTQRF 
interacted with only Trp320. Therefore, due to ligand bias, it is conceivable that 
camel LVV-hemorphin-7 could produce its effect on MOR. 
In the case of IRAP, both LVVYPWTRRF and LVVYPWTQRF 
demonstrated analogous binding interactions. The binding pose of both camel and 
non-camel hemorphin peptides showed that their N-terminal residues were stabilized 
in the S1 pocket by forming sustained hydrogen bonds with Gly428 and Tyr549 
(Figure 12). Studies have shown that Tyr549 is an essential residue for binding and 
stabilizing the catalytic transition state and is extremely conserved in the M1 family 
of metalloproteases (Wong, Zhou, & Rini, 2012). Moreover, it also interacted with 
Phe544 and Tyr961 in the active site. Importantly, the interaction with Phe544 was 
earlier demonstrated as an essential interaction for substrate and ligand binding 
(Albiston et al., 2010). HEXXH Zn
2+
 binding motif and the GXMEN exopeptidase 
motif are two conserved motifs present in the catalytic domain of IRAP. Mutagenesis 
studies of these motifs revealed that Gly428, Ala429, and Asn432 are critical for 
binding both inhibitors and peptide substrates, and also indicated that peptide 
inhibitors of IRAP competitively bind to its catalytic site (Ye et al., 2007). In the 
present study, the N-terminal residues of LVVYPWTRRF peptide formed 
interactions with the GAMEN loop residues Gly428 and Ala429, whereas 
LVVYPWTQRF interacted with only Gly428 (Figs. 21 and 22). Particularly, Val2 of 
LVVYPWTRRF exhibited interactions with Gly428 and Ala429 (Figure 10B). 
However, Val3 of both LVVYPWTRRF and LVVYPWTQRF peptides showed 









of Val3 residue results in the annihilation of binding to IRAP (Lee et al., 2003). Tyr4 
and Trp6 residues formed interactions with Glu441 and Phe550. It has been 
suggested that monosubstitutions of Tyr4 and Trp6 with alanine leads to a 10-fold 
reduction in binding affinity (Lee et al., 2003). Additionally, the N-terminal residues 
of hemorphins are essential for the inhibition of IRAP by forming sustained 
interactions with key IRAP residues. It has been reported that the removal of C-
terminal residues of LVV-hemorphin-7, such as Thr7, Gln8, Arg9, and Phe10 did not 
substantially alter their binding affinity for IRAP. However, a moderate reduction in 
affinity was demonstrated with the removal of Arg9 residue in cerebellar 
membranes. Interestingly, during MD simulations, LVVYPWTQRRF residues Arg8 
and Arg9 were noticed to form consistent interactions with charged residues Lys456, 
Glu509, Asp510, Asp513, and Glu818 in relation to LVVYPWTQRF bound 
simulations (Figures 22A, and 22B). These sustained interactions could lead to a 












Chapter 4:  In silico and In vitro Comparison of the Angiotensin-I 




In silico and in vitro studies were performed to determine the ACE inhibitory 
activities of both camel and non-camel hemorphins. 
4.1.1 Molecular docking 
Molecular docking and binding free energy calculations methods were used 
to identify the binding pose of human hemorphins LVVYPWTQRF and YPWTQRF 
and camel hemorphins LVVYPWTRRF and YPWTRRF.  The docked poses of each 
peptide obtained from peptide docking were examined using the GScore scoring 
function  (Friesner et al., 2006). 
4.1.2 Docking of non-camel and camel LVV-hemorphin-7 to ACE 
The binding score and residues of ACE that formed interactions with 
LVVYPWTQRF, LVVYPWTRRF, YPWTQRF, and YPWTRRF peptides are listed 
in Table 4. The active site of ACE is comprised of three subsites, which are also 
essential for ACE inhibition, termed S1, S2, and S1′. These subsites contain residues 
that form interactions with potential inhibitors (Abdelhedi et al., 2018; Priyanto et 
al., 2015). Ala354, Glu384, and Tyr523 comprise the S1 subsite; Gln281, His353, 
Lys511, His513, and Tyr520 comprise the S2 subsite, and Glu162 constitutes the S1′ 
subsite (Ma et al., 2018). These hemorphin peptides interacted with important 
residues in the active site of ACE. LVVYPWTQRF and LVVYPWTRRF peptides 









hydrophobic and electrostatic interactions with ACE as demonstrated by the two 







Table 4: List of interactions formed by the top binding pose of LVVYPWTQRF, LVVYPWTRRF, YPWTQRF, and YPWTRRF hemorphin 


























Tyr51, Trp59, Tyr62,Ala63, Ile88, Ala89, 
Val119, Leu122, Ala125, Leu139, Leu140, 
Cys352, Trp357, Tyr360, Cys370, Val379, 
Val380, Phe391, Tyr394, Ala418, Phe457, 













Tyr62, Ala63, Ile88, Leu139, Leu161, 
Ala204, Ala207, Ala216, Met223, Trp279, 
Val379, Val380, Phe391,Tyr394, Pro407, 





Asn277, Ala354,  
Ala356, Asn377, 
Glu384 
Tyr62, Ala63, Trp279, Cys352, Trp357, 
Phe359, Tyr360, Cys370, Val379, Val380, 















Tyr62, Ala63, Ile88, Trp279, Trp357, 
Cys370, Val379, Val380, Phe391, Tyr394, 


















The top binding pose of LVVYPWTQRF peptide exhibited a GScore and an 
MM-GBSA binding energy of −14.045 kcal/mol and −134.860 kcal/mol, 
respectively (Table 4). The C-terminal residue Phe10 of LVVYPWTQRF formed a 
hydrogen bond and hydrophobic interactions with Thr282 and Phe527 of ACE. 
Phe10 also formed a polar interaction with the S2 subsite residue Gln281 and three 
electrostatic interactions with residues Glu376, His383, and Asp453. A hydrogen 
bond was formed between Glu162 residue of S1′ subsite and the sidechain of Arg9. 
Moreover, it also exhibited an electrostatic interaction with Lys454, and three 
hydrophobic interactions with Cys352, Val379, and Val380. LVVYPWTQRF 
residues Thr7, and Gln8 were situated in the S1 and S2 subsites of ACE. A hydrogen 
bond was formed between the sidechain of Gln8 and Glu384, Thr7 formed hydrogen 
bonds with Ala354 and Tyr523 residues of ACE. Additionally, Gln8 residue of the 
peptide also exhibited electrostatic and polar interactions with Glu411, Lys511, and 
His513 and two hydrophobic interactions with Phe457, and Tyr520. A cation-π 
interaction was observed between His410 and Trp6. A hydrogen bond was also 
formed between the backbone amino group of Trp6 and Ala356. LVVYPWTQRF 
peptide residues Tyr4, Pro5, and Trp6 formed interactions hydrophobically with 
Leu139, Leu140, Trp357, Phe391, Tyr394, and Pro407, and electrostatically with 
Glu143, Asp358, Lys368, Glu403, and Arg522. The N-terminus residues (Leu1, 
Val2, and Val3) of LVVYPWTQRF formed hydrophobic interactions with ACE 
residues Tyr51, Trp59, Tyr62, Ala63, Ile88, Ala89, Val119, and Leu122. Hydrogen 
bonds were formed between the sidechain amino group of Leu1 and sidechain 







Figure 23:  The active site of Angiotensin-I converting enzyme (ACE) shown in red circle and a closer look at the interaction of LVV-










Figure 24: Closer view of the docked pose of LVVYPWTQRF peptide and the hydrogen bond interactions it forms with ACE shown as black 
dashed lines. The ACE protein is shown with a green cartoon representation and its interacting residues are highlighted in pink stick 











Figure 25: Closer view of the docked pose of LVVYPWTRRF peptide and the hydrogen bond interactions it forms with ACE shown as black 
dashed lines.  The ACE protein is shown with a green cartoon representation and its interacting residues are highlighted in pink stick 










Figure 26: Interactions of human hemorphin (LVVYPWTQRF) with ACE. Colored 
circles represent amino acids that form interaction with bound ligand. Red circles 
indicate negatively charged amino acids, dark blue colors indicate positively charged 
amino acids, light blue circles indicate polar amino acids, and green circles indicate 
hydrophobic amino acids. Hydrogen bonds are shown with purple arrows – dashed 
arrows for hydrogen bonds involving amino acid side chain and regular arrows for 
hydrogen bonds involving amino acid backbone. π–π interactions are represented 









Figure 27: Interactions of camel hemorphin (LVVYPWTRRF) with ACE. Colored 
circles represent amino acids that form interaction with bound ligand. Red circles 
indicate negatively charged amino acids, dark blue colors indicate positively charged 
amino acids, light blue circles indicate polar amino acids, and green circles indicate 
hydrophobic amino acids. Hydrogen bonds are shown with purple arrows – dashed 
arrows for hydrogen bonds involving amino acid side chain and regular arrows for 
hydrogen bonds involving amino acid backbone. π–π interactions are represented 







The binding mode of LVVYPWTRRF peptide was observed to be slightly 
different from that of LVVYPWTQRF. Precisely, the C-terminus residues binding 
and positioning in the S1 and S2 subsites of the active site along with the orientation 
of the N-terminus residues were different. The GScore and an MM-GBSA binding 
energy calculated for the top binding pose was −18.824 kcal/mol and −147.566 
kcal/mol (Table 4). The C- terminal residue Phe10 exhibited polar interactions with 
S2 subsite residues such as Asn277, Gln281, Thr282, and Asn285. Phe10 also 
formed two electrostatic interactions with Glu376 and Asp453, and two hydrophobic 
interactions with Val379 and Val380. LVVYPWTRRF residues Thr7, Arg8, and 
Arg9 engrossed the S1, S2, and S1' subsites. The backbone functional groups of 
Arg9 such as amino groups formed hydrogen bonds with S1′ subsite residue Glu162 
and with S2 subsite residue His353, whereas its sidechain amino group showed a 
hydrogen bond with Thr166. Additionally, Arg9 also produced two hydrophobic 
interactions with Leu161 and Trp279. The backbone and sidechain amino groups of 
Arg8 exhibited hydrogen bonds with S1 subsite residue Glu384 and Asp415. Arg8 
also interacted electrostatically with His383 and Glu411, and hydrophobically with 
Phe457 and Phe527. LVVYPWTRRF residue Thr7 showed two hydrogen bonds 
with the S1 subsite residues Ala354 and Tyr523. However, Trp6 exhibited a 
hydrogen bond and a cation-π interaction with Ala356 and His410, respectively. 
Trp6 also formed two polar interactions with His387 and His513. Moreover, 
LVVYPWTRRF residues Pro5 and Trp6 interacted electrostatically with Trp357, 
Asp358, Tyr394, Glu403, and Pro407. Tyr4 formed a hydrogen bond with Trp59 and 
a π-π stacking with Tyr360. The backbone of N-terminal residues Leu1 and Val2 
produced hydrogen bonds with Glu123 and Trp220, respectively. Additionally, Leu1, 






Leu139, Ile204, Ala207, Met223, Val518, and Pro519, and electrostatically with 
Arg124 (Figures 25 and 27). 
4.1.3 Docking of non-camel and camel hemorphin-7 to ACE 
The GScore and MM-GBSA binding energy calculated for the top binding 
pose of YPWTQRF peptide with ACE were −15.955 kcal/mol and M −112.525 
kcal/mol, respectively (Table 4). The first residue of YPWTQRF, Tyr1 showed a 
hydrogen bond and π-π stacking with Glu123 and Trp59 of ACE, respectively. The 
N-terminal residues of YPWTQRF, Tyr1 and Pro2 interacted hydrophobically with 
Tyr62, Ala63, Trp357, Tyr360, and Val380. The backbone functional groups of Trp3 
such as amino and carboxyl groups, exhibited hydrogen bonds with Ala356, while 
the sidechain of Trp3 produced a cation-π interaction with His410. Moreover, 
YPWTQRF peptide residues Thr4 and Gln5 occupied the S1 and S2 subsites. The 
backbone and sidechain functional groups of Thr4 produced hydrogen bonds with 
two ACE residues Ala354 and Tyr523. Gln5 exhibited a hydrogen bond with 
Glu384. Additionally, Thr4 and Gln5 residues also interacted hydrophobically with 
Phe359, Tyr394, Phe457, Phe512, and Tyr520. The C-terminal residues Arg6 and 
Phe7 exhibited hydrogen bonds with S1′ subsite residue Glu162, and Asn277. A 
hydrogen bond was also formed between Arg6 and Asn377. Additionally, Arg6 
produced three polar interactions with Gln369, Thr371, and Thr372, and also 
interacted hydrophobically with Cys352 and Cys370. Phe7 residue of YPWTQRF 
peptide formed four polar interactions with Thr166, Gln281, Thr282, and Asn285, 
and also interacted electrostatically with Glu376, His383, Asp415, and Lys511 






On the other hand, YPWTRRF peptide produced a slightly different binding 
pose, specifically the N-terminus residues (Tyr1 and Pro2) and the C-terminus 
residues (Arg5 and Phe7). The C-terminus residue Phe7 produced a hydrogen bond 
with S2 subsite residue Gln281. Phe7 also exhibited interactions with Thr282, 
Glu376, Asp453, Lys454, and Phe457. Arg6 showed hydrogen bonds with Asn377, 
and the S1′ subsite residue Glu162. Arg6 also formed five polar interactions with 
Thr166, Asn285, Gln369, Thr371, and Thr372 residues of ACE. The substituted 
residue of YPWTRRF peptide, Arg5 formed a hydrogen bond with S1 subsite 
residue Glu384 and Asp415. Arg5 showed a polar interaction with S2 subsite residue 
His353 and also interacted hydrophobically with Phe527. However, the Trp3 and 
Thr4 residues of both YPWTRRF and YPWTQRF peptides produced similar 
interactions with ACE. Moreover, Pro2 produced interactions with Trp357, Val518, 
and Asn66. Hydrogen bonds were formed between the backbone amino and 
sidechain hydroxyl groups of Tyr1 and with Lys118, Tyr360, and Arg402. Tyr1 also 
interacted electrostatically with Glu403 and hydrophobically with Tyr62, Ala63, 
Val399, and Phe512. Additionally, the first residue of YPWTRRF also exhibited π-π 
stacking with Trp59 (Figures 29 and 31). Finally, a GScore and a MM-GBSA 
binding energy calculated for the top binding pose of YPWTRRF peptide with ACE 







Figure 28: Closer view of the docked pose of YPWTQRF peptide and the hydrogen bond interactions it forms with ACE shown as black dashed 
lines.  The ACE protein is shown with a green cartoon representation and its interacting residues are highlighted in pink stick representation; the 










Figure 29: Closer view of the docked pose of YPWTRRF peptide and the hydrogen bond interactions it forms with ACE shown as black dashed 
lines.  The ACE protein is shown with a green cartoon representation and its interacting residues are highlighted in pink stick representation; the 









Figure 30: Interactions of human hemorphin (YPWTQRF) with ACE. Colored 
circles represent amino acids that form interaction with bound ligand. Red circles 
indicate negatively charged amino acids, dark blue colors indicate positively charged 
amino acids, light blue circles indicate polar amino acids, and green circles indicate 
hydrophobic amino acids. Hydrogen bonds are shown with purple arrows – dashed 
arrows for hydrogen bonds involving amino acid side chain and regular arrows for 
hydrogen bonds involving amino acid backbone. π–π interactions are represented 









Figure 31: Interactions of camel hemorphin (YPWTRRF) with ACE. Colored circles 
represent amino acids that form interaction with bound ligand. Red circles indicate 
negatively charged amino acids, dark blue colors indicate positively charged amino 
acids, light blue circles indicate polar amino acids, and green circles indicate 
hydrophobic amino acids. Hydrogen bonds are shown with purple arrows – dashed 
arrows for hydrogen bonds involving amino acid side chain and regular arrows for 
hydrogen bonds involving amino acid backbone. π–π interactions are represented 







4.1.4 Molecular dynamics simulations 
In order to determine the stability and dynamics of the nteractions between 
ACE and hemorphin peptides, all-atom MD simulations were run in triplicate using 
Desmond (Bowers et al., 2006). 
4.1.5 Simulations of different peptides of non-camel and camel hemorphins 
bound to ACE 
The results of MD simulations showed that both LVVYPWTQRF-ACE and 
LVVYPWTRRF-ACE complex systems remained stable for the full duration of 200 
ns simulations. The RMSD of ACE was stabilized at approximately 2.0 Å for both 
LVVYPWTQRF and LVVYPWTRRF peptide bound structures (Figures 32A and 
32B).  Both LVVYPWTQRF and LVVYPWTRRF peptide bound simulations 
demonstrated that most protein residues exhibited lower fluctuations, but for loop 
regions (Figures 33A and 33B), and the secondary structures were maintained 
throughout the simulations. Gln8, Arg9, and Phe10 residues of the C-terminal of 
LVVYPWTQRF peptide were bound stably in S1, S2, and S1′ subsites by forming 
hydrophobic and hydrogen interactions. Precisely, Glu162, Gln281, Glu384, Asp453, 
Lys511, His513, and Tyr523 residues of ACE retained interactions with Gln8, Arg9, 
and Phe10 residues during simulations. The analysis of the MD trajectory showed 
that Arg9 formed stable interaction with S1′ subsite residue Glu162, and S2 subsite 
residue Gln281. Thr7 and Gln8 residues were situated in the S1 and S2 subsites and 
formed consistent interactions with Ala354, Glu384, Lys511, His513, and Tyr523. 
The first three residues of LVVYPWTQRF peptide interacted with Glu123, Arg124, 






Additionally, LVVYPWTQRF peptide maintained interactions with Trp59, 
Glu143, His353, Glu411, Arg522, and Phe527. Similar to LVVYPWTQRF peptide, 
the last three residues of LVVYPWTRRF peptide occupied subsites of ACE active 
site (S1, S2, and S1′) and showed consistent interactions with the essential residues 
of these subsites. Arg9 residue maintained sustained interaction with S1′ subsite 
residue Glu162. Phe10 residue exhibited sustained interactions with Asn277, 
Gln281, and Phe457. Notably, the mutated Arg8 residue of LVVYPWTRRF 
demonstrated consistent interactions with Glu384, Glu411, Asp415, and Ser526, 
which were not observed in the LVVYPWTQRF-bound simulations (Figure 35). 
Pro5, Trp6 and Thr7 residues of LVVYPWTRRF interacted consistently with 
His353, Ala354, Ala356, His410, His513, and Tyr523. Moreover, the first three 
residues of LVVYPWTRRF peptide interacted with Lys118, Trp220, Glu123, 
Arg124, Glu403, Ser517, and Arg522 during the simulation time. Figures 34 and 35 
demonstrate the average (from three runs) percentage of the equilibrated simulation 
time during which several residues of the LVVYPWTQRF and LVVYPWTRRF 








Figure 32: RMSD plots of Cα atoms of ACE protein extracted from triplicate 200 ns 
simulations of hemorphin-ACE complex. Data extracted from three independent runs 
are shown with red, green, and blue. A) Simulation results of LVVYPWTQRF 
peptide bound to ACE; B) Simulation results of LVVYPWTRRF peptide bound to 
ACE; C) Simulation results of YPWTQRF peptide bound to ACE; D) Simulation 










Figure 33: RMSF plots of Cα atoms of ACE protein extracted from triplicate 200 ns 
simulations of hemorphin-ACE complex. Data extracted from three independent runs 
are shown with red, green, and blue. A) Simulation results of LVVYPWTQRF 
peptide bound to ACE; B) Simulation results of LVVYPWTRRF peptide bound to 
ACE; C) Simulation results of YPWTQRF peptide bound to ACE; D) Simulation 









Figure 34: The average percentage of equilibrium simulation time during which ACE 
residues retain interaction with human hemorphin (LVVYPWTQRF) peptides from 
triplicate 200 ns simulations. To extract the equilibrium simulation data, the initial 
30 ns of each of the 3 simulations were removed. Charged, hydrophobic, and polar 








Figure 35: The average percentage of equilibrium simulation time during which ACE 
residues retain interaction with camel hemorphin (LVVYPWTRRF) peptides from 
triplicate 200 ns simulations. To extract the equilibrium simulation data, the initial 
30 ns of each of the 3 simulations were removed. Charged, hydrophobic, and polar 
amino acids are shown with orange, green and blue color respectively.  
 
The best docked complexes of YPWTQRF and YPWTRRF bound to ACE 
were also simulated for 200 ns in triplicates.  The protein RMSD stabilized at 
approximately 2.5 Å in YPWTQRF-bound simulations (Figure 32C). The secondary 






exhibited lower fluctuations, except loop regions (Figure 33C). Arg6 and Phe7 were 
bound stably in the S1′ and S2 subsites, respectively, by producing consistent 
interactions with ACE residues Glu162, Gln281, His353, Lys511, and Tyr523. Gln5 
formed sustained interactions with Glu384 and Asp415 during the simulation runs. 
Thr4 formed interaction with Ala354 and Glu411 residues of the S1 subsite. Tyr1, 
Pro2, and Trp3 residues at the N-terminus interacted with Asn66, Ala356, Trp357, 
Tyr360, and Glu403 (Figure 36). Similar to YPWTQRF, Arg6 and Phe7 residues of 
YPWTRRF engrossed the S1′ and S2 subsites, respectively, by exhibiting consistent 
interactions with Glu162, Gln281, and His513 (Figure 37). They also retained 
consistent interactions with Asn277, Asn374, Glu376, and Phe457. Glu162 residue 
of S1′ pocket formed interaction with Arg6 for the full duration of simulations. Arg5 
of YPWTRRF peptide exhibited consistent interactions with Glu411, Asp415, 
Lys51, and Ser526. It also produced sustained interactions with the S1 subsite 
residues Ala354 and Glu384. His353 and Tyr523 residues of ACE interacted with 
Thr4. Moreover, Tyr1, Pro2, and Trp3 residues at the N-terminus displayed 
consistent interactions with Ala356, Trp357, His387, Phe391, Glu403, and Ser516 









Figure 36: The average percentage of equilibrium simulation time during which ACE 
residues retain interaction with human hemorphin (YPWTQRF) peptides from 
triplicate 200 ns simulations. To extract the equilibrium simulation data, the initial 
30 ns of each of the 3 simulations were removed. Charged, hydrophobic, and polar 










Figure 37: The average percentage of equilibrium simulation time during which ACE 
residues retain interaction with camel hemorphin (YPWTRRF) peptides from 
triplicate 200 ns simulations. To extract the equilibrium simulation data, the initial 
30 ns of each of the 3 simulations were removed. Charged, hydrophobic, and polar 








The RMSD of the protein Cα atoms stabilized at approximately 2 Å in 
YPWTRRF-bound simulations, and the protein structure displayed structural stability 
for the full duration of simulations (Figure 32D). Overall, ACE residues exhibited 
fewer fluctuations except from loop regions and, the secondary structure remained 
preserved throughout the simulations (Figure 32D). Figures 33 and 34 demonstrate 
the average percentage of equilibrated simulation time during which several residues 
of ACE interacted with two peptides. 
4.1.6 In vitro ACE inhibition assay 
The data obtained from the molecular docking and MD simulation indicated 
that LVVYPWTRRF and YPWTRRF had more hydrogen bonds, electrostatic and 
hydrophobic interactions with critical amino acids in the active site that are essential 
for ACE inhibitory activity than LVVYPWTQRF and YPWTQRF, respectively. On 
the basis of this, it was hypothesized that camel LVVYPWTRRF and YPWTRRF 
peptides could demonstrate lower IC50 than non-camel LVVYPWTQRF and 
YPWTQRF. To investigate this, the ACE inhibitory activity of all four peptides was 
studied with the help of an in vitro ACE inhibition assay. 
4.1.7 Determination of ACE inhibitory potential of non-camel and camel 
hemorphin peptides 
Firstly, longer hemorphin peptides (LVVYPWTQRF and LVVYPWTRRF) 
of both camel and human were investigated for their ACE inhibitory activity at 
different doses.  ACE inhibitory activity was observed at all tested doses (Figure 
38A). Both camel and human peptides demonstrated saturation at 200 µM. 






curve of camel LVVYPWTRRF peptide at all tested doses, relative to 
LVVYPWTQRF peptide (Figure 38A). Notably, this shift was statistically 
significant (p < 0.0001, n = 3) at 10 µM, as demonstrated in Figure 38A. 
Additionally, dose-response experiments established the left shift of 
LVVYPWTRRF. This suggests that LVVYPWTRRF peptide exhibited a more 
potent in vitro inhibitory action on ACE. Both LVVYPWTQRF and 
LVVYPWTRRF peptides demonstrated a dose-dependent inhibitory activity on ACE 
and IC50 values were in the micromolar range (Figure 39). IC50 of LVVYPWTRRF 
peptide (6.601 µM) was significantly lower than LVVYPWTQRF peptide (12.649 
µM) (p < 0.05, n = 3). 
Moreover, the ACE inhibitory potential of both YPWTRRF and YPWTQRF 
was also determined at different doses. Similarly, dose-response data showed that 
YPWTRRF peptide exhibited a left shift at all tested doses, in comparison to 
YPWTQRF peptide (Figure 38B). Moreover, this left shift was especially significant 
at 10 µM, 50 µM, and 100 µM concentrations (p < 0.05, n = 3). Interestingly, 
YPWTRRF exhibited significantly lower IC50 (9.310 µM) when compared to 







Figure 38: Dose-response curves of different hemorphin peptides. Per dose ACE 
inhibitory activity is demonstrated in percentage. (A) Comparison of ACE inhibitory 
activity of LVVYPWTRRF with LVVYPWTQRF at different doses; (B) 
Comparison of ACE inhibitory activity of YPWTRRF with YPWTQRF  at different 
doses; (C) Comparison of ACE inhibitory activity of LVVYPWTRRF with 
YPWTRRF at different doses; (D) Comparison of ACE inhibitory activity of 
LVVYPWTQRF with YPWTQRF. The dose response comparisons were carried out 
using statistical analysis. For this, two-way ANOVA and Sidak’s multiple-
comparisons test was used to determine the degree of significance among different 
peptides. Data are shown as mean ± SEM of three independent experiments.  







4.1.8 Comparison of the ACE inhibitory activity of different hemorphin 
peptides 
Next, the ACE inhibitory role of the N-terminus residues (Leu1, Val2, and 
Val3) of both LVVYPWTQRF and LVVYPWTRRF peptides were assessed. For 
this, the ACE inhibition potential of LVVYPWTRRF with YPWTRRF and 
LVVYPWTQRF with YPWTQRF was evaluated (Figure 10C and 10D). The IC50 of 
LVVYPWTRRF (6.601 µM) was observed to be lower when compared YPWTRRF 
(9.310 µM) (Figure 39). 
A comparison of the ACE inhibitory potential of LVVYPWTQRF and its 
shorter isoform YPWTQRF peptide showed that LVVYPWTQRF demonstrated 
substantially lower ACE inhibitory potential than YPWTQRF at 10 µM, 50 µM, and 
100 µM (Figure 38D). Interestingly, LVVYPWTQRF peptide exhibited significantly 
lower IC50 (12.649 µM) than YPWTQRF (25.894 µM) (Figure 39). This clearly 
indicated a positive role of the N-terminus residues (LVV-) of both LVVYPWTQRF 









Figure 39: IC50 of different hemorphin peptides. IC50 values are shown in micro 
molar (µM) units, and comparisons of IC50 was carried out using one-way ANOVA 
and Sidak’s multiple-comparisons test to determine statistical significance between 
different peptides of hemorphin. Data are shown as mean ± SEM of three 
independent experiments. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, 









Hemorphins are a class of bioactive opioid peptides released during 
proteolytic cleavage of hemoglobin. Their therapeutic potential has been highlighted 
in various studies (Cejka et al., 2004; Fruitier-Arnaudin et al., 2002; Lee et al., 2004). 
Molecular binding behavior and binding stability of both camel and non-camel LVV-
hemorphin-7 on several targets have also been described in earlier work (Ali et al., 
2019). Here, extensive in silico approaches and an in vitro ACE inhibition assay 
were employed to determine the precise binding and ACE inhibitory activity of four 
different human and camel hemorphin peptides.  Results showed that 
LVVYPWTRRF and YPWTRRF peptides bind more stably to vital residues in the 
ACE active site, in comparison to LVVYPWTQRF and YPWTQRF, respectively. 
The in vitro ACE inhibition assay also supported this finding.  
A vital role is played by ACE, which is a membrane-bound zinc 
metallopeptidase in the regulation of blood pressure by catalyzing the conversion of 
angiotensin I into angiotensin II, which is a well-known vasoconstrictor (Fleming, 
2006).  A zinc ion binding motif is present in ACE, coordinated by His383, His387, 
and Glu411, which is essential for the formation of the ACE-inhibitor complex. 
Moreover, the active site of ACE is comprised of three subsites, which are also 
essential for ACE inhibition, termed S1, S2, and S1′. These subsites contain residues 
that form interactions with potential inhibitors (Abdelhedi et al., 2018; Priyanto et 
al., 2015). Ala354, Glu384, and Tyr523 comprise the S1 subsite; Gln281, His353, 
Lys511, His513, and Tyr520 comprise the S2 subsite, and Glu162 constitutes the S1′ 






By using extensive molecular docking and simulations, the binding mode of 
each peptide with ACE was determined. Overall, all studied hemorphins stably 
interacted with the active site residues of ACE. The last three residues at the C-
terminus of each peptide encompassed all three active subsites of ACE (Figures 24, 
25, 28, and 29). Arg9 and Phe10 residues of LVVYPWTQRF anchored the peptide 
in the S2 and S1′ pockets by producing hydrogen bonds with Glu162, Gln281, and 
Asp453. LVVYPWTQRF peptide residues Thr7 and Gln8 inhabited the S1 and S2 
subsites by producing hydrogen bonds with Ala354, Lys511, His513, Tyr520, and 
Tyr523. They also exhibited consistent interactions with His383, and Glu411 (Figure 
34). The positioning of LVVYPWTRRF peptide in the active site of ACE was 
observed to be slightly different. LVVYPWTRRF was observed to be deeply seated 
in the active site of ACE. LVVYPWTRRF was stabilized by Arg9 and Phe10 due to 
the formation of hydrogen bonds with Glu162, Asn277, Thr282, Asn374, and 
Glu376. Arg9 and Phe10 residues also exhibited polar interaction with Gln281 
(Figures 25 and 27). LVVYPWTRRF residues Thr7 and Arg8 showed consistent 
interactions with vital S1 and S2 subsite residues during the simulation runs. In 
addition to this, Arg8 of LVVYPWTRRF also showed consistent interactions with 
Glu411, Asp415, and Ser526, compared to LVVYPWTQRF (Figures 34 and 35). 
YPWTQRF and YPWTRRF displayed dissimilar binding modes. Particularly, the 
positioning of Tyr1 and Pro2 residues of the N-terminus, and Arg5, and Phe7 
residues of the C-terminus (Figures 28 and 29). Importantly, YPWTRRF showed 
strong interactions with all vital residues of ACE, such as Glu162, Ala354, Ala356, 
His387, Glu411, Glu415, Lys511, and Tyr523 during the simulations, in comparison 






FDA approved and widely prescribed ACE inhibitors such as captopril and 
lisinopril formed interaction with Glu162, His353, Ala354, Glu384, His387, Glu411, 
Lys511, His513, Tyr520, and Tyr523 of ACE (Natesh, Schwager, Evans, Sturrock, 
& Acharya, 2004; Wang, Wu, Xu, Xie, & Guo, 2011). However, clinically used ACE 
inhibitor enalaprilat, does not form any interaction with Glu162. This could be a 
reason for the lower affinity of enalaprilat when compared to lisinopril (Wang et al., 
2011). These amino acids are important for designing prospective ACE inhibitors. 
Amongst all the hemorphins investigated in this study, only camel hemorphin-7 
interacted with His387. Apart from His387 and Tyr520 residues, all the other 
hemorphins interacted with all of the essential residues, in the active site of ACE. 
In silico data showed that LVVYPWTRRF and YPWTRRF possessed higher 
affinity in comparison to LVVYPWTQRF and YPWTQRF, respectively. For 
validating this, an ACE inhibition assay was carried out to determine the IC50 of 
these peptides. LVVYPWTRRF and YPWTRRF demonstrated IC50 values of 6.601 
µM and 9.310 µM, respectively (Figure 39). Interestingly, the IC50 of 
LVVYPWTRRF and YPWTRRF peptides were considerably lower than 
LVVYPWTQRF (12.649 µM) and YPWTQRF (25.894 µM). This clearly showed 
that LVVYPWTRRF and YPWTRRF demonstrated more potent ACE inhibitory 
activity in comparison to LVVYPWTQRF and YPWTQRF. Nevertheless, the 
difference between camel hemorphins did not prove to be substantial (Figure 39). 
The results of non-camel hemorphin peptides were in agreement with the prior 
studies that were carried out to determine the ACE inhibition potential of hemorphins 
(Lantz et al., 1991; Zhao & Piot, 1997). Prior studies showed that LVVYPWTQRF 






hemorphins, such as YPWTQRF (Zhao & Piot, 1997). The results also demonstrated 
the significance of the hydrophobic N-terminus leucine-valine-valine residues for 
enhanced ACE inhibition. Moreover, the removal of leucine residue from the N-
terminus of LVVYPWTQRF substantially decreased the ACE inhibitory potential of 
VVYPWTQRF when compared to LVVYPWTQRF. LVVYPWTQRF being a more 
potent inhibitor of ACE as compared to VVYPWTQRF has also been reported in 
another comparative study as well (Ali et al., 2019). These results indicate the 
importance of N-terminus in ACE inhibition.  
From the perspective of structural activity, it has been demonstrated through 
various comparative studies that the ACE inhibition potential of a peptide is 
dependent on the presence of particular residues at N- and C-termini (Iwaniak et al., 
2014). At the N-terminus of a peptide, the presence of hydrophobic residues, in 
particular leucine, valine, isoleucine and glycine, showed substantially higher ACE 
inhibitory activity, whereas at the C-terminus, aromatic amino acids, such as 
phenylalanine, proline, tryptophan, and tyrosine are important (Silvestre et al., 2012). 
In addition, the presence of charged residues, particularly arginine and lysine, near 
the C-terminus were also reported to be important to the peptide's inhibitory potential 
for ACE (Sun et al., 2017). Furthermore, a number of studies have already illustrated 
this phenomenon, which showed that by the elongation of the N-terminus, the ACE 
inhibitory potential of certain peptides could be enhanced (Kohmura et al., 1989; Liu 
et al., 2014). The results from in silico and in vitro techniques showed that both 
LVVYPWTRRF and LVVYPWTQRF formed more stable interactions with the 
active site residues of ACE and showed higher inhibition in comparison to shorter 






found to bind to residues outside ACE's active site. This indicates that this part of the 
molecule does not appear to have any direct interactions with the active site residues, 
despite the ACE inhibitory effect. The peptide’s substantially enhanced ACE 
inhibitory activity with the LVV- sequence may be attributed to the peptide's more 
stable binding in the presence of this sequence. Moreover, the comparative analysis 
of LVVYPWTRRF and LVVYPWTQRF revealed that LVVYPWTRRF to be a 
more potent ACE inhibitory peptide as compared to LVVYPWTQRF (Figure 38A). 
More importantly, the N-terminus residues of LVVYPWTRRF revealed more 
consistent interactions with Tyr62, Lys118, Glu123, Arg124, Trp220, Glu403, 
Arg522, and Ser517, whereas an arginine substitution at position 8 exhibited more 
consistent interactions with Glu411, Glu415, and Ser526 in comparison to 
LVVYPWTQRF (Figures 34 and 35). Such a binding mode of the mutated arginine 
residue demonstrated that residues from the N-terminus had been pulled deeper into 
the binding pocket. Hence, this could be one of the reasons for the higher ACE 
inhibition potential of camel LVVYPWTRRF. These results are in agreement with 
prior studies, that stated the significance of leucine and valine at the N-terminus and 
arginine near the C-terminus for enhanced inhibition of ACE (Sun et al., 2017; Zhao, 
Sannier, Garreau, Guillochon, & Piot, 1994). Furthermore, for the non-competitive 
inhibition of ACE, studies have shown that the binding of peptide residues outside 
the ACE active site, especially with Tyr62 and Asn70, also play an important role 
(Ni, Li, Liu, & Hu, 2012). Apart from that, a novel dual inhibitor inhabiting both the 
primary and secondary sites has also been described (Akif et al., 2011). The 
secondary binding site residues of ACE were found to be Lys118, Glu123, Arg124, 
Trp220, Glu403, and Arg522. This demonstrates the plasticity of ACE active site in 






pattern was observed when LVVYPWTRRF was compared to the shorter camel 
hemorphin peptide (YPWTRRF) (Figures 36, and 37). MD simulations also showed 
that consistent interactions were produced by the N-terminus residues of 
LVVYPWTQRF with Glu123, Arg124, and Glu143 along with active site residues of 
ACE, compared to YPWTQRF (Figures 34 and 36). Likewise, comparative analysis 
of shorter camel (YPWTRRF) and non-camel (YPWTQRF) peptides showed that 
YPWTRRF exhibited substantially lower IC50 and more consistent interactions with 
ACE active site residues as compared to YPWTQRF (Figures 38B and 39). 
Moreover, interactions of the mutated arginine with Glu411, Asp415, and Ser526 
placed the peptide more stably in the active site, compared to human hemorphin-7. 
Importantly, prior studies that investigated the ACE inhibitory activities of peptides 
have already positively linked the presence of arginine near the C-terminus with 













Chapter 5:  Pharmacological Action of LVV-Hemorphin-7 on Angiotensin 
II Type 1 Receptor 
 
5.1 Results 
In silico and in viro assays were performed to determine the pharmacological 
action and appropriate binding mode of LVV-hemorphin-7 on AT1R. 
5.1.1 Weak agonistic effect of LVV–Hemorphin-7 on AT1R 
BRET technology in HEK293 cells was used to determine the 
pharmacological effects of camel and human LVV-hemorphin-7 on the functional 
AT1R-Gαq coupling and β-arrestin 2 recruitment to AT1R, in real time and live 
cells, as described in earlier studies (Ayoub et al., 2015). The activation of Gαq-
mediated IP1 production, as an important AT1R downstream signaling pathway, was 
also examined. In this study, for the measurement of BRET assays in HEK293 cells, 
AT1R-Rluc was used as the BRET donor, co-expressed with either mini Gαq (mGsq) 
probe consisting of the GTPase domain of Gαq fused to Venus, as BRET acceptor 
(Wan et al., 2018), or yPET–β-arrestin 2. BRET experiments were carried out in the 
presence or absence of treatment of cells with different doses of AngII, camel LVV–
hemorphin-7 or human LVV-hemorphin-7. The results indicated that AngII 
potentiated the BRET signals in a dose dependent manner between AT1R-Rluc and 
both Venus-Gαq and yPET–β-arrestin 2 (Figures 40A and 40B) (Table 5). 
Nevertheless, a partial effect on AT1R-Gαq coupling and β-arrestin 2 recruitment 
was observed only at high doses of camel and human LVV–hemorphin-7 (10–100 
µM) (Figures 40A and 40B). This also suggested that both camel and human LVV–






doses. Since, both camel and human LVV-hemorphin-7 produced similar potency, 







Figure 40: LVV-hemorphin-7’s action on AT1R. BRET experiments were performed on human embryonic kidney (HEK293) cells briefly co-
expressing AT1R-Rluc (as BRET donor) and either Venus-Gαq or yPET-β-arrestin 2 (as BRET acceptors) simulated or not with either AngII, 
LVV-hemorphin-7 or both. For the purpose of BRET measurements, HEK293 cells co-expressing AT1R-Rluc and either Venus-Gαq (A) or 
yPET-β-arrestin 2 (B) were simulated with different doses of AngII or LVV-hemorphin-7 at 37°C for 30 minutes and BRET measurements were 















Table 5: Log EC50 values of LVV-hemorphin-7 and AngII. Two-way ANOVA and Tukey multiple-comparisons test was performed to measure   
the statistical significance between different treatment conditions. 
 






 Control         LVVhemorphin-7  
 
-7.68  0.17          -8.78  0.14 
(p<0.001, n=6) 
  Control        LVV-hemorphin-7  
 
-7.57  0.19         -8.93  0.17 
(p<0.0001, n=7) 
 





 Control        LVV-hemorphin-7  
 
-7.75  0.23           -8.91  0.19 
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5.1.2 Positive allosteric effects of LVV–hemorphin-7 on AT1R  
Multiple dose–response and real-time kinetic BRET assays were performed 
to determine the possible pharmacological action of LVV–hemorphin-7 on AngII-
mediated AT1R activation. In order to measure the effects of dose–response 
experiments, cells were initially incubated with different doses of LVV-hemorphin-7 
for 15 min, after that BRET reading were calculated upon stimulation of AT1R with 
different doses of AngII. Curves plotted from AngII BRET results between AT1R-
Rluc and Venus-Gαq or yPET–β-arrestin demonstrated a substantial left shift (more 
than one log, p < 0.001, n = 3), 2 in cells incubated with either 10 or 100 µM of 
LVV–hemorphin-7 in comparison to control cells (Figures 41A and 41B). Moreover, 
to obtain statistically significant data, these dose–response experiments were 
repeated both in the presence of LVV–hemorphin-7 (10 µM) and absence (control). 
The additional dataset supported the previous experiment results, and a left shift of 
the AngII dose curves for BRET was observed between AT1R-Rluc and Venus-Gαq 
(p < 0.001 for the whole dose curve, n = 6) or yPET–β-arrestin 2 (p < 0.001 for the 
whole dose curve, n = 5) in cells pretreated with 10 µM of LVV–hemorphin-7 in 
comparison to control cells (Figures 41C and 41D) (Table 5). These results for the 
first time showed a positive pharmacological action of LVV–hemorphin-7 on AT1R 
activation briefly expressed in HEK293 cells. On the basis of these results, where a 
combination of 10 µM of LVV–hemorphin-7 and 10 nM of AngII, produced 
approximately 25% of AT1R-mediated response was selected and used for further 
BRET kinetics and functional assays. 
In order to further confirm the positive pharmacological action of LVV–






around by either prior incubation of cells for 15 min or not in the presence of 
different doses of LVV–hemorphin-7 and then cells were activated with 10 nM of 
AngII for 20 min. The results clearly indicated that AngII-mediated BRET signals 
between AT1R-Rluc and Venus-Gαq or yPET–β-arrestin 2 were substantially 
increased by LVV–hemorphin-7 in a dose-dependent manner with EC50 in the 
micromolar range (Table 5) (Figures 42A and 42B). 
In this study, the thrombin receptor or protease-activated receptor 1 (PAR1) 
was used as a negative control, and the pharmacological action of LVV–hemorphin-7 
were also investigated on this GPCR. The results indicated that LVV-hemorphin-7 
did not produce any noteworthy changes in the dose–response curves of thrombin-
mediated BRET increase between PAR1-Rluc and either Venus-Gαq or yPET–β- 







Figure 41: Positive allosteric modulation of LVV-hemorphin-7 on AT1R activation 
demonstrated by dose-response BRET technique. For dose-response BRET analysis, 
human embryonic kidney (HEK293) cells briefly co-expressing AT1R-Rluc and 
either Venus-Gαq (A, and C) or yPET-β-arrestin 2 (B, and D) were used. In A and B, 
HEK293 cells were initially incubated or not (control) with different doses of LVV-
hemorphin-7 for 15 minutes and then challenged with different doses of AngII for 30 
minutes. In C and D, HEK293 cells were initially incubated or not (Control) with 10 
µM of LVV-hemorphin-7 for 15 minutes and then cells were treated with different 
doses of AngII for 30 minutes. Data are represented as means ± SEM of 5-6 













Figure 42: Positive allosteric modulation of LVV-hemorphin-7 on AT1R activation 
demonstrated by dose-response BRET technique. For dose-response BRET analysis, 
human embryonic kidney (HEK293) cells briefly co-expressing AT1R-Rluc and 
either Venus-Gαq (A) or yPET-β-arrestin 2 (B) were used. In A and B, HEK293 cells 
were initially incubated with different doses of LVV-hemorphin-7 for 15 minutes 
and then challenged with 10 nM of AngII for 30 minutes. Next, HEK293 cells briefly 
co-expressing PAR1-Rluc and either Venus-Gαq (C) or yPET-β-arrestin 2 (D) were 
initially incubated or not (control) with 10 µM of LVV-hemorphin-7 for 15 minutes 
and then challenged with different doses of thrombin, as a negative control for 30 
minutes. Data are represented as means ± SEM of 3 (C and D) or 5-6 independent 
experiments carried out in triplicate.  
5.1.3 Confirmation of the positive allosteric effects of LVV–hemorphin-7 on 
AT1R 
Several real-time BRET kinetics were performed to further observe the PAM 
effects of LVV–hemorphin-7 on AT1R activation. For this, HEK293 cells briefly co-
expressing AT1R-Rluc with either Venus-Gαq or yPET–β-arrestin 2 were used and 
stimulated with different combinations of AngII and LVV–hemorphin-7 in different 






real time immediately after cells were stimulated or not with either LVV–hemorphin-
7 (10 µM), AngII (10 nM), or both. The results of real time kinetics experiments 
demonstrated that the combination of LVV-hemorphin-7 and AngII substantially 
increased the BRET signals within AT1R-Rluc/Venus-Gαq and AT1R-Rluc/yPET–
β-arrestin 2 pairs, in comparison to a single treatment of cells with AngII (Figure 
39A and 39B) (Table 6). Additionally, LVV-hemorphin-7 also produced a partial 
agonistic effect on BRET between AT1R-Rluc and yPET–β-arrestin 2 (Figure 43B). 
However, this effect was observed to be very weak between AT1R-Rluc and Venus-
Gαq (Figure 43A). 
Next, sequential real-time kinetics experiments were carried out where BRET 
readings were determined before the treatment of cells for 5 min, which formed the 
baseline level. After 5 min, cells were treated with or not LVV–hemorphin-7 (10 
µM) (treatment 1 or T1) for 10 min, and lastly cells were challenged or not with 
AngII (10 nM) (treatment 2 or T2) for 25 min. The results of these kinetics 
experiments demonstrated a very weak, approximately 10% potentiation of BRET 
signals specifically in cells treated with LVV–hemorphin-7 only after 35 min of 
measurements. Nevertheless, AT1R-Rluc/Venus-Gαq and AT1R-Rluc/yPET–β-
arrestin 2 pairs exhibited significantly higher AngII-induced BRET signals in cells 
which were initially stimulated with LVV–hemorphin-7, in comparison to those 
treated with vehicle (Figures 43C, and 43D) (Table 6). Moreover, BRET kinetics 
experiments were also carried out in such a way that cells were initially challenged 
with 10 nM of AngII for  approximately15 to 20 min to initiate BRET potentiation 
between AT1R-Rluc/Venus-Gαq and AT1R-Rluc/yPET–β-arrestin 2 pairs before 






results of these experiments demonstrated a substantial BRET increase beyond the 
AngII-induced level in both cases signifying the positive allosteric effect of LVV–
hemorphin-7. This indicates that LVV-hemorphin-7 can also produce PAM effect 
even after AngII binding to AT1R. Overall, these kinetic results were in agreement 
with the dose–response tests as demonstrated in Figure 38 showing the PAM effect 











Figure 43: Positive allosteric modulation of LVV-hemorphin-7 on AT1R activation 
demonstrated by real-time BRET kinetic analysis. For this, HEK293 cells briefly co-
expressing AT1R-Rluc and either Venus-Gαq or yPET-β-arrestin 2 were used. In A 
and B, BRET measurements were determined before (baseline) and upon cell 
treatment (arrow) with either 10 nM AngII, 10 µM LVV-hemorphin-7, or both for 50 
minutes. However, in C and D, BRET measurements were determined without any 
treatment (baseline) for 5 minutes and then HEK293 cells were challenged or not 
(vehicle) with 10 µM of LVV-hemorphin-7 (T1) for 10 minutes and then further 
simulation or not (vehicle) with 10 nM of AngII (T2) for 25 minutes. While, in E and 
F, HEK293 cells were initially treated with 10 nM of AngII and BRET readings were 
calculated for approximately 20 minutes without any further treatment with 10 µM of 
LVV-hemorphin-7 and additional BRET readings were determined for 25 minutes. 
Data are represented as means ± SEM of 5-8 independent experiments carried out in 







Table 6: Percentage Emax values of AngII in the various BRET assays. An 
appropriate statistical analysis was performed to determine the degree of 
significance. Kinetics 1 and 2 correspond to the data in Figure 39A/B and Figure 






(BRET kinetics 1) 
 
Emax 




109  2 
(p>0.05, n=9) 
263  6 
(p<0.0001, n=6) 
 







104  4 
(p>0.05, n=8) 
240  5 
(p<0.0001, n=5) 
 







5.1.4 Activation of AT1R by LVV-hemorphin-7 
In order to observe the effect of AT1R inhibition on both AngII and LVV–
hemorphin-7–mediated BRET potentiation, irbesartan was used as a selective AT1R 
antagonist on cells briefly co-expressing AT1R-Rluc with either Venus-Gαq or 
yPET–β-arrestin 2 (Figures 44A and 44B) challenged or not with either 10 µM of 
LVV–hemorphin-7, or 10 nM of AngII, or both. These experiments results initially 
established the substantial positive allosteric effects of LVV–hemorphin-7 on AngII-
induced BRET potentiation in both BRET case scenarios with AT1R-Rluc and either 
Venus-Gαq or yPET–β-arrestin 2 (Figures 44A and 44B). Interestingly, a complete 
inhibition of AngII-induced BRET signal was detected and their increase by LVV–
hemorphin-7 immediately after treatment with 10 µM dose of irbesartan (Figures 
44A, and 44B). Indeed, these results clearly indicate that the PAM action of LVV–









Figure 44: AT1R-selective antagonist (irbesartan) inhibited both AngII- and LVV-
hemorphin-7-mediated BRET potentiation. Before measuring BRET signals, 
HEK293 cells briefly co-expressing AT1R-Rluc and either Venus-Gαq (A) or yPET-
β-arrestin 2 (B) were initially stimulated or not (control using DMSO) with 10 µM of 
irebesartan at 37ºC for 15 minutes. Next, cells were treated or not (basal) with either 
10 nM of AngII, 10 µM of LVV-hemorphin-7, or both, at 37ºC for 30 minutes were 
carried out. Data are represented as means ± SEM of 3 independent experiments 
performed in duplicate. 
5.1.5 Effects of LVV–hemorphin-7 on AT1R-mediated downstream signaling  
In order to associate the BRET results with downstream signaling pathways 
of AT1R, the pharmacological action of LVV–hemorphin-7 on AT1R-mediated IP1 
production was determined as an indicator for Gαq/phospholipase C activation. To 
measure this, experimental conditions similar to BRET experiments were used. For 
this, initially HEK293 cells were used, briefly co-expressing Venus-Gαq and AT1R-
Rluc. Initially, the assumed agonistic effect of LVV–hemorphin-7 was determined on 
AT1R-mediated IP1 production in cells challenged with different doses of either 
LVV-hemorphin-7 or AngII as control. As expected, LVV-hemorphin-7 did not 






induced IP1 production in a dose-dependent manner and with the expected potency 
(Figure 45A) (Table 6). Additionally, the positive allosteric effect of LVV–
hemorphin-7 was determined on AngII-mediated IP1 response by treating cells with 
the different doses of AngII with or no pretreatment of cells for 15 min with 10 µM 
of LVV–hemorphin-7. Similar to BRET experiments, LVV–hemorphin-7 potentiated 
a noteworthy left shift of the AngII dose-dependent curve with a profound effect, 











Figure 45: Positive allosteric modulation of LVV-hemorphin-7 on AT1R-mediated 
IP1 production. For IP1 assays, HEK293 cells briefly co-expressing AT1R-Rluc with 
Venus-Gαq or AT1R-WT was used (Figure A-D). For IP1 measurements in dose-
response experiments, cells were challenged or not with the different doses of either 
AngII or LVV-hemorphin-7 or first pre-treated or not (Control) with 10 µM of LVV-
hemorphin-7 for 15 minutes and then stimulated for 30 minutes with different doses 
of AngII (A-C).  HEK293 cells expressing AT1R-WT were initially pre-treated or 
untreated (control using DMSO) with 10 µM of AT1R antagonist (Irebesartan) at 
37ºC for 15 minutes (D). After that, cells were treated or untreated (basal) with either 
5 nM of AngII, 10 µM of LVV-hemorphin-7, or both, at 37ºC for 30 minutes, before 
IP1 assays were carried out. IP1 data are represented as means ± SEM of 3-7 
independent experiments carried out in duplicate or triplicate. 
In order to rule out the possibility of any artifact in these experiments since 
only AT1R-Rluc co-expressed with Venus-Gαq similar to BRET experiments. 
Therefore, IP1 experiments were also carried out in HEK293 cells briefly expressing 






AngII nicely promoted IP1 production in a dose–response manner, and combined 
treatment of cells with LVV–hemorphin-7 (10 µM) substantially left shifted the 
AngII dose-dependent curve with approximately 25-fold potentiation in AngII EC50 
(Table 6). This also indicates the positive pharmacological effect of LVV–
hemorphin-7 on AT1R-mediated IP1 response. 
Moreover, irbesartan, a selective antagonist of AT1R was used to investigate 
its effect of AT1R inhibition, by using the same conditions and protocols as were 
used for BRET assays. In these experiments, AT1R-WT expressed on HEK293 cells 
was used treated or untreated with 10 µM dose of irbesartan, after that cells were 
treated or not with LVV–hemorphin-7 dose of 10 µM, either individually or together 
with a non-saturating dose of AngII (5 nM). Results clearly indicated that both 
AngII-mediated IP1 formation and its substantial increase by LVV–hemorphin-7 
were fully blocked by the treatment of irbesartan. These results are in agreement with 
the BRET data as demonstrated in Figure 45.  
Overall, the results of IP1 experiments in both AT1R-WT and AT1R-Rluc 
validated the positive allosteric effect of LVV–hemorphin-7 on the activation of 
AT1R and its downstream signaling pathways. 
5.1.6 Molecular docking and molecular dynamics studies 
In order to determine the stability and dynamics of the nteractions between 
ACE and hemorphin peptides, all-atom MD simulations were run in triplicate using 






5.1.7 LVV-hemorphin-7 binds to an intracellular site of AT1R 
SiteMap analysis identified three potential binding sites in AT1R – two were 
intracellular and the third was the extracellular orthosteric site. Since the in vitro data 
indicated positive allosteric effects of LVV-hemorphin-7, two potential binding 
cavities outside the orthosteric site were explored. LVV-hemorphin-7 was docked to 
intracellular sites of AT1R identified by SiteMap. However, one of the intracellular 
sites produced extremely poor docking results and was therefore excluded from 
further studies. The best-docked pose of LVV-hemorphin-7-AT1R complex in the 
other site produced a GScore of -11.05 kcal/mol. MM-GBSA based binding free was 
estimated as -125.05 kcal/mol (Table 7). The docked conformation of LVV-
hemorphin-7 in this site interacted with intracellular loops 2 and 3, and the 
cytoplasmic end of transmembrane helices 3 and 6 (TM3 and TM6) of AT1R. The 
first three residues of the decapeptide formed hydrogen bonds with His132 and 
Lys135, hydrophobic interaction with Tyr127, and an electrostatic interaction with 
Arg137 (Figures 46 and 47).   The side chain of LVV-hemorphin-7 Tyr4 formed a 
hydrogen bond with Val131 (Figures 4C and 46D). Pro5, Trp6 and Thr7 of LVV-
hemorphin-7 formed hydrophobic interactions with Ile130, Pro133, Met134 and 
Ala221 of AT1R. Trp6 also formed and electrostatic interaction with Arg234. C-
terminus residues Gln8, Arg9, and Phe10 of LVV-hemorphin-7 formed hydrogen 
bonds with Lys60 and Arg126. They also exhibited hydrophobic interactions with 
Val62, Ala129, Leu138, Met142, Ala225, Pro233 and Ile238, electrostatic 
interactions with Lys230 and Lys232, and polar interactions with Thr61 and Asn235 






Five hundred nanosecond all-atom MD simulations of the docked system 
embedded in a DPPC membrane were performed in triplicate to investigate the 
binding dynamics and stability of the AT1R-LVV-H7 complex using Desmond 
(Bowers et al., 2006). Protein structure in the simulated systems remained stable with 
a protein Cα root mean square deviation (RMSD) under 3.5 Å (Figure 48A). Per 
residue level root mean square fluctuation (RMSF) highlighted that intracellular 
loops (ICL) ICL1, ICL2 and ICL3 and extracellular loop (ECL) ECL2 were more 
flexible while membrane-embedded regions exhibited limited fluctuations (Figure 
48D). The decapeptide interacted consistently with ICL2, and ICL3, while its 
interactions with TM3 and TM6 were considerably weak. The N-terminus residues 
(Val2 and Val3) formed intermittent interactions with His132 and Ala221 of ICL2 
and ICL3, respectively (Figure 52). Tyr4 formed intermittent interactions with 
Val131 and Lys135 of ICL2. Pro5 showed an intermittent hydrogen bond with 
Met134 of ICL2. Trp6 of the peptide formed an intermittent hydrophobic interaction 
with Arg126 and a consistent hydrophobic interaction with Pro133 and Arg234 of 
ICL2 and ICL3. Gln8 exhibited sustained hydrophobic interactions with Ile130 and 
Pro233. Arg9 also intermittently interacted with Ala129 of ICL2. These ICL2 
residues have been reported to form an allosteric site in other GPCRs (Luderman et 






























4ZUD -11.05 -125.05 Lys60, Arg126, 
Val131, His132, 
Lys135 
Val62, Tyr127, Ile130, Pro133, 
Met134, Leu138, Met142, Ala221, 
Ala225, Pro233, Ile238 
Arg234 




Leu13, Cys18, Ala21, Ile31, 
Tyr35, Trp84, Tyr87, Tyr92, 
Val108, Leu112, Pro162, Ala163, 
Phe182, Ile172, Val179, Ala181, 
Trp253, Ile266, Ala277, Val280, 










Leu13, Pro19, Ala21, Tyr35, 
Phe77, Trp84, Val108, Leu112, 
Tyr113, Ala159, Pro162, Ala163, 
Ile172, Cys180, Ala181, Phe182, 
Tyr184, Leu195, Phe204, Ile266, 








Figure 46: Structure of AT1R with the docked peptide. AT1R structure is shown in 
purple cartoon representation while its interacting residues are shown in green stick 
representation. Docked peptide is shown in orange stick representation. Black dotted 
lines represent hydrogen bonds and blue lines represent and π- π interactions. (A) 
Structure of AT1R.  (B) AT1R with AngII docked in the orthosteric site and LVV-
H7 docked to the intracellular site shown in space-filling representation. (C) Closer 
view of the docked pose of LVV-H7 and the hydrogen bond it forms with AT1R 
shown as black dashed lines. (D) Image in (C) shown with interacting residues 







Figure 47: 2D ligand interaction diagram of LVV-hemorphin-7 with AT1R. LVV-
hemorphin-7 interacting residues with intracellular binding pocket of AT1R (PDB: 
4ZUD). Colored circles represent amino acids that form interaction with bound 
ligand. Red circles indicate negatively charged amino acids, dark blue colors indicate 
positively charged amino acids, light blue circles indicate polar amino acids, and 
green circles indicate hydrophobic amino. Hydrogen bonds are shown with purple 
arrows–dashed arrows for hydrogen bonds involving amino acid side chain and 
regular arrows for hydrogen bonds involving amino acid backbone. π–π interactions 







Figure 48: Plots of RMSD and RMSF of protein Cα atoms extracted from three 
independent 500 ns simulations of AT1R complexes. Data of three independent runs 
are plotted with blue, green and red colors. (A) RMSD of AT1R-LVV-H7 complex; 
(B) RMSD of AT1R-AngII complex; (C) RMSD of AT1R-LVV-H7-AngII complex; 
(D) RMSF of AT1R-LVV-H7 complex; (E) RMSF of AT1R-AngII complex; (F) 
RMSF of AT1R-LVV-H7-AngII complex. 
5.1.8 Binding of LVV-H7 to AT1R potentiated the binding of AngII 
The effect of intracellular binding of LVV-H7 on AngII binding affinity was 
evaluated. AngII was first docked in the orthosteric site of AT1R. In the docked 
pose, the C-terminus of AngII was embedded deep in the active site and the N-
terminus was extended towards the lid (Figure 49A). The best binding pose of Ang II 
had a GScore of -12.01 kcal/mol. The calculated MM-GBSA binding energy for this 
pose was -129.31 kcal/mol (Table 7). AngII formed multiple hydrogen bonds, 
hydrophobic, electrostatic and polar interactions that was consistent with previous 
studies (Fillion et al., 2013; Singh, Unal, Desnoyer, & Karnik, 2019) (Figure 50). 






Next, the last frame from a 500 ns simulation of LVV-H7 docked to AT1R 
intracellularly was taken and AngII was docked to the orthosteric binding site in this 
complex. Interestingly, the binding of AngII was improved. The best binding pose of 
AngII produced a GScore of -13.51 kcal/mol and MM-GBSA binding free energy of 
-160.71 kcal/mol (Table 7). This suggested that intracellular binding of LVV-H7 
allosterically enhanced the binding affinity of AngII in extracellular orthosteric 
binding site. This observation is consistent with the BRET data obtained in HEK293 
cells (Figure 41, 42 and 43). Notably, Asp1, Tyr4 and Phe8 residues of AngII were 
positioned differently when LVV-H7 was bound to AT1R (Figure 49). The C-
terminus of AngII bound slightly deeper inside the binding pocket in the presence of 
LVV-H7 (Figure 49B). This allowed Phe8 of AngII to form a hydrogen bond with 
Lys199. Pro7 of AngII showed hydrogen bond with Arg167 both in the presence and 
absence of LVV-H7 (Figure 49).  Tyr4 of AngII, without LVV-H7 formed a π–π 
stacking with Tyr184 (Figure 49A). The sidechains amino groups of Arg2 of AngII 
formed hydrogen bonds with Asp263 and Asp281 of AT1R with and without LVV-
H7 bound. Lastly, Asp1 of AngII, in the presence of LVV-H7, formed a hydrogen 
bond with Gln267 (Figures 49A and 49B). In the absence of LVV-H7, Asp1 was 
observed to form hydrogen bonds with Ser16, and Asp17 (Figure 37A and 37B). 
Overall, AngII was able to form more hydrogen, hydrophobic and polar interactions 






Figure 49: Binding pose of AngII with AT1R in the presence and absence of LVV-H7. AT1R structure is shown in purple cartoon representation 
while its interacting residues are shown in green stick representation. Docked peptide is shown in orange stick representation. Black dotted lines 
represent hydrogen bonds and blue lines represent and π- π interactions. (A) Interaction of the docked pose of AngII in the absence of LVV-H7 
and hydrogen bonds it forms with AT1R shown as black dashed lines. (B) Interaction of the docked pose of AngII in the presence of LVV-H7 










Figure 50: 2D ligand interaction diagram of AngII with AT1R. A) AngII interacting residues with orthosteric binding site of AT1R (PDB: 
4ZUD). Colored circles represent amino acids that form interaction with bound ligand. Red circles indicate negatively charged amino acids, dark 
blue colors indicate positively charged amino acids, light blue circles indicate polar amino acids, and green circles indicate hydrophobic amino. 
Hydrogen bonds are shown with purple arrows–dashed arrows for hydrogen bonds involving amino acid side chain and regular arrows for 










Figure 51: 2D ligand interaction diagram of AngII with AT1R-LVV-hemorphin-7. AngII interacting residues with orthosteric binding site of 
AT1R docked with LVV-H7. Colored circles represent amino acids that form interaction with bound ligand. Red circles indicate negatively 
charged amino acids, dark blue colors indicate positively charged amino acids, light blue circles indicate polar amino acids, and green circles 
indicate hydrophobic amino. Hydrogen bonds are shown with purple arrows–dashed arrows for hydrogen bonds involving amino acid side chain 










The best binding pose of AT1R-Ang II and AT1R-LVV-H7-Ang II 
complexes were extracted, and the complexes were simulated for 500 ns in triplicates 
to assess the binding stability and dynamics of AngII with AT1R in the presence and 
absence of LVV-H7. The membrane embedded AT1R structures remained stable 
when AngII and LVV-H7 were bound with a Cα RMSD that was under 4 Å (Figures 
48B and 48C). RMSF of AT1R, where both LVV-H7 and Ang II were bound, 
showed that ICL2 (residues 131-137) and ECL2 (residues 180-191) fluctuated more 








Figure 52: Average percentage of simulation time from three 500 ns runs during which AT1R residues maintain contact with LVV-H7. The 
average percentage of simulation time is shown next to the dotted line. Charged, hydrophobic, and polar residues are represented with orange, 











Figure 53: Average percentage of simulation time from three 500 ns runs during which AT1R residues maintain contact with AngII in the 
absence of LVV-H7. The average percentage of simulation time is shown next to the dotted line. Charged, hydrophobic, and polar residues are 











Figure 54: Average percentage of simulation time from three 500 ns runs during which AT1R residues maintain contact with AngII in the 
presence of LVV-H7. The average percentage of simulation time is shown next to the dotted line. Charged, hydrophobic, and polar residues are 











Figure 55: Histograms of the percentage of simulation time where an AT1R residue 
maintained contact with a peptide. (A) AT1R-LVV-H7; (B) AT1R-AngII; (C) 
AT1R-LVV-H7-AngII. 
The stability of interactions between AT1R and the peptides were assessed 
from the simulations of AT1R-AngII complex in the presence and absence of LVV-
H7 (Figures 53 and 54). AT1R residues Trp84, Val108, Leu112, Arg199 and Ile288, 
located at the bottom of the orthosteric binding site, interacted with Pro7 and Phe8 of 






LVV-H7-AngII complex, and this inward movement was linked to a more sustained 
interaction of Arg199 with Phe8 during simulations when compared to the AT1R-
Ang II complex (Figures 53 and 54). The interaction of Phe8 with Arg199 has been 
demonstrated to be an essential contact associated with AT1R activation (Fillion et 
al., 2013). Phe8 also formed consistent hydrophobic interactions with Ser109 and 
intermittent interactions with Tyr113 when LVV-H7 was bound. This interaction was 
observed in only one of the simulations when LVV-H7 was not bound to AT1R 
(Figures 53 and 54). His6 showed consistent interactions with Trp84 of AT1R bound 
with LVV-H7 in all runs of simulation, while the same interaction was formed in 
only two runs in the absence of LVV-H7. Pro7 of AngII formed limited interactions 
with Ser105 and Ile288 residues and which were better when LVV-H7 was bound to 
AT1R. Ile5 maintained sustained interactions with Arg167 in both cases for the full 
duration of the simulations. Arg167 is an important to AT1R when compared to 
other structurally similar GPCRs and play a vital role in defining ligand binding 
affinity. Tyr4 of AngII exhibited sustained interactions with Tyr92 of AT1R only 
when LVV-H7 was bound (Figure 54). However, Tyr4 interacted with Tyr35 in both 
cases. AngII residues Arg2 interacted with Asp263 and Asp281of AT1R with and 
without LVV-H7 throughout the simulations. Such an interaction between AT1R and 
AngII has been reported previously (Feng et al., 1995; Wingler, McMahon, Staus, 
Lefkowitz, & Kruse, 2019). The interactions of Asp263 and Asp281 of AT1R with 
Arg2 of AngII were slightly weaker in the absence of LVV-H7. Val3 formed 
consistent interactions with Cys180 and Phe182 in the presence of LVV-H7. While, 
without LVV-H7, these residues of AT1R interacted with Tyr4 of AngII (Figures 53 
and 54). Asp1 of AngII formed sustained interaction with Ser15, Lys20 and Arg23 of 






indicates that the N-terminus of AngII was firmly held by hydrogen bonds as well as 
hydrophobic and polar interactions with Ile12, Leu13, Ser15, Lys20, Arg23, Asp263 
and Asp281 residues of AT1R when LVV-H7 was bound. This permitted the C-
terminus of AngII to bind stably deep inside the orthosteric site. However, in the 
absence of LVV-H7, the N-terminus of AngII formed less stable interactions with 
Ile12, Leu13, Ser15, Lys20 and Arg23 of AT1R (Figures 53 and 54). Such subtle 
changes support the higher binding affinity of AngII in the presence of LVV-H7. 
MM-GBSA based free energy of binding (ΔGbind) was estimated using frames 
extracted every 50 ns from the MD simulations. AT1R-AngII simulations in the 
presence of LVV-H7 exhibited  ΔGbind (-224.8 ± 7.6 kcal/mol, -206.1 ±  10.9 
kcal/mol and -228.4 ± 8.1 kcal/mol) that were higher than AT1R-AngII simulations 
without LVV-H7 (-193.0 ± 14.9 kcal/mol, -161.3 ± 25.2 kcal/mol and -189.9 ± 24.7 
kcal/mol). There is a notable improvement in ΔGbind compared to the initially docked 
structure indicating that AngII remained stably bound in the simulations. 
Furthermore, this also indicates higher binding affinity of AngII in the presence of 
LVV-H7. 
5.2 Discussion 
Here, the pharmacological action of LVV–hemorphin-7 on HEK293 cells 
transiently expressing AT1R was observed. Interesting, a positive allosteric action on 
AT1R activation and signaling was observed for the first time. This effect was 
determined using multiple in vitro assays such as real-time BRET for AngII-
mediated AT1R-Gαq coupling and β-arrestin 2 recruitment. Their related 






production. Additionally, extensive in silico studies indicate the allosteric 
potentiation of AngII binding affinity by LVV-H7 through binding to intracellular 
regions of AT1R. Results clearly showed that LVV–hemorphin-7 produced a 
positive allosteric effects on the activation of AT1R and also enhanced the functional 
coupling with Gαq and its interaction with β-arrestin 2. LVV-hemorphin-7 produced 
substantial potentiation of AngII-induced BRET signals as indicated by both dose–
response and real-time kinetics experiments. The positive allosteric action of LVV-
hemorphin-7 was also found on AngII-mediated Gαq/IP1 generation. Therefore, the 
findings reveal that LVV-hemorphin-7 produces a differential action on AT1R-
mediated signaling. Furthermore, LVV-hemorphin-7 produce positive allosteric 
modulation (PAM)-like effect on Gαq activation and β-arrestin 2 recruitment 
(assessed by BRET). 
Molecular docking and long (MD) simulations were performed to determine 
the most suitable binding pose of LVV-H7 and its effect on AngII binding to AT1R. 
Extensive molecular docking runs identified an intracellular location, previously 
linked to allosteric modulation in other GPCRs, to be the most suitable binding site 
of LVV-H7 (Wang et al., 2018) . Long MD simulations revealed that LVV-H7 
binding in this IC site induced conformational changes in the orthosteric binding 
pocket associated with AngII binding. Interestingly, the C-terminus of AngII was 
embedded deeper in its binding site and formed sustained interaction with Trp84, 
Ser105, Ser109, Lys199 and Ile288 of AT1R when compared to the structure without 
LVV-H7 (Figures 49, 53 and 54). 
These findings are of prime importance to pharmacology of GPCRs and 






another member of the GPCR family - AT1R - that is a target of hemorphins with the 
possible involvement in the pathophysiology and physiology of renal and vascular 
systems, besides hemorphin’s direct effect on opioid receptors (Brantl et al., 1986; 
Cheng et al., 2012; Davis et al., 1989; Glamsta et al., 1992). Additionally, the effect 
of LVV-hemorphin-7 on AT1R is in agreement with the earlier studies indicating 
LVV-hemorphin-7 acting on opioid receptors encompassing the fields of action of 
hemorphins on GPCRs. A partial to full radioligand binding have been confirmed in 
opioid receptors, with a competition with some opioids peptides such as endogenous 
dynorphins and enkephalins but not nonpeptide ligands (Garreau, Zhao, Pejoan, 
Cupo, & Piot, 1995; Zhao & Piot, 1997). Furthermore, an agonist like action of 
LVV–hemorphin-6 has been reported in guinea-pig ileum and GTPγS binding 
assays, respectively (Yukhananov et al., 1994). These studies clearly showed the 
precise binding of hemorphins on the opioid receptors that elucidate the palliative 
potentials of hemorphin found in vivo (Albiston et al., 2001; Cheng et al., 2012; 
Hughes et al., 1975). Indeed, in vitro experiments reported here clearly demonstrated 
the substantial PAM effects of LVV-hemorphin-7 on AT1R, as indicated by different 
BRET and in IP1 assays, and to less extent BRET (100 µM), indicate such an 
interaction between AT1R and  LVV-hemorphin-7. Importantly, results of BRET 
and IP1 dose–response curves are characteristic of PAM of LVV–hemorphin-7 on 
AT1R with no noteworthy effects of LVV-hemorphin-7 were observed when used 
alone. However, a left shift of the AngII dose curves were clearly observed in the 
presence of different doses of LVV–hemorphin-7. Indeed, this suggests that AT1R 
could exhibit an allosteric modulation in the presence of LVV-hemorphin-7 and may 






Positive allosteric binding site of GPCRs have been identified in the past 
(Bruns & Fergus, 1990; Nemeth et al., 1998).  However, recent studies have fully 
characterized the potential of PAM in multiple GPCRs using in silico and in vitro 
approaches (Congreve, Oswald, & Marshall, 2017; Kruse et al., 2013). Allosteric 
binding sites located near the EC face and IC face in different GPCRs have been 
documented (Bock et al., 2012; Kruse et al., 2013). Allosteric sites near the 
orthosteric site in GPCRs often block the entry of other ligands (Proska & Tucek, 
1994; Wang et al., 2018). However, this would not be a problem for allosteric 
ligands that target the IC region. DETQ, an allosteric modulator of dopamine 1 
receptor binds preferentially to ICL2 and significantly enhanced the potency of 
dopamine (Wang et al., 2018). Interestingly, LVV-H7 binds to the IC face of AT1R 
and predominantly targets the ICL2 (Figure 46). LVV-H7 targets ICL2 residues that 
are not conserved in dopamine 1 receptor at AT1R such as Lys135 and Ser136 as 
well as the conserved residues Arg126, Ile130 and Pro133 (Figures 46, and 47). 
These residues are located near the binding site of DETQ on ICL2 of dopamine 1 
receptor (Wang et al., 2018). Moreover, recent studies have shown that AT1R 
stabilizing nanobodies target the intracellular side of AT1R, especially ICL2 residues 
and enhanced the binding affinity of AngII for AT1R (Wingler et al., 2019). This 
phenomenon shows complementary cooperativity anticipated for an allosteric 
interaction. Interestingly, here, LVV-H7 binds to these ICL2 residues of AT1R and 
could potentiate the binding affinity and potency of AngII. Moreover, the allosteric 
binding of LVV-H7 in the intracellular regions of AT1R is consistent with the 
allosteric modulation of GPCRs through the targeting of their intracellular surfaces 






even small molecules (Covic, Gresser, Talavera, Swift, & Kuliopulos, 2002; P. 
Zhang et al., 2015).  
Evaluating the binding mode of AngII in the presence and absence of LVV-
H7 revealed that AngII bound deeper in the orthosteric binding pocket in the 
presence of LVV-H7 (Figure 49). The interaction between Phe8 of AngII with 
Lys199, located at the base of the orthosteric pocket of AT1R was improved in the 
presence of LVV-H7 (Figures 53 and 54). Lys199 has been identified as a residue 
critical for AT1R activation (H. Zhang et al., 2015a). Tyr35 and Trp84 are conserved 
in other GPCRs such as angiotensin, chemokine and opioid receptors and mutating 
these residues would abolish the binding of both peptide and synthetic ligands of 
AT1R (H. Zhang et al., 2015b). In simulations, Tyr35 and Trp84 were observed to 
form more sustained interactions with AngII in the presence of LVV-H7 (Figures 53 
and 54). AT1R activation cascade has also been shown to be initiated by the van der 
Waals interaction between Phe8 and Ile288 (Singh et al., 2019). Interestingly, 
intracellular binding of LVV-H7 enhanced stability of the interaction between Phe8 
with Ile288 (Figures 53 and 54). This could likely lead to a more robust disruption of 
the Asn111-Asn295 interaction, and better AngII binding affinity and potency (Singh 
et al., 2019). The existence of a stable hydrogen bond between Asn111 and Asn295 
is characteristic of the inactive state of AT1R and its disruption is vital for AT1R 
activation (H. Zhang et al., 2015a; H. Zhang et al., 2015b).  Mutagenesis studies have 
also reported that Tyr87, Arg167 and Tyr292 are important for AngII binding (Singh 
et al., 2019). Interestingly, these residues formed more sustained interactions with 






DRY, Yx7K, NPxxY, and helix-8 motifs are highly conserved among GPCRs 
and are located in the cytoplasmic region. These motifs, initially reported in 
rhodopsin, act as microswitches (Elgeti et al., 2011). Functional studies of AT1R 
have illustrated the stability of these motifs in the inactive state (Elgeti et al., 2011; 
Lin, Han, & Sakmar, 2000). ICL2 residues of AT1R, where LVV-H7 bound, are 
associated with structural changes that induce a transition from an inactive to an 
active conformation in GPCRs (Wang et al., 2018). Trajectory analysis of AT1R-
LVV-H7 complex indicated that the binding of LVV-H7 to ICL2 and ICL3 of AT1R 
induced conformational changes in the DRY motif present at the cytoplasmic end of 
TM3 that are important for GPCR activation (Singh et al., 2019; Wang et al., 2018). 
GPCR activation involves the breakage of a stable interaction that exists between 
Asp125 and Arg126 of the DRF motif in the inactive state (Matsoukas et al., 2013; 
Singh et al., 2019). Interestingly, LVV-H7 binds to the DRF motif and forms an 
intermittent interaction with Arg126 residue of AT1R throughout the simulations 
(Figure 52). Additionally, the side chain of Arg126 was observed to slightly orient 
itself towards TM6 in the presence of LVV-H7. These changes have been associated 
with the opening of the groove where G-protein binds and could, therefore, enhance 
the coupling of G-protein to AT1R (Rasmussen et al., 2011; Singh et al., 2019).  
In the physiological context, the positive allosteric modulator effects of 
LVV–hemorphin-7 on AT1R captivatingly indicate a hypertensive action. Such an 
effect is somehow is not in agreement with the previous antihypertensive effects of 
hemorphins demonstrated in several in vivo and in vitro studies (Ali et al., 2020; 
Fruitier-Arnaudin, Cohen, Coitoux, & Piot, 2003; Lantz et al., 1991; Zhao & Piot, 






through the direct inhibition of ACE (Zhao & Piot, 1997). Additionally, hemorphins 
have been reported to enhance the hypotensive and vasodilatory effect of bradykinin 
(Ianzer et al., 2006). Lastly, studies have shown that serum hemorphin-7 levels after 
long distance running were determined to be very high (Glamsta et al., 1992), while 
they were observed quite low in diabetic and obese patients, which are associated to 
high blood pressure and cardiovascular risks (Maraninchi et al., 2013). Thus, 
conflicting activities of hemorphins on ACE (inhibition) and AT1R (activation) and 
their physiological outcomes, hypotensive and hypertensive, respectively, 
demonstrate the intricacy of hemorphin’s action on RAS. One possibility of 
explaining these opposing effects is by assuming that the blockage of ACE which 
results in a reduction of AngII levels can be compensated by the positive effect of 
hemorphins on AT1R. This would suggest that low doses of AngII could be 
sufficient to activate RAS in this condition.  In addition, it is possible that 
hemorphins regulate water reabsorption and blood pressure under different 
conditions by biasing RAS towards activation via their positive modulatory activities 
on AT1R or inhibition of ACE effect and AngII levels. The data presented here can 
be viewed and interpreted in both physiological and pathophysiological 
circumstances. Certainly, it is not established yet if hemorphins release from the 
hemoglobin is a normal or a pathogenic mechanism with an effect on blood pressure 
and water balance. Additionally, it is also unknown that which part of hemorphin’s 
action ACE, or AT1R is actually the determinant of the system and how it interacts 
under physiological and pathophysiological conditions. In the physiological context, 
the two contradictory action of hemorphins could be components of the precise 
control of the blood pressure (and maybe even water balance) via the stimulatory and 






in the normal range. For example, if elevated blood pressure occurs for some reason 
and this could be correlated with high ACE expression and/or activity, in such 
circumstances hemorphins could be released to counterbalance this condition so as to 
prevent any risk of consistent or chronic hypertension. Similarly, if there is a 
hypotensive/vasodilatation condition due to lower expression/activity of AT1R, 
hemorphins could then be produce and released to raise blood pressure by 
stimulating AT1R-dependent vasoconstriction. However, in pathological conditions, 
the increased expression/activity of AT1R correlated with possible decrease in the 
expression/activity of ACE and the enhanced release of hemorphins could be 
indicative of the pathophysiology of hypertension and of RAS. In such a scenario, 
hypertension may be either the cause or the outcomes of the action of hemorphins. 
Therefore, it could be speculated that in different physiological and 
pathophysiological conditions, the biological system including all these components 
(hemorphins, AT1R, or ACE) could rely on the circulating concentrations of 
hemorphins along with the comparative expression levels of the two RAS targets, 
ACE and AT1R. Until now, there is no reliable data available on the possible 
relationship between the quantity of hemorphins released in blood and the expression 
profiles of AT1R and ACE and their effects on the regulation of blood pressure and 
hypertension. This indicates that the stoichiometry of hemorphins/AT1R versus 
hemorphins/ACE in hypotensive and hypertensive situations remain elusive. A 
previous study has revealed that the blood of long-distance running subjects 
contained a higher concentration of hemorphins (Glamsta, Morkrid, Lantz, & 
Nyberg, 1993). This could be true with either a positive modulator effect of 
hemorphins (hypertensive) via action on AT1R due to exercise or their negative 






unnecessary hypertension. Moreover, very low hemorphin levels have recently been 
documented in diabetic and obese patients that are associated to hypertension and 
cardiovascular risks indicating therapeutically beneficial effects of hemorphins on 
ACE inhibition (Maraninchi et al., 2013). Thus, it would be important to explore the 
possible effects of hemorphins on other primary RAS and kidney actor such as 
bradykinin, adrenergic, and vasopressin receptors, identified to have functional 






Chapter 6:  Structural and Genetic Changes of Camel Hemoglobin   
6.1 Results 
Genetic and in silico approaches were used to investigate the structural and 
genetic changes of camel hemoglobin and were compared with human hemoglobin. 
6.1.1 Hemoglobin α and β genes sequences 
Hemoglobin α and β genes of 170 camel samples from different breeds were 
amplified to determine the variation near the heme, ATP and 2,3-BPG binding sites. 
PCR was first used to amplify hemoglobin α and β genes of all samples. These 
samples were then purified and sent for DNA sequencing using the primers used for 
PCR. Chromatograms obtained from sequencing were inspected using Finch TV 
Viewer and the sequences were aligned using BioEdit Sequence Alignment Editor to 
identify locations that harbor variations. One synonymous variation (Ser82) was 
observed in hemoglobin α gene in all camel breeds. The frequency of this variation 
in each breed is given in Table 8. The chromatogram showing the variation is given 
in Figure 56. The coding regions of both genes were devoid of any other variation. 












Figure 56: Chromatograms of camel samples. (A) Chromatogram of a wild camel; 
(B) Chromatogram of a camel with synonymous variation. Arrow in red color shows 











Table 8: List of coding and non-coding variations observed in hemoglobin genes of 
different breeds of camel. 
















































g.563C>T  NA 34/50 
g.608C>T NA 2/50 
g.644C>T NA 17/50 
g.655A>C NA 3/50 
g.677C>T NA 24/50 
g.684C>T NA 26/50 
g.694C>T NA 11/50 
g.704C>T NA 5/50 
g.707C>T NA 2/50 
g.715C>T NA 30/50 
g.1033T>C NA 44/50 








Table 8: List of coding and non-coding variations observed in hemoglobin genes of 
different breeds of camel (Continued). 














g.563C>T  NA 25/50 
g.608C>T NA 0/50 
g.644C>T NA 5/50 
g.655A>C NA 0/50 
g.677C>T NA 15/50 
g.684C>T NA 17/50 
g.694C>T NA 9/50 
g.704C>T NA 0/50 
g.707C>T NA 8/50 
g.715C>T NA 18/50 
g.1033T>C NA 48/50 














g.563C>T  NA 23/50 
g.608C>T NA Nil 
g.644C>T NA 12/50 
g.655A>C NA Nil 
g.677C>T NA 11/50 
g.684C>T NA 14/50 
g.694C>T NA 4/50 
g.704C>T NA Nil 
g.707C>T NA 9/50 
g.715C>T NA 17/50 
g.1033T>C NA 46/50 








Table 8: List of coding and non-coding variations observed in hemoglobin genes of 
different breeds of camel (Continued). 














g.563C>T  NA 7/20 
g.608C>T NA 1/20 
g.644C>T NA 3/20 
g.655A>C NA 0/20 
g.677C>T NA 5/20 
g.684C>T NA 8/20 
g.694C>T NA 6/20 
g.704C>T NA 1/20 
g.707C>T NA 3/20 
g.715C>T NA 5/20 
g.1033T>C NA 16/20 
 
6.1.2 Molecular dynamics (MD) simulation of camel and human hemoglobin 
MD simulations were performed on camel and human hemoglobin at 
different temperatures (27°C, 30°C, 34°C, and 41°C) and salt concentration (0 mM, 
150 mM, 300 mM, and 600 mM) to investigate the structural stability and flexibility 
of hemoglobin residues. The salt concentration of 150 mM was maintained in each 
simulation when the effects of different temperature conditions were measured. 
While, a temperature of 27°C was used in each simulation to assess the overall 
impact of different salts concentrations on hemoglobin stability. Sixteen different 
complex systems were prepared. The information of each prepared complex system 
is given in Table 9. One microsecond MD simulations were performed for each 






hemoglobin structure under different salt concentrations and temperature conditions. 
The dynamical features were investigated by evaluating RMSD and RMSF. 
Table 9: MD simulation conditions used for simulating complex systems of camel 
and human hemoglobin. 






3GDJ 27 0 1000 
3GDJ 27 150 1000 
3GDJ 27 300 1000 
3GDJ 27 600 1000 
3GDJ 27 150 1000 
3GDJ 30 150 1000 
3GDJ 34 150 1000 
3GDJ 41 150 1000 
2HHB 27 0 1000 
2HHB 27 150 1000 
2HHB 27 300 1000 
2HHB 27 600 1000 
2HHB 27 150 1000 
2HHB 30 150 1000 
2HHB 34 150 1000 








6.1.2.1 RMSD and RMSF of camel and human hemoglobin at different salt 
concentration  
RMSD of camel and human hemoglobin was measured at different salt 
concentration (0 mM, 150 mM, 300 mM and 600 mM). Each simulation was 
performed at a constant temperature of 27°C. RMSD of Hb from each simulation 
system was computed and plotted to determine the dynamic features of camel and 
human Hb throughout the simulation runs (Figure 57). The backbone Cα atoms of 
camel Hb showed the RMSD of approximately 2 Å at all salt concentration except 
600mM where the complex system stabilized under 3 Å. All systems reached 
equilibrium after few nanoseconds of simulation except the complex system of 600 
mM (Figure 57A). This system attained equilibrium after 500ns (Figure 57A). The 
average calculated RMSD values were 1.97 Å, 1.82 Å, 1.83 Å and 2.42 Å for the salt 
concentration of 0 mM, 150 mM, 300 mM and 600 mM respectively. Human Hb 
showed higher RMSD values at all salt concentration (Figure 57B). The average 
estimated RMSD values of human Hb were 3.56 Å, 4.07 Å, 3.23 Å, and 3.24 Å for 
the salt concentrations of 0 mM, 150 mM, 300 mM and 600 mM, respectively. 
Moreover, all human Hb complex systems required more time to reach equilibrium. 
This indicates that camel hemoglobin structure showed more stability at different salt 
concentrations, compared to human hemoglobin. The structural integrity of all 
simulations of camel and human Hb were retained as indicated by their RMSD. 
To evaluate the flexibility of camel hemoglobin at constant temperature, 
T=27°C, with various salt concentrations (NaCl), the RMSF of Cα atoms on a 
residue from the average structure obtained from the MD frames was calculated. The 






different salt concentrations and high peaks were observed in some residues in the 
loop or turn region (Figure 57C). The residue numbering used in RMSF plots of 
hemoglobin shows the seuential combination of residues from the four chains (α1, 
β1, α2, and β2) in the structure. Importantly, camel hemoglobin residues α2:46 -55 
(represented by residues 330-342 in Figure 57C) showed more fluctuations at 600 
mM NaCl concentration. α1:46-50 showed high fluctuations at 0 mM and 600 mM 
salt concentrations (Figure 57C). β1:47-53 exhibited more fluctuations at only 0 mM. 
However, the same region remained stable in all other simulations. β2:5-11 exhibited 
higher fluctuations at 150 mM and 300 mM salt concentrations. However, the same 
region in β1 showed more fluctuations at 0 mM only (Figure 57C). The residue 
His87 of α1 subunit and His92 of β1 and β2 subunits showed more fluctuations at 
higher salt concentrations. However, His87 of α2 showed more fluctuation at 0 mM 
salt concentration. At 150 mM and 300 mM, Ser70-Phe71-Gly72 in the β1 and β2 
subunits showed more fluctuations.  
Residues of human hemoglobin compared to camel hemoglobin showed more 
fluctuations at all salt concentrations (Figure 57D). Loop region residues 42-51, and 
70-77 of α1 subunit exhibited more fluctuations particularly at 300 mM and 600 mM. 
Helical residues 78-91 of α1 subunit also showed higher fluctuations at higher salt 
concentrations. Interestingly, the same helical residues of camel α1 subunit 
demonstrated extremely low fluctuations at all salt concentrations (Figure 57D). 
However, such fluctuations were not observed in the same residues of both camel 
and human α2 subunits. Moreover, residues 111-140 of α1 subunit of human Hb 
showed higher fluctuations at higher salt concentrations especially at 300 mM.  






salt concentrations. However, such a pattern was not observed in α2 subunits of both 
camel and human Hb.  Val2 of β1 and β2 subunits of human Hb showed more 
fluctuations particularly at higher salt concentrations, compared to camel Hb (Figure 
57D). Helical residues 11-15 of camel Hb showed slightly higher fluctuations at all 
salt concentrations, particularly at 0 mM. However, the same residues in human β2 
subunit showed slightly more fluctuations compared to camel Hb (Figure 57D). Loop 
residues 39-59 of β1 subunit of human Hb exhibited higher variations at all salt 
concentrations compared to camel β1 subunit.  However, such a trend was observed 
in only 39-45 residues of β2 subunits of both human and camel Hb (Figure 57D). 
Residues 80-98, 84-98 which formed loops in β1 and β2 subunits showed higher 
fluctuations in human Hb compared to camel Hb at all salt concentrations, 
respectively (Figure 54D). Lys82 of both β1 and β2 chains is considered an essential 
residue for the binding of 2,3-BPG and ATP (Chen et al., 2017). However, His92 is 
an important residue of β1 and β2 subunits which form the binding sites for oxygen. 
Interestingly, these residues fluctuated more in human Hb at all salt concentrations. 
Residues 141-147 of β1and β2 chain of human Hb exhibited higher fluctuations 
particularly at higher salt concentrations. However, camel Hb demonstrated limited 
variations at all salt concentrations (Figure 57).  His143 and His146 of β1 and β2 
chains are also important for the binding of 2,3-BPG and ATP (Berg et al., 2002). 
Overall, human Hb showed higher fluctuations at all salt concentrations, compared to 









Figure 57: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 1000 ns 
run of camel and human hemoglobin simulation at different salt conditions. Data from different salt conditions are shown in red, green, blue and 
purple. (A) RMSD of camel hemoglobin; (B) RMSD of human hemoglobin; (C) RMSF of camel hemoglobin and, (D) RMSF of human 










6.1.2.2 RMSD and RMSF of camel and human hemoglobin at different 
temperature conditions 
The camel and human hemoglobin protein was simulated separately for one 
microsecond at four different temperature conditions (27°C, 30°C, 34°C, and 41°C). 
The final salt concentration was kept constant (150 mM) for these simulations. 
RMSD of main-chain atoms for the entire Hb was plotted to investigate the structural 
changes of camel and human Hb (Figure 58). RMSD of the Cα atoms of camel Hb 
with respect to the initial structure stabilized under 2 Å in all the simulations except 
the one at 34°C. At 34°C the complex system of camel hemoglobin stabilized at 
approximately 2.5 Å. This indicates that the structure of hemoglobin exhibited a 
stable conformation from low to high temperature conditions. The average RMSD 
values were 2.04 Å, 2.17 Å, 2.76 Å and 2.34 Å for the temperature, 27°C, 30°C, 
34°C and 41°C respectively. In the case of 27°C and 30°C, the hemoglobin structure 
reached equilibrium during the initial nanoseconds of the simulation, but the 
structure required more time in the case of high temperature (34°C and 41°C). In 
comparison to camel Hb, human Hb needed more time to reach equilibrium at all 
temperature conditions. The RMSD of backbone Cα atoms of human Hb with respect 
to the initial structure stabilized under 4.5 Å in all the simulations which were higher 
compared to RMSD of camel Hb (Figure 58). The average RMSD values were 3.86 
Å, 3.31 Å, 2.76 Å and 3.91 Å for the temperature, 27°C, 30°C, 34°C and 41°C 
respectively. 
In order to evaluate and compare flexibility in camel Hb at various 
temperature conditions, the RMSF of Cα atoms on a residue, from the average 






exhibited more fluctuations at higher temperature conditions especially in loop 
regions (Figure 58C).  The loop region residues 41-52 of α1, and α2 subunit showed 
higher fluctuations compared to other residues particularly at higher temperature 
conditions. The β1 helical residues 1-7 demonstrated higher fluctuations at lower 
temperature conditions.  However, the same residues of β2 subunits showed more 
fluctuations at 34°C. Val2 and His3 of both β1 and β2 subunits are considered 
important for the binding of 2,3-BPG and ATP (Chen et al., 2017). Higher 
fluctuations were observed for residues near to the heme binding sites in each 
subunit. The residues in these regions exhibited high RMSF values than the other 
residues. The loop residues 44-55 of β1 and β2 showed higher fluctuations at 41°C. 
Loop residues 72-82 of β1 exhibited higher fluctuations at only 34°C. The same 
residues of β2 exhibited more fluctuations at higher temperature conditions (30°C, 
34°C, and 41°C) (Figure 58C). The helical residues 2-7 and loop residues 15-19 of 
α2 showed higher fluctuations 34°C and 41°C, respectively. However, the same 
residues of α1 subunit exhibited limited fluctuations at all temperature conditions. 
His87 of α subunits and His92 of β1 subunits demonstrated more fluctuations at 
higher temperature conditions. These residues are essential for the binding of four 
heme groups and served as oxygen binding sites. Importantly, conserved residues α1-
Phe43 and α1-Phe46 showed more fluctuations at higher temperature conditions 
(Figure 58). These functional residues are present in the heme pocket distal to heme 
where oxygen binds (Laberge et al., 2008). Moreover, α1 conserved residues Leu86 
and Leu91 also exhibited higher fluctuations when the temperature was increased 
(Figure 58C). These residues are part of the proximal heme pocket residues (Laberge 






The helical residues 1-10 and loop residues 11-17 of α1 of human Hb showed 
higher fluctuations at higher temperature conditions when compared to camel Hb 
(Figure 58D). The loop region residues 41-52 of α1 and   α2 subunits showed higher 
fluctuations at lower temperature conditions compared to camel Hb (Figure 58). 
Moreover, the loop residues 44-55 of β1 of human Hb showed higher fluctuations at 
higher temperature conditions compared to camel Hb.  Loop residues 72-82 of 
human β1 and β2 exhibited higher fluctuations at lower temperature conditions 
compared to camel Hb. Interestingly, at higher temperature conditions these residues 
showed limited fluctuations in both camel and human Hb. Overall, in comparison to 

















Figure 58: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 1000 ns 
run of camel and human hemoglobin simulation at different temperature conditions. Data from different temperature conditions are shown in red, 
green, blue and purple. (A) RMSD of camel hemoglobin; (B) RMSD of human hemoglobin; (C) RMSF of camel hemoglobin and, (D) RMSF of 











6.1.3 Molecular docking of 2,3-BPG and ATP with camel hemoglobin 
The binding pose and binding affinity of 2,3-BPG and ATP was investigated 
with camel deoxyhemoglobin structure (PDB ID: 3GDJ). 2,3-BPG and ATP 
preferentially bind to deoxyhemoglobin and target the same binding site which is 
located in the central cavity of hemoglobin molecule. The best binding pose of 2,3-
BPG had a GScore of -5.165 kcal/mol. The carbonyl and phosphate groups of 2,3-
BPG formed hydrogen bonds and salt bridges with Lys82 of β2 chain (Figure 59A). 
Lys82 of β1 showed hydrogen bonds and salt bridge formation with carbonyl and 
phosphate groups of 2,3-BPG. His146 residue of β2 formed hydrogen bond with 
phosphate group. 2,3-BPG showed polar interactions with His143 of both β1 and β2 
chains. Additionally, β1 chain formed hydrophobic interactions with Leu81 and 
Ala140, electrostatic interaction with Asp79, and polar interactions with Asn80 and 
Asn139 (Figure 59A).  
GScore of the best binding pose of ATP with camel hemoglobin was -7.44 
kcal/mol. Phosphate groups formed hydrogen bonds and a salt bridge with Lys82 
residue of both β1 and β2 chains (Figure 59C). They also formed hydrogen bond and 
polar interaction with His146 and His143 of β2 respectively. Additionally, Leu81 
and Asp79 of β1 exhibited hydrophobic and electrostatic interactions with phosphate 
groups of ATP. Hydroxyl group present on the ribose sugar of ATP formed hydrogen 
bonds with Asp79 of β2 (Figure 59C). The β1 residues His143 and His146 were 
involved in the formation of polar interactions with adenine group. Residues Arg144 
and Tyr145 of β1 formed electrostatic and hydrophobic interactions with adenine. 






59C). Overall, camel hemoglobin formed more interactions with ATP, compared to 
human hemoglobin.  
6.1.4 Molecular docking of 2,3-BPG and ATP with human hemoglobin 
The binding pose and binding affinity of 2,3-BPG and ATP of camel 
hemoglobin was compared with human deoxyhemoglobin structure (2HHB). The 
best binding pose of 2,3-BPG showed GScore of -4.925 kcal/mol. These findings 
were in agreement with previous studies performed to determine the binding affinity 
of 2,3-BPG with hemoglobin (Chen et al., 2017). 2,3-BPG formed interactions with 
critical residues of only β1 chain of hemoglobin as reported by previous studies. 
Both phosphate groups of 2,3-BPG formed hydrogen bonds and salt formation with 
Lys82 of β1 chain of hemoglobin (Figure 59B). The phosphate group of 2,3-BPG 
showed electrostatic interaction with His143 of β1 chain. Additionally, phosphate 
group also formed hydrogen bond with Val2, hydrophobic interaction with Leu81 
and electrostatic interaction with Asn80 (Figure 59B). However, carbonyl group of 
2,3-BPG showed hydrogen bond formation with Asn139.  
The best binding pose of ATP exhibited GScore of -7.205 kcal/mol. All three 
phosphate groups of ATP formed hydrogen bonds and salt formation with Lys82 of 
β2 chain (Figure 59D). The third phosphate group also showed hydrogen bond and 
hydrophobic interaction with Val2 and Leu81 of β2 chain respectively. The 
phosphate groups also formed polar interactions with Asn79 and His143 of β1 and 
β2 chains respectively (Figure 59D). The hydroxyl group of ribose sugar of ATP 
formed hydrogen bonds with Asn79 of β1 subunit. The adenine group of ATP 






respectively. Adenine also formed hydrophobic and polar interactions with Val2 and 
Asn80 of β1 (Figure 59D). 
 
Figure 59: Docked pose of 2,3-BPG and ATP with camel and human hemoglobin. B) 
Docked pose of 2,3-BPG with human hemoglobin. C) Docked pose of ATP with 
camel hemoglobin. D) Docked pose of ATP with human hemoglobin. β1 and β2 
subunits of camel and human hemoglobin are represented with blue and green 
cartoons respectively. Interacting residues are shown in gray stick representation, the 
docked ligands are represented as yellow stick, hydrogen bonds and salt bridges are 









































































6.1.5 Molecular dynamics (MD) simulations of 2,3-BPG and ATP bound to 
camel and human hemoglobin 
MD simulations were performed to determine the binding stability of 2,3-
BPG and ATP with camel and human hemoglobin in the presence of different salt 
concentrations (0 mM, 150 mM, 300 mM, and 600 mM) and different temperature 
conditions (27°C, 30°C, 34°C, 41°C). For measuring the impact of different 
temperatures on the binding stability of 2,3-BPG-Hb and ATP-Hb complexes, a 
single salt concentration of 150 mM was used for all simulations, whereas for 
determining the effect of different salt concentrations, a single temperature of 27°C 
was used for all simulations. Thirty two different complex systems were prepared. 
The information of each prepared complex system is given in Table 11. For each 
complex, two hundred nanosecond MD simulations were performed to determine the 
binding stability of 2,3-BPG and ATP bound to camel and human hemoglobin.  
Table 11: MD simulation conditions used for simulating complex systems of 2,3-
BPG and ATP with camel and human hemoglobin. 






3GDJ 2,3-BPG 27 0 200 
3GDJ 2,3-BPG 27 150 200 
3GDJ 2,3-BPG 27 300 200 
3GDJ 2,3-BPG 27 600 200 
3GDJ 2,3-BPG 27 150 200 
3GDJ 2,3-BPG 30 150 200 
3GDJ 2,3-BPG 34 150 200 
3GDJ 2,3-BPG 41 150 200 
3GDJ ATP 27 0 200 
3GD ATP 27 150 200 






Table 11: MD simulation conditions used for simulating complex systems of 2,3-
BPG and ATP with camel and human hemoglobin (Continued). 






3GDJ ATP 27 600 200 
3GDJ ATP 27 150 200 
3GDJ ATP 30 150 200 
3GDJ ATP 34 150 200 
3GDJ ATP 41 150 200 
2HHB 2,3-BPG 27 0 200 
2HHB 2,3-BPG 27 150 200 
2HHB 2,3-BPG 27 300 200 
2HHB 2,3-BPG 27 600 200 
2HHB 2,3-BPG 27 150 200 
2HHB 2,3-BPG 30 150 200 
2HHB 2,3-BPG 34 150 200 
2HHB 2,3-BPG 41 150 200 
2HHB ATP 27 0 200 
2HHB ATP 27 150 200 
2HHB ATP 27 300 200 
2HHB ATP 27 600 200 
2HHB ATP 27 150 200 
2HHB ATP 30 150 200 
2HHB ATP 34 150 200 
2HHB ATP 41 150 200 
 
6.1.6 MD simulations of camel and human hemoglobin bound to 2,3-BPG at 
different salt concentrations 
2,3-BPG is an important co-factor present abundantly in erythrocytes and is 






to determine the effect of osmotic pressure on the structural stability, residual 
flexibility and the binding stability of 2,3-BPG with camel and human hemoglobin. 
The RMSD of both camel and human hemoglobin-2,3-BPG complexes at different 
salt concentration remained stable throughout the simulation time. RMSD of the Cα 
atoms of camel and Hb bound to 2,3-BPG with respect to the initial structure were 
stabilized under 3.5Å in all the simulations (Figures 60A and 60B). However, human 
hemoglobin bound to 2,3-BPG demonstrated higher RMSD at 600 mM. To 
determine the effect of 2,3-BPG on the backbone stability and residual flexibility of 
camel and human hemoglobin, the RMSF of backbone Cα atoms of both camel and 
human hemoglobin were investigated (Figures 60C and 60D). Overall, camel 
hemoglobin showed limited fluctuations compared to human hemoglobin. The  loop 
residues 44-52 and 45-52 of  α1 and α2 subunits showed similar fluctuations at all 
salt concentrations, in both camel and human hemoglobin bound to 2,3-BPG, except 
150 mM, where camel Hb-2,3-BPG complex showed lower fluctuations (Figures 
60C and 60D).  The loop residues 78-93 of α1 subunit exhibited higher fluctuations 
at higher salt concentrations in both camel and human Hb-2,3-BPG complexes. 
However, the fluctuations of the same residues of α1 subunit were observed higher in 
human Hb-2,3-BPG complex at 600 mM, compared to camel. The loop residues 111-
120, and the helical residues 120-132 of α1 exhibited higher fluctuations at higher 
salt concentrations in human Hb-2,3-BPG complex, compared to camel complex 
system.  The helical residues 2-13 and loop residues 14-20 of β1 and β2 subunits of 
camel Hb showed higher fluctuations at 300 mM. However, residues 1-32 of β1 and 
β2 subunits of human Hb, composed of loops and helical regions exhibited higher 
fluctuations at 600 mM, compared to camel. The loop residues 44-55 of β1 showed 






residues of β2 showed higher fluctuations at higher salt concentrations (300 mM and 
600 mM) in camel Hb-2,3-BPG complex. However, the same residues showed 
higher fluctuations at all salt concentrations in human Hb. Loop residues 80-100 of 
β1 and β2 showed higher fluctuations at only 0 mM and 600 mM, (Figures 60C and 
60D). While the same residues in human demonstrated higher fluctuations at higher 
salt concentrations (300 mM and 600 mM). Importantly, residues 79 and 82 of β1 of 
camel Hb showed higher fluctuations at higher salt concentrations, while the same 
residues of β2 subunit showed higher fluctuations at only 300 mM. However, the 
same residues in human Hb showed higher fluctuations at higher salt concentrations 
(300 mM and 600 mM). Additionally, residues 139, 143 and 146 of both β1 and β2 
subunits exhibited lower fluctuations at higher salt concentrations, compared to 
human Hb.  Overall, the fluctuations of these important residues of β1 and β2 
subunits were observed higher in human compared to camel at all salt concentrations, 







Figure 60: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 200 ns 
run of 2,3-BPG bound camel and human hemoglobin simulations at different salt conditions. Data from different salt conditions are shown in red, 
green, blue, and purple. (A) RMSD of camel Hb-2,3-BPG complex simulations; (B) RMSD of camel Hb-2,3-BPG complex simulations: (C) 
RMSF of camel Hb-2,3-BPG complex simulations and, (D) RMSF of human Hb-2,3-BPG complex simulations. Note that the residue number 










The contact duration of critically important residues of hemoglobin β subunits with 
2,3-BPG were observed during the simulations. Several hydrogen bonds, 
hydrophobic interactions, salt bridges, cation–π, and π–π and interactions were 
observed to form, break, and reform throughout the simulation runs. Asp79 of both 
β1 of β2 subunits of camel Hb exhibited consistent interactions at all salt 
concentrations. While the same residue of β1 chain of human Hb formed intermittent 
interaction at lower salt concentrations only. Lys82 of both β chains of human and 
camel Hb formed sustained interactions for the full duration of the simulations at all 
salt concentrations. Moreover, Asn139 of β1 chain of camel Hb exhibited sustained 
interactions with 2,3-BPG at higher salt concentration. However, Asn139 of both β 
chains of human Hb formed interactions with 2,3-BPG at lower salt concentrations 
only. The residue His143 of β1 and β2 of camel hemoglobin formed more sustained 
interactions with 2,3-BPG at higher salt concentrations, compared to human 
hemoglobin. Similarly, His146 of camel β subunits formed more sustained 
interactions with 2,3-BPG at higher salt concentrations (300 mM and 600 mM). 
However, such interactions were not observed in human Hb.  Additionally, Asn80 of 
camel β2 subunit showed more sustained interactions at 300 mM, and 600 mM, 
while, the same residue of β1 of human Hb showed interactions with 2,3-BPG at 0 








Figure 61: The percentage of simulation time during which different residues of 
camel hemoglobin interacted with 2,3-BPG. Orange, green, and blue colors represent 
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of camel 
hemoglobin-2,3-BPG complex at 0mM; (B) Simulations of camel hemoglobin-2,3-
BPG complex at 150 mM; (C) Simulations of camel hemoglobin-2,3-BPG complex 












Figure 62: The percentage of simulation time during which different residues of 
human hemoglobin interacted with 2,3-BPG. Orange, green, and blue colors 
represent charged, hydrophobic and polar amino acids, respectively. (A) Simulations 
of human hemoglobin-2,3-BPG complex at 0mM; (B) Simulations of human 
hemoglobin-2,3-BPG complex at 150 mM; (C) Simulations of human hemoglobin-
2,3-BPG complex at 300 mM; and, (D) Simulations of human hemoglobin-2,3-BPG 
complex at 600 mM. 
6.1.7 MD simulations of camel and human hemoglobin bound to 2,3-BPG at 
different temperature conditions  
Next, the RMSD of both camel and human hemoglobin-2,3 BPG complexes 
at different temperature conditions were determined. The structures of both camel 
and human Hb remained stable during simulation runs. The RMSD of the Cα atoms 






stabilized under 3.5 Å and 4 Å in all the simulations, respectively (Figures 63A and 
63B). However, human hemoglobin bound to 2,3-BPG demonstrated higher RMSD 
at 34°C. In order to measure the effect of 2,3-BPG on the backbone stability and 
residual flexibility of camel and human hemoglobin, the RMSF of backbone Cα 
atoms of both camel and human hemoglobin were investigated (Figures 63C and 
63D). Overall, camel hemoglobin showed limited fluctuations compared to human 
hemoglobin. The  loop residues 41-52 of α1 of camel Hb showed limited fluctuation 
at all temperature conditions, compared to human Hb when bound to 2,3-BPG. 
Whereas, loop residues 46-52 of α2 subunit of both camel and human  showed 
similar fluctuations at all conditions, especially at 41°C. Additionally, fluctuations in 
human Hb were observed to be higher at 34°C and 41°C, compared to camel Hb 
(Figures 63C and 63D). The loop residues 78-87 of α1 subunit in camel Hb showed 
higher fluctuations at lower temperature condition (27°C). However such an effect 
was not observed in human Hb.  The loop residues 44-55 of β1 demonstrated similar 
fluctuations in both camel and human hemoglobin. However, these residues of β2 
chain showed higher fluctuations at higher temperature conditions (34°C and 41°C) 
in human Hb, compared to camel Hb (Figures 63C and 63D). The loop residues 81-
97 of β1 chain of camel Hb demonstrated more fluctuations at only 34°C, while the 
same residues of human Hb showed higher fluctuations at all temperature conditions.  
Additionally, the same residues of β2 chain of human Hb exhibited higher 
fluctuations at higher temperature conditions when compared to camel Hb.  More 
importantly, residues 79, 82, 139, 143, and 146 of β1 and β2 subunits of camel Hb 








Figure 63: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 200 ns 
run of 2,3-BPG bound camel and human hemoglobin simulations at different temperature conditions. Data from different temperature conditions 
are shown in red, green, blue, and purple. (A) RMSD of camel Hb-2,3-BPG complex simulations; (B) RMSD of camel Hb-2,3-BPG complex 
simulations: (C) RMSF of camel Hb-2,3-BPG complex simulations and, (D) RMSF of human Hb-2,3-BPG complex simulations. Note that the 










The contact duration of important interacting residues of camel and human 
Hb with 2,3-BPG at different temperature conditions were also determined. Asp79 of 
both β1 of β2 subunits of camel Hb exhibited intermittent interactions at different 
temperature conditions (Figure 64). However, such interactions were not observed in 
human Hb. Lys82 of both β chains of human and camel Hb formed sustained 
interactions for the full duration of the simulations at all temperature conditions 
(Figures 64 and 65). Moreover, Asn139 of both β chains of human Hb exhibited 
intermittent interactions with 2,3-BPG, especially at lower temperature conditions. 
However, camel hemoglobin did not produce such interactions in any simulation run. 
The residues His143, His146 of β1 and β2 of camel hemoglobin formed more 
sustained interactions with 2,3-BPG at higher salt concentrations, compared to 
human hemoglobin. However, such interactions were not observed in human Hb.  
Additionally, Asn80 of  camel β2 subunit showed more sustained interactions at 300 
mM, and 600 mM, while, the same residue of  β1 of human Hb showed interactions 
with 2,3-BPG at 0 mM and 150 mM only.The contact duration of important 
interacting residues of camel and human Hb with 2,3-BPG at different temperature 
conditions were also determined. Asp79 of both β1 of β2 subunits of camel Hb 
exhibited intermittent interactions at different temperature conditions. However, such 
interactions were not observed in human Hb. Lys82 of both β chains of human and 
camel Hb formed sustained interactions for the full duration of the simulations at all 
temperature conditions. Moreover, Asn139 of both β chains of human Hb exhibited 
intermittent interactions with 2,3-BPG, especially at lower temperature conditions. 
However, camel hemoglobin did not produce such interactions in any simulation run. 
The residues His143, His146 of β1 and β2 of camel hemoglobin formed more 






human hemoglobin. However, such interactions were not observed in human Hb.  
Additionally, Asn80 of camel β2 subunit showed more sustained interactions at 300 
mM, and 600 mM, while, the same residue of β1 of human Hb showed interactions 
with 2,3-BPG at 0 mM and 150 mM only (Figures 64 and 65). 
 
Figure 64: The percentage of simulation time during which different residues of 
camel hemoglobin interacted with 2,3-BPG. Orange, green, and blue colors represent 
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of camel 
hemoglobin-2,3-BPG complex at 27°C; (B) Simulations of camel hemoglobin-2,3-
BPG complex at 30°C ; (C) Simulations of camel hemoglobin-2,3-BPG complex at 







Figure 65: The percentage of simulation time during which different residues of 
human hemoglobin interacted with 2,3-BPG. Orange, green, and blue colors 
represent charged, hydrophobic and polar amino acids, respectively. Orange, green, 
and blue colors represent charged, hydrophobic and polar amino acids, respectively. 
(A) Simulations of human hemoglobin-2,3-BPG complex at 27°C; (B) Simulations 
of human hemoglobin-2,3-BPG complex at 30°C ; (C) Simulations of human 
hemoglobin-2,3-BPG complex at 34°C; and, (D) Simulations of human hemoglobin-
2,3-BPG complex at 41°C. 
6.1.8 MD simulations of ATP bound to camel and human hemoglobin at 
different salt conditions  
ATP is another important co-factor present in erythrocytes and is also 
involved in binding with deoxyhemoglobin. However, its levels in erythrocytes are 
significantly lower compared to 2,3-BPG. Camel and human hemoglobin bound to 






hemoglobin with respect to initial structure showed stability at 2.5 Å in all salt 
concentrations except 150 mM (Figure 66A). Camel Hb-ATP complex systems were 
observed more stabilized with lower RMSD at higher salt concentrations (300 mM 
and 600 mM) compared to lower salt concentrations (Figure 66A). However, the 
structural integrity of human Hb-ATP complex systems at different salt 
concentrations were retained with a RMSD of Cα atoms from the initial structure that 
was under 3.5 Å (Figure 66B). Moreover, to determine and compare backbone 
stability and residual fluctuations of the camel and human Hb-ATP complex at 
different salt concentrations, RMSF of backbone Cα atoms were measured and 
plotted (Figures 66A and 66B). Overall, camel Hb showed lower fluctuations, 
compared to human hemoglobin. Loop residues 45-51 of α1 subunit showed more 
variations only at 150 mM, while the same region in human hemoglobin fluctuated 
more at 150 mM and 300 mM. The similar residues of α2 subunits of both camel and 
human Hb exhibited higher fluctuations at 300 mM and 600 mM (Figure 66). These 
residues fluctuated more in camel Hb compared to human Hb. The Loops residues 1-
5, and 16-20 of camel β1 chain exhibited more fluctuations at higher salt 
concentrations (300 mM and 600 mM), compared to human Hb. Loop residues 44-55 
and 80-100 residues of β1 of human Hb showed higher fluctuations at higher salt 
concentrations, while the same residues of camel Hb exhibited more fluctuations at 
lower salt concentrations. However, the same residues of β2 of camel and human Hb 
showed higher fluctuations at higher and lower salt concentrations, respectively 
(Figures 66C and 66D). Interestingly, these regions fluctuated more in human Hb, 
compared to camel hemoglobin. Importantly, residues 79, 82, 139, 143, and 146 of 
β1 and β2 subunits of camel Hb showed lower fluctuations at higher salt 







Figure 66: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 200 ns 
run of ATP bound camel and human hemoglobin simulations at salt conditions. Data from different salt conditions are shown in red, green and 
blue. (A) RMSD of camel Hb-ATP complex; (B) RMSD of human Hb-ATP complex simulations (C) RMSF of camel Hb-ATP complex 
simulations and, (D) RMSF of human Hb-ATP complex simulations. Note that the residue number used in the RMSF plots uses a sequential 










The contact duration of important interacting residues of camel and human 
Hb with ATP were determined. Asp79 of both β1 of β2 subunits of camel Hb 
exhibited intermittent interactions at lower salt concentrations (Figure 67). While the 
same residue of β1 chain of human Hb formed intermittent interaction at 600 mM 
only (Figure 67). Lys82 of both β chains of human and camel Hb formed sustained 
interactions for the full duration of the simulations at all salt concentrations. 
Moreover, Asn139 of both β chains of human Hb exhibited intermittent interactions 
with ATP in all simulation runs. However, such interactions were not observed in 
camel Hb. The residue His143 and His146 of β1 and β2 of camel hemoglobin formed 
more sustained interactions at 300 mM, with ATP, respectively. However, His143 of 
β1 chain in human hemoglobin produced consistent interaction at all salt 
concentrations. His146 of camel β1 chain formed more sustained interactions with 
ATP at 0 mM and 300 mM. However, such an interaction was not observed in 
human Hb. Moreover, Arg144, a substituted residue in camel Hb β1 subunit formed 
interactions with ATP at higher salt concentrations. Human Hb did not produce such 
an interaction.  Additionally, Asn80, and Leu81 of camel β2 subunit showed more 
sustained interactions at 300 mM, compared to other salt concentrations. However, 
Asn80 residue of β1 of human Hb showed interactions with ATP at 600 mM only 











Figure 67: The percentage of simulation time during which different residues of 
camel hemoglobin interacted with ATP. Orange, green, and blue colors represent 
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of camel 
hemoglobin-ATP complex at 0 mM; (B) Simulations of camel hemoglobin-ATP 
complex at 150 mM; (C) Simulations of camel hemoglobin-ATP complex at 300  











Figure 68: The percentage of simulation time during which different residues of 
human hemoglobin interacted with ATP. Orange, green, and blue colors represent 
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of human 
hemoglobin-ATP complex at 0 mM; (B) Simulations of human hemoglobin-ATP 
complex at 150 mM; (C) Simulations of human hemoglobin-ATP complex at 300 
mM; and, (D) Simulations of human hemoglobin-ATP complex at 600 mM. 
6.1.9 MD simulations of ATP bound to camel and human hemoglobin at 
different temperature conditions  
 Camel and human hemoglobin bound to ATP were simulated at different 
temperature conditions. Camel and human Hb structures remained stable during 
simulation runs. The RMSD of Cα atoms of both camel and human hemoglobin with 
respect to initial structures showed stability under 3.5 Å in all simulations (Figures 
69A, 69B).  In order to determine and compare the backbone stability and residual 






conditions, RMSF of backbone Cα atoms were measured and plotted (Figures 69C 
and 69D). Loop residues 12-18 of α1 exhibited more fluctuations in human Hb only, 
especially at 30°C and 34°C. Loop residues 48-51 of  α1 subunit of camel Hb 
showed higher fluctuations at lower temperature condition (27°C),  while α1 subunit 
residues 44-54 of human Hb showed higher fluctuations at higher temperature 
conditions (34°C and 41°C). However, similar residues of α2 subunits of both camel 
and human Hb exhibited higher fluctuations at higher temperature conditions 
(Figures 69C and 69D). These residues fluctuated more in camel Hb compared to 
human Hb. The loop residues 74-94 of both α1 and α2 subunits of human Hb 
exhibited more fluctuations at higher temperature conditions when compared to 
camel Hb. The loop residues 113-118 of α1 chain of human Hb also demonstrated 
higher fluctuations at 30°C and 41°C, compared to camel Hb. The loop residue 1-5 
and helical residues 6-13 of β1 chain of camel Hb showed higher fluctuations at 
41°C, compared to human Hb. While the loop residues of 1-5 of β2 subunit of only 
human Hb exhibited higher fluctuations at 34°C. Loop residues 44-54 and 82-100 of 
β1 and β2 of camel Hb showed higher fluctuations at higher temperature conditions 
(34°C and 41°C). While in human Hb, the residues 44-54 β1 exhibited more 
fluctuations at lower temperature conditions, and 87-100 residues of both β1 and β2 
showed higher fluctuations at higher temperature conditions. Moreover, the residues 
82-100 of β1 and β2 of camel Hb showed limited fluctuations at higher temperature 
conditions, compared to human Hb (Figure 69). Importantly, residues 79, and 82 of 
β1 and β2 subunits of camel Hb showed lower fluctuations, compared to human Hb. 
However, 139, 143, and 146 of β1 and β2 subunits demonstrated higher fluctuations 







Figure 69: Root mean square standard deviation (RMSD) and root mean square fluctuation (RMSF) of protein Cα atoms obtained from a 200 ns 
run of ATP bound camel and human hemoglobin simulations at different temperature conditions. Data from different temperature conditions are 
shown in red, green, blue, and purple. (A) RMSD of camel Hb-ATP complex simulations; (B) RMSD of human Hb-ATP complex simulations; 
(C) RMSF of camel Hb-ATP complex simulations and, (D) RMSF of human Hb-ATP complex simulations. Note that the residue number used in 










The contact duration of important interacting residues of camel and human 
Hb with ATP were determined. Asp79 of both β1 of β2 subunits of camel Hb 
exhibited consistent interactions at all temperature conditions (Figure 70). However, 
such interactions were not formed in human Hb (Figure 71). Lys82 of both β chains 
of human and camel Hb formed sustained interactions throughout the simulations at 
all temperature conditions. Asn139 of both β chains of human Hb exhibited 
consistent interactions with ATP in all simulation runs. However, Asn139 of camel 
Hb showed extremely weak interactions with ATP. The residue His143 of β1 of 
human hemoglobin formed more sustained interactions with ATP at 34°C, and the 
same residue β2 exhibited intermittent interactions at all temperature conditions, 
except at 30°C. However, in camel only β1 chain produced intermittent interaction at 
only 34°C and 41°C. His146 of human β chains also formed intermittent interactions 
with ATP at only lower temperature conditions. However, such an interaction was 
not observed in camel Hb. Moreover, Arg144, a substituted residue in camel Hb β1 
subunit formed interactions with ATP at 34°C. Human Hb did not produce such an 







Figure 70: The percentage of simulation time during which different residues of 
camel hemoglobin interacted with ATP. Orange, green, and blue colors represent 
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of camel 
hemoglobin-ATP complex at 27°C; (B) Simulations of camel hemoglobin-ATP 
complex at 30°C ; (C) Simulations of camel hemoglobin-ATP complex at 34°C; and, 









Figure 71: The percentage of simulation time during which different residues of 
human hemoglobin interacted with ATP. Orange, green, and blue colors represent 
charged, hydrophobic and polar amino acids, respectively. (A) Simulations of human 
hemoglobin-ATP complex at 27°C; (B) Simulations of human hemoglobin-ATP 
complex at 30°C ; (C) Simulations of human hemoglobin-ATP complex at 34°C; 
and, (D) Simulations of human hemoglobin-ATP complex at 41°C. 
6.2 Discussion 
This study provide insights into the stability of camel and human hemoglobin 
under various dehydrated conditions, as well as the stability of interaction of 2,3-
BPG and ATP, which are essential for the unloading of oxygen from hemoglobin, 
with camel and human hemoglobin using several long MD simulations. Overall, 






revealed that camel hemoglobin structures showed more stability when compared to 
human hemoglobin. Additionally, in camel hemoglobin, critical regions important 
for the binding of heme, 2,3-BPG, and ATP molecules demonstrated limited 
fluctuations in the studied conditions.  Molecular docking and MD simulations 
indicated that 2,3-BPG, and ATP molecules, which are abundantly present in 
erythrocytes, formed more stable interactions with essential residues with camel 
hemoglobin when compared to human hemoglobin.  
Generally, mammalian erythrocytes are highly sensitive to osmotic fragility 
except camels (Bogner et al., 2005; Schmidt-Nielsen et al., 1956). Importantly, 
camels RBCs are extremely resistant to osmotic fragility and are inherently adapted 
to endure the sudden fluctuations in blood osmolarity without affecting its function 
(Oyewale et al., 2011). In order to measure the changes resulting from different salt 
concentrations, MD simulations were performed, since no prior attempt has been 
made to look at the residue level fluctuations of this macromolecule. Indeed, 
simulations are clearly representative of fluctuations being affected by different salt 
concentrations (Figure 57). The natural capability of protein function is highly 
dependent on the extent of the innate fluctuations of a macromolecule (Frauenfelder, 
Parak, & Young, 1988; Steinbach et al., 1991). Here, simulations in the presence of 
different salt concentrations demonstrated fluctuations of the important regions 
essential for the oxygen binding (Figure 57). Interestingly, the high fluctuations were 
observed in residues near to the heme binding sites in each subunit. The residues in 
these regions exhibited high RMSF values than the other residues.  Importantly, 
His87 of α subunits and His92 of β subunits demonstrated more fluctuations at 






groups and served as oxygen binding sites.  Importantly, conserved residues 
α1:Phe43 and α1:Phe46 showed more fluctuations at higher salt conditions (Figure 
57). These functional residues are present in the heme pocket distal to heme where 
oxygen binds (Laberge & Yonetani, 2008). Moreover, α1 conserved residues Leu86 
and Leu91 also exhibited higher fluctuations when salt concentration was increased. 
These residues are part of proximal heme pocket residues (Laberge & Yonetani, 
2008). Interestingly, in comparison to human hemoglobin, camel hemoglobin 
demonstrated lower fluctuations at all salt concentrations.  Similarly, when different 
temperature conditions were used camel hemoglobin showed lower fluctuations at 
higher temperature conditions especially in the regions important for the binding of 
heme groups and thus considered as oxygen binding sites, compared to human 
hemoglobin (Figure 58).  Therefore, these changes could affect the affinity of oxygen 
molecule with camel hemoglobin. 
2,3-BPG and ATP are two important co-factors present abundantly in the 
erythrocytes that bind to hemoglobin (Castilho, Glass, & Manco, 2003). Prior studies 
have demonstrated that both these co-factors preferentially bind to deoxyhemoglobin 
(Chen et al., 2017; Chu et al., 2008). Additionally, their binding with 
deoxyhemoglobin is responsible for stabilizing the deoxyhemoglobin or tense (T) 
state of the hemoglobin. Generally, oxygen is unloaded from hemoglobin to tissue 
cells during the deoxyhemoglobin state. Therefore, these two co-factors have 
significant role in the unloading of oxygen molecules and also in the regulation of 
transition from oxyhemoglobin (relaxed state) to deoxyhemoglobin (tensed state). 
During the transition from deoxyhemoglobin to oxyhemoglobin, the binding pocket 






cavity, is disrupted and therefore not available for these co-factors to bind in 
oxyhemoglobin state (Berg et al., 2002). Thus, only deoxyhemoglobin or tensed state 
of Hb was selected for the molecular docking and MD simulations of 2,3-BPG and 
ATP with camel and human Hb. The molecular docking of 2,3-BPG and ATP 
identified the active site residues of Hb and were situated at the entrance of β1/β2 
cavity. These findings are in agreement with previous studies (Arnone, 1972; Chen et 
al., 2017). Importantly, both 2,3-BPG and ATP share the same binding site on Hb. In 
comparison to ATP, 2,3-BPG is the more abundant co-factor present in erythrocytes 
of most mammals present at a concentration 4-13 mmol/l. While, observed ATP 
concentration in the mammal’s RBCs is 1.3 mmol/l. Additionally, ATP is mostly 
present as ATP-Mg
2+
 in the erythrocytes, which binds weakly to hemoglobin. Thus, 
this suggests that ATP has minimal effect on oxygen affinity, while 2,3-BPG 
predominantly binds with deoxyhemoglobin and play a major role in the regulation 
of oxygen affinity and unloading of oxygen to tissue cells. Importantly, the levels 
and precise functions of these co-factors in the erythrocytes of camel have not been 
reported so far. Therefore, extensive computational modeling approaches were used 
to determine the binding mode, and stability of critical interactions between camel 
deoxyhemoglobin and 2,3-BPG or ATP. Several stresses such as different salt 
concentrations and different temperature conditions were used to determine the 
impact of these conditions on the binding stability of 2,3-BPG and ATP with camel 
Hb. Additionally, these results were compared with human Hb. Previous studies have 
reported that Lys82 and His143 residues of both β subunits are highly essential for 
the binding of 2,3-BPG and ATP with deoxyhemoglobin subunit. However, Asp79, 
Asn139 and His146 residues are also considered vital for the binding of these co-






human Hb and were in agreement with prior studies (Chen et al., 2017). 
Additionally, ATP formed similar interactions with human Hb, except His143 of β2, 
and His146 of both β subunits. MD simulations indicated that 2,3-BPG formed more 
sustained interactions with essential residues Lys82, His143, and His146 of camel 
hemoglobin at higher salt concentrations (Figure 61). However, 2,3-BPG only 
maintained interactions with His143 at lower salt concentrations and with Lys82 of 
human Hb at all salt concentrations (Figure 62). This indicate that at higher osmotic 
pressure induced by increased concentrations of NaCl, camel Hb formed stronger 
interactions with 2,3-BPG and support the release of oxygen to tissue cells. The 
effect of different temperature conditions on the binding stability of 2,3-BPG with 
camel and human Hb indicated that 2,3-BPG maintained intermittent interactions 
with critical residues of both camel and human Hb at lower temperatures (Figures 64 
and 65). These findings are in agreement with previous studies which mentioned that 
lower temperature favored the binding of 2,3-BPG with Hb (Benesch, Benesch, & 
Yu, 1969).  Human Hb residues (Asn139, His143) also showed more consistent 
interactions at lower temperature conditions, compared to camel. However, Lys82 
formed sustained interactions with both camel and human Hb at all temperature 
conditions. Importantly, Asp79, Asn80 residues of camel Hb exhibited more 
consistent interactions with 2,3-BPG even at higher temperature conditions, 
compared to human Hb (Figures 64 and 65).   
The binding stability of ATP with camel and human Hb residues at different 
temperature and salt conditions exhibited similar results. ATP formed more sustained 
interactions with Asp79, Asn80, His143, and His146 residues of camel Hb at higher 






and human Hb exhibited consistent interactions throughout the simulations at all salt 
concentrations (Figure 70). However, the binding stability of camel residues His143, 
and His146 with ATP were weaker when compared to 2,3-BPG at higher salt 
concentrations. However, at different temperature conditions, human Hb residues 
His143, and His146 produced more consistent interactions with ATP, especially at 
lower temperature conditions, compared to camel Hb (Figures 70 and 71). While, 
Asp79, Asn80, and Arg144 of camel Hb showed more consistent interactions with 
ATP at higher temperature conditions, compared to human Hb (Figures 70 and 71). 
Hb Lys82 residue formed interactions with ATP for the full duration of simulation 
time at all temperature conditions in both camel and human. 
The findings of this study are of significant importance in understanding the 
behaviour of camel hemoglobin under different dehydrated conditions, particularly 
the involvement of erythrocytes co-factors during dehydrated conditions. Indeed, 
hemoglobin is the most well studied protein both genetically, and biochemically 
(Oyewale et al., 2011). However, from structural prospective, the behavior of 
hemoglobin under different stresses have not been greatly explored. This study 
provided useful insights into the interactions of 2,3-BPG and ATP with camel and 
human Hb with implications in the physiology of these mammals under dehydrated 
conditions. Interestingly, camels can fluctuate their body temperature from 
approximately 34°C to 40°C during daytime (Oyewale et al., 2011; Schmidt-Nielsen 
et al., 1956). Moreover, camels have an exceptional ability to live without drinking 
water for longer period of time. These two conditions in combination produces a 
severe dehydrated environment in camels. Other mammals cannot withstand such 






dehydration and high temperature conditions are significantly associated with 
increased respiratory rate in mammals (Barcroft & Izquierdo, 1931; Gaalaas, 1945; 
Rubini & Bosco, 2013). Higher temperature conditions decrease the overall binding 
affinity of oxygen molecules with hemoglobin and is also involved in an increased 
production of 2,3-BPG as a result of hyperventilation. These phenomena support 
more unloading of oxygen into tissues to meet their oxygen demand during high 
temperature and hyperventilation. It is also important to mention that these effects 
are due to Bohr effect (Yonetani et al., 2002). It states that hemoglobin’s lower 
affinity for oxygen is associated with an increase in partial pressure of carbon 
dioxide and a decrease in blood pH. For instance, higher temperature, and 
hyperventilation enhances the metabolic activities within tissues lead in the 
generation of more carbon dioxide. As a result of high CO2, more hydrogen ion (H
+
) 
will be produced which ultimately lead to lower pH and the production of more 2,3-
BPG.  These effects ultimately reduce the affinity of hemoglobin for oxygen. 
However, hyperventilation for longer period of time or chronic hyperventilation 
blocks the potential of Bohr effects and increases the hemoglobin binding affinity for 
oxygen with lesser release to peripheral tissues, including important organs such as 
brain, liver, kidney, and heart (Benner, Patel, Singh, & Dua, 2020). Importantly, 
more stable interactions of 2,3-BPG especially with camel hemoglobin at higher 
dehydrated conditions support these arguments and are vital to fulfill the oxygen 
demands of the peripheral tissues. This could be the reason why a camel’s vital 
organs and peripheral tissues remain functional for longer period of time during 






Chapter 7: Conclusion 
This study looked at a number of aspects related to structural, genetic and 
pharmacological properties of camel hemoglobin and hemoglobin-derived peptides. 
First, the work presented here provides structural insights into the binding of camel 
and human hemorphins with MOR, IRAP and ACE. Importantly, camel hemorphins 
demonstrated more stable interactions with these drug targets and also produced 
more potent ACE inhibitory activity, compared to human hemorphins. This study 
also identified, for the first time, a G protein-coupled receptor, angiotensin II type 1 
receptor (AT1R) that is a target of hemorphins. In silico and in vitro data indicated 
that LVV-hemorphin-7 binds to the intracellular side of AT1R and allosterically 
potentiated the potency of AngII as well as its downstream signaling. Additionally, 
this study explored the genetic and structural variations of camel hemoglobin and 
how these variations could contribute to the overall stability and residue-level 
flexibility in camel hemoglobin in response to dehydrated conditions when compared 
to human hemoglobin. The study helped in determining the stability of crucial 
residues important for the binding of co-factors like heme, 2,3-BPG and ATP. 
Several critical residues of camel hemoglobin α and  subunits exhibited fluctuations 
that were notably different when compared to humans. This study also showed that 
camel hemoglobin exhibited more stability in severe dehydrated conditions when 
compared to human hemoglobin. Additionally, in silico data indicated a more stable 
binding of 2,3-BPG and ATP with  subunits of camel hemoglobin when compared 
to human hemoglobin when severe dehydrated conditions were used. These results 
illustrate that under extreme dehydrated conditions, especially with high salt 
concentrations, 2,3-BPG could bind more strongly to camel hemoglobin and help 






Chapter 8: Future Prospects 
The synthesis, metabolism and therapeutic potential of hemoglobin-derived peptides 
(hemorphins) continue to be both fascinating and challenging. The tissue-specific 
release and its ability to bind diverse targets are yet to be clearly elucidated. 
Hemorphins have been studied for the last three or four decades. Even though 
hemorphins are endogenous peptides with several therapeutic and pharmacological 
activities, astonishingly, these peptides have not been actively explored in the last 
decade. Moreover, a huge gap still exists between in vitro and in vivo data using 
human subjects and animal models and mechanistic basis at the cellular and 
molecular level. Indeed, different aspects of hemoglobin-derived peptides discussed 
in this study clearly demonstrate the direct pharmacological and biological action of 
hemorphins on key receptors and enzymes. However, a big gap still exists in our 
understanding of the precise mode of action and the specific binding sites on the 
targets. Future studies should aim specifically toward dissecting the cellular and 
molecular pathways and to investigate the critical residues of hemorphins that 
interact with a target. Additionally, in depth structure activity relationship and 
binding assays involving hemorphins and putative targets should be considered using 
both in vitro and in silico studies. A lot is known about hemorphins. However, the 
story is still enormously incomplete and further studies are needed to understand and 
to unlock the true potential of hemoglobin derived peptides for therapeutic and 
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